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Background: Research indicates that hidradenitis suppurativa (HS) can have a 
significant psychosocial impact on individuals, with a range of factors found to be 
associated with outcomes. Systematic reviews to date have explored anxiety, depression 
and quality of life in other dermatological diseases, however there has only been one 
which focuses on prevalence of anxiety and depression in HS. The aim was to 
systematically review the prevalence of anxiety, depression and poor quality of life in 
HS, and any associated factors. Findings informed the development of recommendations 
for assessment and interventions in HS, and areas for future research. 
Method: Databases that were searched included EMBASE, MEDLINE, PsychINFO 
using Ovid, PubMed, Cumulative Index to Nursing and Allied Health Literature, Web of 
Science and three grey literature databases. Search terms regarding anxiety, depression 
and quality of life in people with HS were used, papers retrieved were screened according 
to inclusion/exclusion criteria.  
Results: Twenty-three studies were eligible for inclusion in the review. Nineteen papers 
assessed quality of life, whereas eight measured depression and three measured anxiety. 
Prevalence rates of anxiety, depression and poorer quality of life were found to be higher 
than control groups including other skin diseases and the general population. Prevalence 
rates were 27% for anxiety, between 5.5% and 38.6% for depression, and quality of life 
was within the ranges of moderate to very large impact. Several factors were associated 
with these outcomes including demographic, psychosocial, lifestyle and clinical factors. 
The methodological quality for most studies was rated as fair, three were good and seven 
were poor. But these findings were not related to prevalence rates/main outcome data. 
Conclusions: The findings of this review suggest that routine assessments of people with 
HS may benefit from inclusion of anxiety, depression and quality of life measures, in 
addition to measures of factors found to be associated with these psychosocial outcomes. 
These may include illness beliefs, sexual function, disease severity and pain. It will be 
useful for future research to focus on developing psychological interventions to support 
people with HS who are at risk of or are experiencing poor health outcomes, and target 
factors such as illness perceptions and sexual dysfunction. Further research is required 
using longitudinal and cohort study designs to identify factors that are predictive of poorer 





Hidradenitis suppurativa (HS) is a chronic, painful and debilitating inflammatory 
dermatological disease of the apocrine glands (groin, armpits and anogenital areas), 
which presents as malodorous abscesses, nodules, fistulas and scarring (Dhaou, 
Boussema, Aydi, Baili & Rokbani, 2013). The global prevalence rate is 1 - 4% (3:1 ratio 
of women to men), with the average age of onset being in early twenties and remaining 
typically active during the thirties and forties (Dufour, Emtestam & Jemec, 2014). 
Currently there is no cure for HS, and dermatological treatment is dependent on disease 
severity (Elkin, Daveluy & Avanaki, 2020). There are a number of different HS severity 
measures that are used clinically and in research including Hurley staging (Hurley, 1989), 
Modified Sartorius Score (Sartorius, Emtestam, Jemec & Lapins, 2009; Sartorius, Lapins, 
Emtestam & Jemec, 2003), HS-Physician’s Global Assessment (HS-PGA; Kimball et al., 
2012; Zouboulis et al.., 2015), Hidradenitis Suppurativa Clinical Response (HiSCR; 
Kimball et al., 2016), and International Hidradenitis Suppurativa Severity Scoring System 
(Kimball et al., 2014; Scuderi et al, 2017; Zouboulis et al., 2017). 
 
Research has indicated that HS can have a significant psychosocial impact. 
Indeed, lesions often result in soreness and pain as well as feelings of shame and 
embarrassment, which can lead to higher rates of sick leave than the general population 
and impaired quality of life (Alikhan, Lynch & Eisen, 2009). Quality of life (QoL) can 
be defined using different terms, such as wellbeing, functioning and health-related quality 
of life and measured using a range of tools with varying constructs. Research into 
dermatological diseases such as psoriasis and HS are increasingly using standardised 
quality of life screening tools that measure constructs including psychological, physical 
and social functioning (de Korte, Sprangers, Mombers & Bos, 2004; Kofler et al., 2018). 
A validated measure that has been used widely in dermatological research and clinical 
use is the Dermatology Quality of Life Index (DLQI; Finlay & Khan, 1994), which has 
ten items each with cut-off points (Hongbo, Thomas, Harrison, Salek and Finlay, 2005)  
indicating no effect on patient’s life (0 - 1), small effect (2 - 5), moderate effect (6 - 10), 
very large effect (11 - 20), extremely large effect (21 - 30). Another common measure is 
the Skindex-29 (Chren, Lasek, Flocke & Zyanski, 1997), which has three domains 
assessing symptoms, emotions and functioning; each domain has a cut-off to establish 
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severe impairment. Higher prevalence of impaired quality of life has been found in people 
with HS, compared to other dermatological diseases such as psoriasis and atopic 
dermatitis (Gooderham & Papp, 2015; Kohorst, Kimball & Davis, 2015; Wolkenstein, 
Loundou, Barrau & Auquier, 2007). This review will consider quality of life in the 
context of participants’ subjective ratings of the impact that HS has on their wellbeing, 
using validated quality of life questionnaires to enable comparisons with other studies 
and populations. 
 
Higher prevalence of anxiety and depressive symptoms has also been found in 
HS, compared to the general population (Onderdijk et al., 2013; Shavit et al., 2015), and 
more common in females than males (Shavit et al., 2015). The World Health Organisation 
(WHO, 2017) reported that the point prevalence rate of anxiety disorders globally was 
estimated to be 3.6% in 2015, and more common among females (4.6%) than males 
(2.6%). Prevalence of anxiety in people with HS was found to be higher than this at 4.9% 
in a recent systematic review and meta-analysis by Machado et al. (2019), and 6.9% in a 
nationwide Finnish study of 4381 people with HS (Huilaja, Tiri, Jokelainen, Timonen & 
Tasanen, 2018). In Huilaja et al.’s (2018) study the prevalence of anxiety was also higher 
in HS than in people with psoriasis (5%) and melanocytic nevi (3.8%, the control group). 
 
In terms of depression, prevalence rates vary widely across studies in the general 
population. Globally in 2015 the point prevalence was estimated to be 4.4%, and also 
more common among females compared to males (WHO, 2017). However, a meta-
analysis between 1994 and 2014 across 30 countries found an aggregate point prevalence 
of 12.9% (Lim et al., 2018). Variable findings are also evident in research of people with 
HS. A population-based study by Vazquez, Alikhan, Weaver, Wetter and Davis (2013) 
found 43% of 268 participants with HS were diagnosed with depression. Machado et al. 
(2019) found that across 10 studies of HS, the prevalence of depression was 16.9%, 
however this was 26.8% in studies that used a screening instrument. These findings 
suggest that there may be a higher prevalence of depression in people with HS than the 
general population, but that this could be over or underestimated based on the methods 
used to assess this. 
 
Depressive symptoms have been found to be more prevalent in HS than other 
dermatological diseases (Onderdijk et al., 2013). In Huilaja et al.’s (2018) nationwide 
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study, major depression was more common in HS (15.3%) compared to the psoriasis 
group (12.1%) and melanocytic nevi group (8.3%). It should be noted however that 
depression prevalence in psoriasis has also been found to vary broadly, ranging from 4% 
to 68% in three systematic reviews (Daudén et al., 2013; Dowlatshahi, Wakkee, Arends 
& Nijsten, 2014; Roque Ferreira, Pio-Abreu, Reis & Figueiredo, 2017), which can make 
this more difficult when comparing prevalence to HS. Differences in prevalence rates of 
psoriasis may also be due to the method of assessment, for example Dowlatshahi et al.’s 
(2014) systematic review found a 15% difference in prevalence of depression between 
the Beck Depression Inventory (BDI; Beck, Ward, Mendelson, Mock & Erbaugh, 1961) 
and the Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983). 
 
There are various factors that may contribute to prevalence of anxiety, depression 
and poor quality of life in HS. Specific locations of lesions (head, nape and anogenital 
areas) have been linked with internal stigma, low self-esteem and impaired quality of life 
(Matusiak et al., 2010). A qualitative study of the psychosocial impact of HS indicated 
that people with HS reported experiencing feelings of being unworthy, helpless, 
unattractive and having a lack of control over their illness (Esmann & Jemec, 2011). 
Research across 13 European countries and numerous skin diseases including HS, also 
found that 23.1% reported sexual problems and that this was linked with anxiety, 
depression and suicidal ideation (Sampogna et al., 2017). 
 
Impaired quality of life and depression have also been shown to be positively 
correlated with level of severity of HS, duration, pain, and more lesion locations (Alavi, 
Anooshirvani, Kim, Coutts & Sibbald, 2015; Kurek, Peters, Sabat, Sterry & Schneider-
Burrus, 2013; Matusiak, et al., 2010; Wolkenstein et al., 2007). There is research debating 
the role of proinflammatory cytokines in impacting the development of mood disorders, 
including depression (Goldstein, Kemp, Soczynska & McIntyre, 2009; Kohler et al., 
2017). The same cytokines have been found to be involved in the development of HS 
(Huilaja et al., 2018; Kelly & Prens, 2016; van der Zee et al., 2011). Notwithstanding, 
there has been considerable variation in the extent to which disease severity correlates 
with outcomes such as depressive symptoms, anxiety and quality of life (Pavon Blanco, 
Turner, Petrof & Weinman, 2018; Onderdijk et al., 2013). There has been increasing 
evidence to show that illness perceptions across various chronic illnesses (including 
psoriasis, heart failure, rheumatoid arthritis and chronic obstructive pulmonary disease) 
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are also significantly related to quality of life, anxiety and depression in addition to 
disease severity (Scharloo et al., 1998, 2000). Illness perceptions are cognitive models of 
illness including beliefs about cause, timeline, control or cure, consequences and identity 
(Petrie & Weinman, 2006).  Pavon Blanco et al. (2018) recently found that illness 
perceptions about HS were more strongly associated with depression, anxiety and quality 
of life than disease severity. This finding suggests that psychological factors may be 
important to consider when assessing HS and its impact on quality of life, depression and 
anxiety, independently of the clinical presentation of HS.  
 
Review Aims 
Systematic reviews to date have explored the prevalence of depression, anxiety 
and quality of life in other dermatological diseases (de Korte et al., 2004; Dowlatshahi et 
al., 2014) and Rosacea (Krasuska, Millings, Lavda & Thompson, 2015). There is 
currently only one systematic review that has evaluated the prevalence of depression and 
anxiety in adults with HS (Machado et al., 2019). To the best of the author’s knowledge, 
there is not a formal systematic review or ongoing reviews to summarise the available 
self-reported data from validated screening tools in terms of prevalence of anxiety, 
depression and quality of life in HS, and related factors. There were also no ongoing 
systematic reviews in line with this research question registered on the international 
Prospective Register of Systematic Reviews (PROSPERO). This review may indicate 
areas to develop in routine assessment and interventions of people with HS. Therefore, 
the main aims of this systematic review are as follows:  
- To assess the prevalence of anxiety, depression and poor quality of life in HS. 
- To consider what factors are associated with anxiety, depression and quality of 





2.1  Search Strategy 
The search was conducted in line the Preferred Reporting Items for Systematic 
Reviews and Meta-Analysis (PRISMA) guidelines ( Moher, Liberati, Tetzlaff, Altman & 
PRISMA Group, 2009) using the following six databases: EMBASE (Ovid), MEDLINE 
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(Ovid), PsychINFO (Ovid), PubMed, Cumulative Index to Nursing and Allied Health 
Literature (CINAHL) and Web of Science. The search strategy comprised of four 
components: 
1. “Hidradenitis Suppurativa” OR “Hidradenitis” OR “Acne Inversa” 
AND 
2. “Anx*” OR “Anxiety adj disorder$”  
OR 
3. “Mood” OR “Depress*” OR “Mood adj disorder$” OR “Depress* adj disorder$” 
OR “distress” 
OR 
4. “Quality adj2 life” OR “Life adj quality” OR “HRQL” OR “QoL” OR “Well adj 
being” OR “Well-being” OR “Wellbeing” OR “functioning”  
 
Search limits of papers published between 1990 – current and published in English 
language were added to each database search. Searches of grey literature databases 
(unpublished literature such as doctoral dissertations and conference reports) using 
OpenGrey, EthOS and WorldCat, and manual searches of reference sections in retrieved 
studies were also performed (see Appendix A). The search on EMBASE, MEDLINE, 
PsychINFO and PubMed was conducted on 28/01/19 and the search on CINAHL, Web 
of Science grey literature databases was conducted on 16/02/19. This search strategy was 
conducted by a second reviewer to confirm that these searches could be replicated in each 
database and to resolve any large differences found in numbers of studies retrieved. They 
conducted the search on all databases on 16/09/19 apart from PsychINFO on 12/09/19 
and the grey literature on 18/09/19. The same number of papers were retrieved using 
PsychINFO and the grey literature databases, whereas larger numbers of papers were 
retrieved from the remaining databases. These numbers ranged from an increase in 18 to 
181 papers, which was to be expected due to the 7 to 8-month time gap between the first 
and second review. 
 
2.2       Study Selection Process 
Studies from the six databases were gathered in EndNote and duplicates were 
removed. After titles and abstracts were reviewed for relevance full-text papers were 




- Papers published between 1990 – 2019 
- Quantitative studies 
- Observational cohort and cross-sectional studies 
- Studies published in English language 
- Studies reporting original research in peer-reviewed journals 
- HS diagnosed by physician 
- Studies reporting HS data separately from other dermatological diseases (with 
sufficient sample detail) 
 
Exclusion Criteria 
- Interventional and qualitative studies 
- Case studies 
- Reviews, abstracts, communications, correspondence 
- Studies focused on other health conditions 
- HS data not reported separately from other conditions 
- Mean age of subjects below 18 / focus on paediatric population 
- Number of participants < 10 
- Studies not focused on psychological outcomes 
- Non-validated/unpublished measures of anxiety, depression and quality of life 
- Studies without an overall/total score on a validated measure of quality of life / 
anxiety / depression 
 
Historically severity of HS has been measured by clinicians using clinical/physical 
measures, however research has highlighted the importance of assessing both physical 
and psychological severity using validated self-reported measures (Pavon Blanco et al., 
2018). This is also the case in another inflammatory skin disease (Kirby et al., 2001). In 
view of these findings and the importance of using validated measures for accuracy, 
studies that did not state an overall or total score of quality of life, anxiety or depression 
as measured by a validated self-reported questionnaire were excluded. This was due to 
this limiting the ability to draw overall conclusions about these areas and make clear 
comparison between studies that used different measures. A second independent reviewer 
(APB) assessed 20% of the full text articles screened and 22% of the final eligible studies 
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for whether they met the inclusion/exclusion criteria. These studies were selected by using 
the random generator function in Microsoft Excel. 
 
2.3     Quality Assessment 
The National Heart, Lung, and Blood Institute (NHLBI) Quality Assessment Tool 
for Observational Cohort and Cross-Sectional Studies (Appendix C) was used to assess 
methodological quality of the papers (National Institutes of Health [NIH], 2014) and a 
second reviewer assessed all papers. Disagreements were resolved through discussion, 
and a third researcher was consulted if agreement was not reached. The NHLBI tool 
includes 14 questions to assess the quality of studies, with “yes / no” responses or “cannot 
determine / not applicable / not reported” depending on study characteristics. Question 8 
of this tool refers to whether exposures that can vary in amount or level are examined at 
different levels of the exposure as related to the outcome (NIH, 2014); this question was 
answered based on whether HS duration and/or severity was assessed in relation to the 
outcomes. This tool allowed reviewers to rate the quality as “poor”, “fair” or “good”, and 
was selected as it has been used in numerous systematic reviews investigating prevalence 
of depression, anxiety and quality of life in physical health problems (Briggs, Kenny & 
Kennelly, 2016; Christensen, Ipsen, Doherty & Langberg, 2016; Ismail et al., 2017; 
Maass, Roorda, Berendsen, Verhaak & de Bock, 2015). 
 
2.4       Data Extraction 
Study characteristics were extracted from the eligible articles including author 
names, year of publication, journal, study design, sample type (including location of 
study), number of participants with HS, number of participants in comparison group(s) if 
applicable, mean age (standard deviation and range if available) and gender. Study 
findings included measures of outcomes and possible contributing factors, overall results 
of prevalence of quality of life / anxiety / depression, and factors that had significant 
effects on prevalence.  
 
As a minimum requirement study designs and findings were looked at 
pragmatically despite how they had been labelled in the article. Four authors were 
contacted to request information that was not presented in their papers (including 
participant numbers, demographics and a total measure of quality of life). Their 
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permission was granted for these to be included in this review. Data extraction for quality 
of life was conducted and interpreted in line with how each paper measured and referred 
to quality of life. 
 
2.5   Data Synthesis 
The mean scores for quality of life were amalgamated in a graph in order to 
quantify the prevalence of poor quality of life in HS across the studies. The 
methodological quality of the studies was also included in this graph to take into account 
the robustness of their findings and where the true value may lie. It should be noted that 
this is not a meta-analysis, however this method of data synthesis was used in order to 





3.1   Study Selection 
At the initial search stage 1925 were identified and 982 titles and abstracts were 
reviewed for relevance (studies with a focus on HS and psychological outcomes) 
following removal of duplicates. The most frequent reason for exclusion at this screening 
stage was that articles were not focused on psychological outcomes (n = 690), and the 
second most common reason was that the articles were either reviews, abstracts or 
correspondence (n = 128). There were 45 full texts that were evaluated for eligibility, and 
23 of these papers were included in the review (Tables 1 and 2 include details of these 
papers). Figure 1 shows the numbers of papers reviewed and excluded at each stage and 
Appendix B shows the reasons for exclusion. 
 
3.2    Overall Study Characteristics 
All studies were cross-sectional (see Table 1) however not all studies stated their 
study design. Three papers reported being prospective studies, however when looked at 
in detail it was not evident why they had been labelled as prospective. One study stated 
that it was a case series, however the data reported was not in line with the criteria for a 
case series design. 
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Figure 1.  












































Note. See Appendix B for details on reasons for exclusion. 
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Additional records identified 
through other sources 
(n = 3) 
Records after duplicates removed 
(n = 982) 
Records screened 
(n = 982) 
Records excluded 
(n = 937)* 
Full-text articles 
assessed for eligibility 
(n = 45) 
Full-text articles 
excluded 
(n = 22) 
 
- Unable to access = 3 
- Non-validated 
measures = 8 
- Intervention study = 5 
- HS not reported 
separately from other 
conditions = 1 
- No overall measure of 
QoL / anxiety / 
depression = 2 
- Other = 3 
 
Studies included 
(n = 23) 
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All participants with HS were recruited either through hospitals or HS clinics apart 
from one study where participants were recruited from a national Blood Donor sample 
(Theut Riis et al., 2019). Seven studies included participants under the age of 18, however 
the mean ages of participants in these papers were over age 30. Overall, the mean age of 
participants with HS ranged from 32.5 – 45.95; the mean age fell within the thirties in 16 
of the studies. 
 
Twenty of the studies (87%) had a majority of female participants, with nine 
papers having more than double the number of females than males. Proportions ranged 
from 10% female and 90% male (Agut-Busquet, Romani, Ribera & Luelmo, 2019) to 
86% female and 14% male (von der Werth & Jemec, 2001). Sample sizes of participants 
with HS ranged from 26 - 500 and overall samples ranged from 26 - 27765. Eleven of the 
studies (48%) had at least one comparison group; eight included healthy controls or the 
general population. Only four of these studies matched controls for age and sex (Alavi, 
Farzanfar, Rogalska, Lowes & Chavoshi, 2018b; Kaaz, Szepietowski & Matusiak, 2018) 
and age, body mass index (BMI) and sex (Kurek et al., 2012; Kurek et al., 2013). Five 
studies compared participants with HS with participants with other skin diseases. Two 
compared HS directly with psoriasis (Kluger, Sintonen, Ranta & Serlachius, 2018; Storer, 
Danesh, Sandhu, Pascoe & Kimball, 2018), whilst three used comparisons with cohorts 
that included various skin conditions (Balieva et al., 2017; Balieva et al., 2018; Onderdijk 
et al., 2013). 
 
3.3 Measures Used to Assess Prevalence and Associated Factors 
Table 2 outlines the tools used to measure anxiety, depression, quality of life and 
other factors that were assessed for associations. 
 
3.3.1 Anxiety 
Anxiety was assessed in three studies (Kouris et al., 2016; Kurek et al., 2013; 
Pavon Blanco et al., 2018). Measures of anxiety included the Generalised Anxiety 
Disorder 2-item (GAD-2; Kroenke, Spitzer, Williams, Monahan & Löwe, 2007) and the 





Depression was assessed in eight studies. Measures included the HADS in two 
studies (Kouris et al., 2016; Kurek et al., 2013), the Major Depression Inventory (MDI; 
Bech & Wermuth, 1998) in two studies (Onderdijk et al., 2013; Theut Riis et al., 2019), 
the Beck Depression Inventory-21 item (BDI-21; Beck et al., 1961) in another two studies 
(Kluger et al., 2017; Kluger et al., 2018), the BDI-Short Form (BDI-SF; Groth-Marnat, 
1990) used in Matusiak et al. (2010), and finally the Patient Health Questionnaire-2 
(PHQ2; Kroenke, Spitzer & Williams, 2003) used in Pavon Blanco et al. (2018). 
 
3.3.3 Quality of Life 
Quality of life was assessed in 21 of the studies. Measures included the DLQI 
(Finlay & Khan, 1994) in 19 studies (90%) and the Euro Quality Visual Analogue Scale 
(EQ-VAS; EuroQol Group, 1990) in two studies. A modified DLQI (six questions), the 
Skindex-29 (Chren et al., 1997), the Hidradenitis Suppurativa Impact Assessment (HSIA; 
Kimball et al., 2018), the Euro Quality of Life Health Outcome Measure (EQ5D; EuroQol 
Group, 1990), the Short Form 36 Version 2 health survey (SF-36v2; Ware Jr et al., 1995), 
the Short Form-12 (SF-12; Ware Jr, Kosinski & Keller, 1996), the 15D (Sintonen & 
Richardson, 1994) and a novel measure developed by the study investigators (Alavi et 
al., 2015) were included in one study each. The Time Trade-Off utility (TTO; Oppe, 
Rand-Hendriksen, Shah, Ramos-Goni & Luo, 2016) was also included in one study which 
measures years participants are willing to trade in return for skin disease-free living 
versus obesity. 
 
3.3.4 Additional Factors 
Disease severity was measured in 20 studies (87%), with several studies using 
multiple severity measures. Hurley staging (Hurley, 1989) was used in 17 studies, 
Sartorius Scores (Sartorius et al., 2003; Sartorius et al., 2009) in four studies, and the 
PGA scale (Kimball et al., 2012; Zouboulis et al.., 2015) in two studies. Other measures 
included Hidradenitis Suppurativa Index 4 (HSI4; Zouboulis et al., 2017), Hidradenitis 
Suppurativa Score (HSS; Sartorius et al., 2009), Hidradenitis Suppurativa Symptom 
Assessment (HSSA; Kimball et al., 2018), Hidradenitis Suppurativa Severity Index 
(HSSI; Grant, Gonzalez, Montgomery, Cardenas & Kerdel, 2010), International HS 
Severity Score System (IHS4; Zouboulis et al., 2017), and one study measured this using 
the average number of painful lesions. 
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Sexual functioning was measured in five studies, four of which used the 
International Index of Erectile Dysfunction (IIEF; Rosen et al., 1997) and the Female 
Sexual Function Index (FSFI; Rosen et al., 2000). The Sexual Quality of Life 
Questionnaire (SQoLM; Abraham et al., 2009), Female Sexual Distress Scale - Revised 
(FSDS-R; DeRogatis, Clayton, Lewis-D'Agostino, Wunderlich & Fu, 2008), Frankfurt 
Self-Concept Scale for Sexuality (FKKS SSEX, Deusinger, 1982) and the Arizona Sexual 
Experience Scale (ASEX; McGahuey et al., 2000) were also used amongst these studies. 
 
Pain was measured using a Visual Analogue Scale (VAS; Jensen & Karoly, 2011) 
in two studies and a numeric rating scale (1-10) in another study. Sleep (Athens Insomnia 
Scale [AIS], Soldatos, Dikeos & Paparrigopoulos, 2000; Pittsburgh Sleep Quality Index 
[PSQI], Buysse, Reynolds, Monk, Berman & Kupfer, 1989) and fatigue (Functional 
Assessment of Chronic Illness Therapy - Fatigue Scale [FACIT-F], Cella, Lai, Cahng, 
Peterman & Slavin, 2002) factors were measured. Illness perceptions (Brief Illness 
Perception Questionnaire [BIPQ], Broadbent, Petrie, Main & Weinman, 2006), odour 
severity and frequency (Likert scales), workability (Work Productivity and Activity 
Impairment-Specific Health Problem [WPAI-SHP], Reilly, Zbrozek & Dukes, 1993), 
loneliness (UCLA Loneliness Scale Version 3, Russel, 1996), C-reactive protein (blood 
drawn), and stigmatization (Evers et al. [2001] “6-Item Scale”) were also explored. 
 
3.4   Methodological Quality of Eligible Studies 
The overall quality ratings of the papers are included in Table 2 and the quality 
assessments for each paper are included in Appendix D. Three studies were rated as 
‘good’ quality, 13 were rated as ‘fair’ and seven were rated as ‘poor’. Quality issues that 
were found in these studies included lack of information on: method (two), participant 
age/gender/numbers (four), mean scores of outcome measures (two), whether potential 
confounding variables had been controlled for (nine), incorrect labelling of study design 
(three), small sample sizes (two), potential selection bias (four) and measurement bias 







3.5.1 Prevalence of Anxiety in HS 
Three studies measured the prevalence of anxiety in HS participants. Pavon 
Blanco et al. (2018) found that the mean score on the GAD-2 across participants was 
below clinical threshold for anxiety, however 27% scored equal to or above threshold. 
The mean score for anxiety in the study by Kouris et al. (2016) also indicated that 
participants with HS were in the normal range. It should be noted that their anxiety scores 
were significantly higher than healthy controls, therefore experiencing more symptoms 
of anxiety than people without HS. Kurek et al. (2013) assessed anxiety as a contributing 
factor to prevalence of depression in participants with HS, however the mean score for 
anxiety was not reported in the paper. 
 
3.5.2 Factors Associated with Anxiety 
Participant beliefs about having HS were found to be a significant factor 
associated with levels of anxiety in Pavon Blanco et al.’s (2018) study. In particular, high 
emotional response, more negative perceived consequences and lower concern about HS 
were significantly related to higher anxiety. Illness beliefs also explained the greatest 
proportion of variance in anxiety over disease severity, which did not explain further 
variance than demographic variables. However, in the study by Kouris et al. (2016) 
greater disease severity (Hurley stage III) was found to be a significant factor associated 
with higher anxiety, compared to stages I and II which did not differ significantly. 
Depression was also positively correlated with anxiety in Kurek et al.’s (2013) study. 
 
3.5.3 Prevalence of Depression in HS 
Eight studies measured the prevalence of depression in HS participants, and all 
eight found that typically participants did not meet the threshold for clinical depression 
(two of these studies present the same data – Kluger et al., 2017; Kluger, et al., 2018). 
Four of the studies compared depression rates in HS with other groups (including healthy 
controls, people with psoriasis and other dermatological diseases), of which three found 
HS participants to score significantly higher on depression scores than the controls. The 
prevalence of participants meeting clinical threshold for depression was between 35 – 
38.6% in four studies (Kluger et al., 2017; Kluger et al., 2018; Kurek et al., 2013; 
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Mean age (SD / range 
if available) 
Gender 
Agut-Busquet et al. 
(2018), Journal of 
Dermatology 






NA Nape: 36.24, range: 23 
- 66.  
Non-nape: 36.83, 
range: 10 - 79 
(this was not available 
in the journal article 
therefore authors were 
contacted) 
Nape: F: 10%. M: 
90%.  
Non-nape: F: 
45.4%. M: 54.6% 
Alavi et al. (2015), 




Adults in HS community 
clinics (Canada) 
55 NA 39 (range: 21 - 69) F: 69%. M: 31% 
Alavi, Farzanfar, Lee 
& Almutairi (2018a), 
Journal of Cutaneous 
Medicine and Surgery 
Cross-sectional Adults with HS in a 
hospital and community 
clinic (Canada) 
51 NA 32.5 (SD: 10.76) F: 71%. M: 29% 




Cross-sectional Adults with HS in a 
hospital and community 
clinic & healthy controls 
matched for age & sex 
(Canada) 
50 50 HS: 35.98 (SD: 13.62). 
Control: 39.80 (SD: 
11.80) 
HS: F: 66%. M: 
34%.  
Control: F: 56%. 
M: 44%. 
Balieva et al. (2017), 
British Journal of 
Dermatology 
Cross-sectional Adults in dermatological 
outpatient clinics & healthy 
controls (workers without 







Total participants with 
skin disease: 47.1 (SD: 
18.0). HS: 40.3 (SD: 
12.2). Control: 41.1 
(SD: 13.6) 
Total participants 
with skin disease: 
F: 56.3%. M: 
43.7%.  
HS: F: 79.2%. M: 
20.8%.  
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Control: F: 66.6%. 
M: 33.4% 
*Balieva et al. (2018), 
Acta Dermato-
Venereologica 
Cross-sectional Adults in dermatological 
outpatient clinics & 








Total participants with 
skin disease: 47.1 (SD: 
18.0). HS: 40.3 (SD: 
12.2). Control: 41.1 
(SD: 13.6) 
(this was not available 
in the journal article 
therefore authors were 
contacted) 
Total participants 
with skin disease: 
F: 56.3%. M: 
43.7%.  
HS: F: 79.2%. M: 
20.8%.  
Control: F: 66.6%. 
M: 33.4% 
(this was not 




Calao et al. (2018), 
PLOS ONE 
Cross-sectional Adults in HS clinics 
(Australia) 
117 NA 39.4 (SD: 13.8, range: 
18.1 - 71.8) 
F: 66.7%. M: 
33.3% 
Janse et al. (2017), 
British Journal of 
Dermatology 
Cross-sectional Adults with HS in 
dermatological clinics and a 
hospital (Holland) 
300 NA 44.6 (SD: 12.1) –
calculated from gender 
numbers presented in 
the paper. 
F: 78%. M: 22% 
Kaaz et al. (2018), 
Acta Dermato-
Venereologica 
Cross-sectional People with HS in a 
hospital & age/sex-matched 
healthy controls (Poland) 
108 50 HS: 36.3 (SD: 12.1, 
range: 15 - 67). 
Control: 40.4 (SD: 9.1, 
range: 23 - 57) 
HS: F: 47%. M: 
53%.  
Control: F: 50%. 
M: 50% 





People with HS in a 
hospital (Greece) 
152 NA 37.4 (SD: 13.5, 
median: 37, range: 13 - 
96) 
F: 60.5%. M: 
39.5% 




Cross-sectional Adults with HS in a 
hospital (Finland) 
26 NA 44.2 (SD: 15.5) F: 61.5%. M: 
38.5% 
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*Kluger et al. (2018), 
Skin Appendage 
Disorders 
Cross-sectional Adults with HS, age 
standardised general 
population & people with 









HS: 44.2 (SD: 15.5) F: 61.5%. M: 
38.5% 
Kouris et al. (2016), 
Dermatology 
Cross-sectional People with HS & healthy 
controls (Greece) 
94 94 HS: 34.55 (SD: 10.30). 
Controls: 34.96 (SD: 
10.42) 
HS: F: 54%. M: 
46%.  
Control: F: 53%. 
M: 47% 







Adults with HS in a 
hospital & age/sex/BMI-
matched healthy controls - 
matched pairs (Germany) 
44 41 HS: 34.3 (SD: 10.7, 
range 18 - 59). 
Control: 37.1 (SD: 
11.0, range: 10 - 59) 
HS: F: 55%. M: 
45%.  
Control: F: 51%. 
M: 49% 
*Kurek et al. (2013), 





Adults with HS in a 
hospital & age/sex/BMI-
matched healthy controls - 
matched pairs (Germany) 
44 41 HS: 34.3 (SD: 10.7, 
range 18 - 59). 
Control: 37.1 (SD: 
11.0, range: 10 - 59) 
HS: F: 55%. M: 
45%.  
Control: F: 51%. 
M: 49% 
Matusiak et al. (2010), 
Acta Dermato-
Venereologica 
Cross-sectional People with HS in a 
hospital (Poland) 
54 NA 39.94 (SD: 11.63, 
range: 16 - 65) 
F: 52%. M: 48% 
Onderdijk et al. 
(2013), Journal of the 
European Academy of 
Dermatology and 
Venereology 
Cross-sectional People with HS in 2 
hospitals & other 
dermatological outpatients 
as controls (Denmark & the 
Netherlands) 
211 233 HS: 43 (SD: 11.8, 
range: 16 - 70). 
Control: 42 (SD: 13.5, 
range: 9 - 77) 
F: 77%. M: 23% 
Pavon Blanco et al. 
(2018), British Journal 
of Dermatology 
Cross-sectional Adults in a HS tertiary 
clinic (England) 
211 NA 38.2 (SD: 11.8, range: 
17 - 71) 
F: 60%. M: 40% 
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Rondags et al. (2019), 
British Journal of 
Dermatology 
Cross-sectional Adults with HS from 2 
tertiary referral centres 
(Netherlands) 
433 NA 39 (SD: 12.4) F: 72.3%. M: 
27.7% 
Sartorius et al. (2009), 
British Journal of 
Dermatology 
Cross-sectional People with HS in 




NA 37.5 (SD: 11.4, range: 
14 - 67) 
F: 86%. M: 14% 




Cross-sectional Adults with HS and adults 
with psoriasis in a hospital 
(US) 
32 47 HS: 34 (SD: 11). 
psoriasis: 51 (SD: 16) 
HS: F: 72%. M: 
28%.  
psoriasis: F: 45%. 
M: 55% 
Theut Riis et al. 
(2019), British Journal 
of Dermatology 
Cross-sectional People with HS 
participating in nationwide 
Danish Blood Donor Study 
(Denmark) 
500 27265 HS: 36.57 (SD: 11.32). 
None-HS: 41.30 (SD: 
12.80) 
HS: F: 49.8%. M: 
50.2%.  
Non-HS: F: 45.7%. 
M: 54.3% 
von der Werth & 
Jemec (2001), British 
Journal of 
Dermatology 
Cross-sectional Adult with HS in 4 
hospitals (UK & Denmark) 
114 NA 40.9 (SD: 11.7, range: 
20 - 76) 
F: 86%. M: 14% 














Table 2.  
Study Findings 





Romani, Ribera & 
Luelmo (2018) 
Disease severity: Hurley staging, Sartorius 
Score, Hidradenitis Suppurativa Index 4 
(HSI4), Physician Global Assessment 
(PGA) scale. QoL: Dermatology Quality of 
Life Index (DLQI) 
Nape: very large impact on QoL (Mean 
DLQI: 14.53 ± 7.17). Non-nape: moderate 
impact on QoL (Mean DLQI: 10.72 ± 
7.18). Overall DLQI mean: 11.02 ± 7.18 
(not available in journal article - this was 
calculated from the two sample means). 
 
Nape involvement Fair 
Alavi, Anooshirvani, 
Kim, Coutts & 
Sibbald (2015) 
Disease severity: Hurley staging. QoL: 
DLQI, Short Form 36 Version 2 (SF-36v2) 
health survey (physical and mental 
component scores), and a questionnaire 
designed by investigators (age, time to 
diagnosis, duration of first symptom, no. of 
lesions, no. of episodes, QoL (mild, 
moderate, severe). Sexual functioning: 
IIEF, FSFI, FSDS-R. 
Moderate impact on QoL. Mean DLQI: 10 
± 8.8.  
 
SF-36v2 scores: significantly lower than 
normal. PCS: 45 ± 10.6. MCS: 47 ± 11.5. 
Disease severity, number 
of lesions 
Fair 
Alavi et al. (2018a) Disease severity: Hurley staging, Sartorius 
System, PGA. QoL: DLQI, Skindex-29. 
Odour severity/frequency: Likert scales (0 
- 10 & 0 - 4). 
Mean DLQI: very large impact (15.10 ± 
1.64). Mean Skindex-29: severe impact 
(65.33 ± 17.80) 
Odour severity (on 
Skindex-29), gender (on 
DLQI) 
Fair 
Alavi et al. (2018b) Disease severity: Hurley staging. QoL: 
DLQI. Sexual functioning: Sexual Quality 
of Life Questionnaire (SQoLM), 
International Index of Erectile Dysfunction 
(IIEF), Female Sexual Function Index 
(FSFI), Female Sexual Distress Scale - 
Revised (FSDS-R). 
Very large impact on QoL. Mean DLQI: 
17.63 ± 6.62 (unclear in journal article 
therefore authors were contacted).  
 
Mean DLQI completed by 46 controls: 
4.98 ± 5.59 (this was not available in the 
journal article therefore authors were 
contacted). 
Disease severity, sexual 





Significantly lower QoL than controls (p < 
.0001) 
Balieva et al. (2017) QoL: Euro Quality Visual Analogue Scale 
(EQ-VAS: 0 - 100, worst-best health state), 
Euro Quality of Life Health Outcome 
Measure (EQ5D: -0.594 – 1 (full health)) 
HS had severely reduced HRQoL - lowest 
self-reported health (Mean EQ-VAS: 56.9 
± 20.7). Significantly lower than controls 
(Mean EQ-VAS: 82.2 ± 15.5). Mean EQ-
VAS of total participants with skin disease: 
69.9 ± 19.7. 
NR Fair 
Balieva et al. (2018) QoL: DLQI Very large impact on QoL: Mean DLQI: 
12.7 ± 7.6 for 46 HS participants. Mean 
DLQI of total participants with skin 
disease: 6.7 ± 6.8 (moderately impaired). 
Mean DLQI for naevi (controls): 1.52 ± 
2.9 (no impact) 
NR Fair 
Calao et al. (2018) Disease severity: Hurley staging. QoL: 
DLQI. 
Very large effect on QoL. Mean DLQI: 
11.8 ± 8.1. 49.6% had a very large or 
extremely large impact on QoL. 
NR Fair 
Janse et al. (2017) Disease severity: Hurley staging, PGA, 
pain score on VAS. QoL: DLQI. Sexual 
Health: FSFI, IIEF, Arizona Sexual 
Experience Scale (ASEX). 
Very large effect on QoL. Mean DLQI: 
12.5 ± 7.5. 
Disease severity and 
activity, pain, sexual 
functioning in women, 
anogenital involvement, 
early onset of HS 
Poor 
Kaaz et al. (2018) Disease severity: Hidradenitis Suppurativa 
Score (HSS), Hidradenitis Suppurativa 
Severity Index (HSSI), Hurley staging. 
QoL: DLQI. Pain: VAS (current & most 
intense experienced). Sleep: Athens 
Insomnia Scale (AIS), Pittsburgh Sleep 
Quality Index (PSQI). 
Very large effect on QoL. Mean DLQI: 
13.0 ± 8.0. 
 
DLQI score for controls not available. 
Sleep quality Fair 
Katoulis et al. (2017) Disease severity: Hurley staging. QoL: 
DLQI. 
Very large effect on QoL. Mean DLQI: 
11.9 ± 7.7. 
Disease severity Fair 
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Kluger et al. (2017) Disease severity: Hurley staging, 
Hidradenitis Suppurativa Symptom 
Assessment (HSSA). Depression: Beck 
Depression Inventory-21 item (BDI-21). 
QoL: DLQI, Hidradenitis Suppurativa 
Impact Assessment (HSIA). Impact on 
workability: Work Productivity and 
Activity Impairment-Specific Health 
Problem (WPAI-SHP) 
Moderate effect on QoL: Mean DLQI: 
8.31. 
 
Mean BDI-21 score: 10.69 ± 10.13 (normal 
range). 38.5% met clinical threshold. 
Disease severity, gender, 
BDI score. 
Good 
Kluger et al. (2018) Disease severity: Hurley staging. QoL: 
DLQI, The 15D. Depression: BDI-21. 
Moderate effect on QoL: Mean DLQI: 8.31 
± 7.39. No comparison group data. 
 
Mean 15D: 0.882 ± 0.083 (clinically 
important). Statistically and clinically 
significantly lower than general population 
(0.935 ± 0.071). Lower than participants 
with psoriasis: 0.900 ± 0.117 (non-
significant difference).  
 
Mean BDI-21: 10.69 ± 10.13 (normal 
range).  No comparison group data. 
Gender, depression and 
DLQI score. 
Fair 
Kouris et al. (2016) Disease severity: Hurley staging. QoL: 
DLQI. Anxiety & Depression: The 
Hospital Anxiety and Depression Scale 
(HADS). Loneliness: UCLA Loneliness 
Scale (Version 3).  
Very large effect on QoL: Mean DLQI: 
11.43 ± 6.61. No DQLI score for controls. 
 
Anxiety in normal range: Mean HADS: 
6.41 ± 3.31. Controls: 5.00 ±1.59. 
Depression in normal range: Mean HADS: 
5.45 ± 2.79. Controls: 4.16 ± 1.54. 
Statistically significantly higher anxiety 
and depression than controls. 
QoL: gender, loneliness, 
depression, anxiety 
 
Depression and anxiety: 
disease severity 
Poor 
Kurek et al. (2012) Disease severity: Sartorius Score. QoL: 
DLQI. Sexual function: FSFI, Frankfurt 
Very large effect on QoL Mean DLQI: 
12.2 ± 7.0. No DQLI score for controls. 
Sexual functioning (for 




Self-Concept Scale for Sexuality (FKKS 
SSEX), IIEF. 
Kurek et al. (2013) Disease severity: Sartorius score. Sexual 
function: FKKS SSEX. Anxiety and 
depression: HADS. C-reactive protein: 
blood drawn. 
Depression in normal range: Mean HADS: 
6.4 ± 0.6. Statistically significantly higher 
than controls (2.6 ± 0.4). About 38.6 % (n 
= 17) met threshold for depression 
(compared to 2.4 %, n = 1 of controls) 
Disease severity, anxiety, 
sexual distress, C-reactive 
protein levels 
Good 
Matusiak et al. 
(2010) 
Disease severity: Hurley staging. QoL: 
DLQI (also using Global Question 
indexing), Quality of Life Enjoyment and 
Satisfaction Questionnaire Short Form (Q-
LES-Q-SF, 0 - 100%), EQ-5D, EQ-VAS. 
Depression: BDI Short Form (BDI-SF). 
Fatigue: Functional Assessment of Chronic 
Illness Therapy - Fatigue Scale (FACIT-F). 
Stigmatization level: Evers et al. “6-Item 
Scale”. 
Very large effect on QoL: Mean DLQI: 
12.67 ± 7.7. 
EQ-5D: 0.66 ± 0.23. EQ-VAS: 56.78 ± 
18.84.  
Q-LES-Q-SF: 56.44 ± 15.17% 
 
Depression in normal range. Mean BDI-
SF: 5.87 ± 4.68. 21% of results suggested 
co-existence of depression (BDI ≥ 10). 
QoL: location and no. of 
lesions, fatigue, disease 
severity, stigmatization 
level, age of onset 
 
Depression: age of onset, 
location of lesions, disease 
severity 
Poor 
Onderdijk et al. 
(2013) 
Disease severity: Hurley staging. QoL: 
DLQI. Depression: Major Depression 
Inventory (MDI): depression rating 
scale/MDI score (³ 20 indicates 
depression) and diagnostic score. Pain & 
itch: Numeric Rating Scales (0 - 10). 
Moderate effect on QoL: Mean DLQI: 8.4 
± 7.5. Statistically significantly higher than 
participants with other dermatological 
conditions (4.3 ± 5.6). 
 
Mean MDI: 11.0 (significantly higher than 
participants with other dermatological 
conditions: 7.2). Clinically defined 
depression rate: 9% (n = 19) - not 
significantly higher than participants with 
other dermatological conditions (6%). 
MDI score (not diagnostic 
score) for HS & controls: 
days with lesions in past 
month, pain, itch, sick-
days due to skin disease in 
last 3 months, Hurley 
classification (HS only), 
number of flares in past 
month (HS only) 
 
QoL for HS & controls: 
MDI score, pain, itchiness, 
sick-days in last 3 months, 
number of flares in past 
month (HS only), Hurley 
classification (HS only) 
Fair 
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Pavon Blanco et al. 
(2018) 
Disease severity: Hurley staging. 
Depression: Patient Health Questionnaire-
2 (PHQ-2). Anxiety: Generalised Anxiety 
Disorder 2-item (GAD-2). QoL: DLQI. 
Illness Perceptions: Brief Illness 
Perception Questionnaire (BIPQ). 
Very large effect on QoL. Mean DLQI: 
14.81 ± 8.45. 
 
Mean anxiety and depression scores below 
clinical threshold. GAD-2: 1.88 ± 1.86, 
27% met threshold. PHQ-2: 2.12 ± 1.88, 
35% met threshold.  
Illness perceptions, disease 
severity 
Good 
Rondags et al. 
(2019) 
Disease severity: Hurley staging, 
International HS Severity Score System. 
QoL: DLQI. 
Moderate effect on QoL: Mean DLQI: 10.0 
(5.0-16.0). No SD available. 
Disease severity Poor 
Sartorius et al. 
(2009) 
Disease severity: Hurley staging, VAS 
(pain) and additional clinical details to give 
an overall HS score. QoL: DLQI. 
 
Moderate effect on QoL: Mean DLQI: 10.3 
± 7.5. 
Disease severity Poor 
Storer et al. (2018)* Disease severity: Hurley staging, psoriasis 
Area Severity index (PASI). QoL: Time 
Trade-Off (TTO) utility - years willing to 
trade in return for skin disease-free living 
versus obesity, DLQI (modified 6-question 
version). 
Participants with HS who are obese 
significantly poorer QoL than participants 
with psoriasis who are obese in social 
interactions, clothing choice, leisure 
activities, ability to work/study. Skin 
disease had greater impact on QoL than 
obesity. 
 
TTO: HS more distressed and willing to 
trade significantly more years of life (7.4 / 
20 year & 16 / 50 years) than those with 
psoriasis (3.2 years & 9.1 / 50 years). 
Obesity Poor 
Theut Riis et al. 
(2019)** 
Depression: MDI. QoL: Short Form-12 
(SF-12: physical and mental component 
scores). 
MDI: Significantly less HS in no 
depression range (94.5%) than non-HS 
(97.4%). Significantly more HS in 
moderate depression range (3.2%) than 
non-HS (0.7%). HS increased MDI by 




SF-12: No significant difference in PCS 
and MCS medians between groups (HS: 
56.56 7 54.96, non-HS: 56.58 & 55.51). 
No significant effect of HS on PCS and 
MCS after adjusting for sex, age, BMI and 
smoking. 
von der Werth & 
Jemec (2001)*** 
Disease severity: average no. of painful 
lesions. QoL: DLQI 
Moderate effect on QoL: Mean DLQI: 8.9 
± 8.3. 
Age at onset, number of 
lesions per month 
Poor 
* A modified version of the DLQI was used (not a validated measure). 
** HS was not formally diagnosed by a clinician in the study - a measure was used that was developed and validated by HS physicians (Vinding 
et al., 2013) 
*** Disease severity was assessed by participants counting the number of lesions (not a validated measure of HS severity)
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Pavon Blanco et al., 2018), 21% in Matusiak et al.’s (2010) study, 9% in 
Onderdijk et al.’s (2013) study and 5.5% in the study by Theut Riis et al. (2019). In 
Onderdijk et al.’s (2013) study mean MDI scores were significantly higher for HS than 
other skin disorders, however the number of people with HS who met clinical threshold 
was not significantly higher than other skin diseases. Theut Riis et al. (2019) found that 
there were significantly more people with HS in the moderate depression range than the 
non-HS group and significantly less in the no depression range. In the studies by Kluger 
et al. (2017) and Kluger et al. (2018) six people with HS were in the mild depression 
range, two were in the moderate range and two were in the severe range. 
 
3.5.4 Factors Associated with Depression 
Disease severity was found to be a factor significantly associated with higher 
levels of depression in four of the studies. In three of these studies this was measured 
using Hurley staging and the other used Sartorius scoring. Pavon Blanco et al. (2018) 
found that Hurley staging accounted for a higher amount of variance in depressive 
symptoms than demographic variables, and Kouris et al. (2016) found that people with 
Hurley Stage III experienced higher levels of depression than people at stage I and II (no 
significant difference between these two stages). Onderdijk et al. (2013) also found that 
Hurley classification positively correlated with depression scores, in addition to the 
number of flares in the last month. They also indicated that both people with HS and other 
dermatological diseases scored higher on depression measures when experiencing itch, 
more days with lesions in the past month, sick-days and pain due to their condition in the 
past 3 months (Onderdijk et al., 2013). In contrast to these findings, Kluger et al. (2017) 
and Kluger et al. (2018) reported that Hurley staging, the number of areas affected by HS 
and duration of HS were not significantly correlated with depression. Kurek et al. (2013) 
also found HS duration to be non-significantly associated with the degree of depression. 
 
Pavon Blanco et al. (2018) reported that although disease severity explained a 
significant amount of variance in depression scores, illness beliefs explained a greater 
amount of variance than disease severity. Specifically, these beliefs related to HS being 
associated with severe consequences and lower treatment control. 
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Female gender was found to be significantly associated with higher depression 
scores in the studies by Kluger et al. (2017) and Kluger et al. (2018), with 90% of the HS 
participants who met clinical threshold for depression being women. However, Kouris et 
al. (2016) found gender not to be significantly correlated. Other factors that were found 
to be significantly related to depression included later age of onset, poorer quality of life, 
higher anxiety, more sexual distress and higher C-reactive-protein levels. Age, age at HS 
diagnosis, comorbidities and number of comorbidities were not significantly related with 
depression. 
 
3.5.5 Prevalence of Poor Quality of Life in HS 
Twenty-two studies measured quality of life in people with HS, and in 19 of these 
the Dermatology Quality of Life Index (DLQI) was used to assess this. Seven of these 
studies found that the mean DLQI for people with HS was between 6 - 10 indicating that 
HS had a moderate impact on participant’s quality of life. The remaining 12 studies found 
that the mean DLQI scores fell within 11 - 20 indicating that HS had a very large effect 
on the participants’ lives. Figure 2 displays the 19 DLQI mean scores in relation to their 
methodological quality rating, in order to establish where the true value of quality of life 
in HS may lie. Kluger et al.’s (2018) mean DLQI is also displayed despite this being 
replicated from their previous study as both studies have different quality ratings. An 
overall mean DLQI score was calculated from the mean DLQI scores of both HS groups 
in Agut-Busquet et al.’s (2018) study as this was not available in the published article. 
The bar chart indicates that the majority of the fair quality studies found that HS typically 
had a very large impact on quality of life, which was also reflected in the poor quality 
studies. The two studies rated as good in methodological quality were split between 
moderate and a very large impact on quality of life. The consistency across varying study 
quality suggests that the true value of the impact of HS on quality of life is very large. It 
is also evident that the standard deviations were relatively large across 16 of the studies 
(this information was not available for one study), indicating the variability in the quality 
of life ratings within the samples. This variability may impact generalisability of the mean 
scores, however it may also indicate a true reflection of the wide-ranging impact of HS 




Figure 2.  
Bar Chart of Mean DLQI Scores and Standard Deviations Across 19 Study Cohorts and 




Alavi et al. (2018b) used the DLQI and the Skindex-29; the Skindex-29 
indicated a severe impact of HS on quality of life (the highest category) whereas the 
DLQI indicated a very large impact (the maximum DLQI range is ‘extremely large 
impact’). The EQ-5D & EQ-VAS were used in two studies (Balieva et al., 2017; 
Matusiak et al., 2010). The EQ-VAS uses a 0 - 100 scale for worst-best health state, and 
in each study the mean rating for participants with HS was 56.9 and 56.78. The EQ-5D 
is rated from -0.594 (worst QoL) to 1 (full health), and in Matusiak et al.’s (2010) study 
the mean score was 0.66. A total index was not calculated in Balieva et al.’s (2017) 
study however it was found that the HS group was highest in the pain/discomfort 
category and had a five- and six-fold increased risk of impaired self-care and mobility / 
engaging in usual activities respectively. The Q-LES-Q-SF (Endicott, Nee, Harrison & 
Blumenthal, 1993) was also used in this study which is reported as a percentage with 
higher percentages indicating greater enjoyment and satisfaction. The overall percentage 
in quality of life was 56.44. The SF-36V1 was used by Alavi et al. (2015) and indicated 
that people with HS were scoring significantly lower than normal on mental and 
physical health indexes, specifically in areas of general health, pain, social functioning 
and the impact of emotional difficulties on the quality of activities such as work and 


































Four studies compared HS participants to healthy controls. Two of these studies 
(Alavi et al. 2018b; Balieva et al., 2018) that used the DLQI found that participants with 
HS had significantly poorer quality of life (very large impact) than healthy controls (small 
and no impact). Moreover, Balieva et al. (2017) used the EQ-VAS and found that the HS 
group reported significantly lower quality of life than healthy controls. Theut Riis et al. 
(2019) used the SF-12 and found that although HS participants rated their mental health 
as lower than the healthy controls there was no overall significant difference in quality of 
life between the two groups. Overall, three out of four studies found people with HS to 
have poorer quality of life than healthy participants. One study (Kluger et al. 2018) 
compared HS to the general population. This study used the 15D to measure quality of 
life which provides an overall score of health-related quality of life on a scale of 0 (dead) 
– 1 (full health). HS participants’ quality of life was in the clinical range (0.882), and was 
also found to be significantly poorer than that in the general population (0.935). 
 
Five studies compared HS to other dermatological diseases. Three studies found 
that people with HS had poorer quality of life scores, compared to participants with other 
skin diseases (Balieva et al., 2017; Balieva et al., 2018; Onderdijk et al., 2013). Balieva 
et al. (2017) reported HS as scoring the lowest self-reported health out of all the skin 
diseases measured and the third lowest on the EQ-VAS. Two studies compared HS 
directly with psoriasis (Kluger et al., 2017; Storer et al., 2018). Kluger et al. (2018) found 
that people with HS scored lower (0.882) than the participants with psoriasis (0.900) on 
the 15D, however this difference was not statistically significant. Storer et al. (2018) used 
Time Trade Off and a modified 6-item version of the DLQI (not a validated measure). 
They found that people with HS were more distressed and willing to trade significantly 
more years of life (7.4 / 20 year & 16 / 50 years) than those with psoriasis (3.2 years & 
9.1 / 50 years). They also found that obese participants with HS scored significantly 
poorer on items of social interaction, clothing choice, leisure activities and ability to 
work/study than obese participants with psoriasis that were of a similar BMI. Overall, 
people with HS had poorer quality of life than people with other skin diseases in all five 
studies measuring this. 
 
3.5.6 Factors Associated with Poor Quality of Life 




Gender was found to be a significant factor associated with quality of life in five 
studies, with females reporting poorer quality of life than males on the DLQI. In the 
majority of these studies the mean DLQI for males fell within the moderate range whereas 
females fell within the very large to extremely large impact range. In Kluger et al.’s 
(2017) study the mean DLQI for males indicated a small effect on quality of life in 
contrast to females who reported a very large impact on quality of life. Despite these 
findings Alavi et al. (2018a) found that gender was associated with quality of life as 
measured by the DLQI but found no difference in gender when using the Skindex-29. 
Three other studies also reported no significant correlation between gender and quality of 
life. 
 
Four studies looked at age of participants in relation to quality of life and did not 
find a significant association (Alavi et al., 2015; Kluger et al., 2017; Kurek et al., 2012; 
von der Werth & Jemec, 2001). Matusiak et al. (2010) found no significant association 
of quality of life with level of education, place of residence and employment status, and 
Janse et al. (2017) found no association with relationship status. 
 
Psychosocial and Lifestyle Characteristics 
Psychosocial and lifestyle characteristics were significantly associated with 
quality of life in eight studies. The quality of life of participants with more negative 
beliefs about their HS was significantly more impaired than those with less negative 
beliefs about HS in Pavon Blanco et al.’s (2018) study. These illness perceptions also 
explained a greater proportion of variance in quality of life than the severity of their 
disease. Depression (four studies) and anxiety (one study) were significant factors 
associated with poorer quality of life in people with HS. Higher scores of loneliness 
(Kouris et al., 2016) and poor sleep (Kaaz et al., 2018) were also associated with poorer 
quality of life. 
 
Difficulties with sexual functioning were assessed in three studies, and the 
majority of findings indicated a significant association with poorer quality of life. These 
associations were either only in females, or higher in females than males. Alavi et al. 
(2018b), Kurek et al. (2012) and Janse et al. (2017) found a significant correlation 
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between female sexual distress and dysfunction with poorer quality of life on four 
different measures of sexual function. In Janse et al.’s study (2017) this correlation also 
remained significant after removing the sexual health question from the DLQI. Alavi et 
al. (2018b) found that female and male sexual dysfunction and distress accounted for over 
46% and 42% variance, respectively, in changes in quality of life after controlling for 
disease severity and number of lesions. No significant correlation was found between 
sexual functioning with quality of life for males. 
 
Smoking (Kluger et al., 2017; Sartorius et al., 2009), BMI (Sartorius et al., 2009) 
and alcohol consumption (Kluger et al., 2017) did not significantly relate to quality of life 
in three studies. A study by Storer et al. (2018) found that obesity was outweighed by the 
psychological burden of HS in relation to impact on quality of life. The only category 
where HS participants reported significantly poorer quality of life than psoriasis 
participants was clothing choice. Obesity and other comorbidities including diabetes type 
II, cardiovascular diseases, anxiety disorders, autoimmune and inflammatory diseases 
were not associated with quality of life in HS (Kluger et al., 2018). 
 
Clinical Characteristics of HS 
In terms of disease severity, higher Hurley staging was significantly associated 
with poorer quality of life in 10 out of 11 studies that used this tool. Higher Sartorius 
Scores were a significant factor of impaired quality of life in one out of two studies, and 
PGA was only used in one study and was also a significant factor. Findings by Matusiak 
et al. (2010) indicated that Hurley staging was the most important factor associated with 
quality of life impairment, whereas Pavon Blanco et al. (2018) found that although Hurley 
staging added a significant amount of variance in quality of life beyond demographics, 
illness perceptions explained a larger proportion.  
 
The number of lesions (measured in three studies) and number of lesions per 
month (measured in one other study) were significant factors associated with poorer 
quality of life in HS. However, location of lesions in two studies, and number of locations 
in one study were not significantly associated with quality of life. In terms of specific 
locations Alavi et al. (2018b) found that having genital lesions was not correlated with 
DLQI score, however participants with lesions in their nape area reported significantly 
higher quality of life impairment than those without nape involvement (Agut-Busquet et 
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al. 2018). Age at onset of HS was also investigated and found to be negatively correlated 
with quality of life in two studies, indicating that later age at onset was associated with 
poorer quality of life. A further two studies found that age of onset was not a significant 
factor associated with quality of life. 
 
Pain was measured in two studies and findings indicated that it was significantly 
associated with poorer quality of life in HS. Itchiness, number of flares in the past month, 
number of sick days in the past three months (Onderdijk et al., 2013), disease activity 
(Janse et al. 2017) and odour severity (Alavi et al., 2018a) were also significant factors 
relating to poorer quality of life. It should be noted that Alavi et al. (2018a) found a non-
significant association of odour severity on quality of life when using the DLQI as 
opposed to the Skindex-29, and Alavi et al. (2018b) also found that odour severity was 
not a predictor of DLQI in a regression model. Other factors that were analysed and found 
to be non-significant were the number of HS episodes, time until diagnosis, duration of 
first symptom (Alavi et al., 2015), region at onset (Kurek et al., 2012), and five studies 




The aim of this review was to systematically explore existing research regarding 
the prevalence of anxiety, depression and poor quality of life in HS and factors associated 
with this. It is hoped that this will inform future research and provide implications for 
clinical practice in HS.  
 
4.1   Prevalence of Anxiety and Associated Factors in People with HS  
The literature that explored anxiety in HS and met the inclusion criteria was 
limited (three studies), as also found in Machado et al.’s (2019) systematic review. 
Overall, people with HS did not typically meet threshold for clinical or clinically 
significant anxiety (Kouris et al., 2016; Pavon Blanco et al., 2018), although a 27% 
prevalence rate was found in Pavon Blanco et al.’s (2018) study, which is higher than 
other recent research (Huilaja et al., 2018; Machado et al., 2019). Anxiety symptoms were 
more prevalent than healthy controls in Kouris et al.’s (2016) study, however this study 
was rated as methodologically poor due to insufficient information provided about the 
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recruitment process and analysis. It was therefore not possible to determine risk of bias. 
The findings from these two studies are in line with research by Machado et al. (2019) 
and Huilaja et al. (2018) that indicated higher prevalence rates than the global population 
in 2015 (WHO, 2017) and healthy controls, however Pavon Blanco et al. (2018) 
demonstrated a substantially larger prevalence rate. Kurek et al. (2013) did not include 
the HADS score for anxiety in their article, only the correlation with other factors, 
therefore it was not possible to establish a clear prevalence rate.  
 
Factors that were associated with higher anxiety within these studies were 
symptoms of depression, more negative illness beliefs about HS, and HS severity being 
at Hurley stage III. The appearance (scarring and abscesses) and malodour of HS can 
negatively impact on body image, which may promote worry about others may perceive 
symptoms and attempts to hide them. This may explain findings that high disease severity 
was a factor in anxiety, as more areas of HS and stronger symptoms would make this 
more difficult for people to conceal. Shavit et al. (2015) also reported that increasing risk 
of accidentally exposing scars or odours relating to HS can contribute to anxiety. The 
severity of these symptoms and fear around how they may be perceived can also lead to 
more sick days (Alikhan et al., 2009), consequentially creating financial strains (Deckers 
& Kimball, 2016), thus contributing further to levels of anxiety.  
 
Pavon Blanco et al. (2018) also demonstrated that negative illness perceptions 
about HS were more strongly associated with anxiety than disease severity. People who 
had a higher emotional response and more beliefs about negative consequences of HS 
had higher levels of anxiety independent of how severe their illness was. This is important 
to consider as it highlights that a clinical measure of HS by medical staff may not be 
representative of how patients see their illness and the impact it has on their mental health. 
Research into other skin diseases has discussed similar findings; Jowett and Ryan (1985) 
suggested that even when disease in is in remission, unpredictability of symptoms and 
prognosis are strong factors in the development of anxiety. 
 
It is difficult to draw conclusions about the prevalence of anxiety in HS from this 
review due to the limited research available, however it is clear that negative beliefs about 
HS, disease severity and depression are factors to consider in relation to anxiety. 
 
 39 
4.2   Prevalence of Depression and Associated Factors in People with HS 
Depression in HS was another area that was limited in the literature (eight studies). 
Overall, participants with HS did not typically meet clinical thresholds for depression 
across these studies; in six of these articles prevalence of clinical depression rates ranged 
from 5.5% to 38.6%. Four of these studies had prevalence rates over 35%. This is higher 
than the overall prevalence found by Machado et al. (2019). Three out of four studies also 
found that people with HS had higher depression scores than healthy controls. Overall, 
prevalence rates that were reported indicated a maximum of 38.6% prevalence of 
depression which was higher than the prevalence of anxiety, and people with HS 
experienced significantly more symptoms of depression than healthy controls. This 
prevalence rate is in line with previous research by WHO (2017) and Lim et al. (2019) 
demonstrating the prevalence of depression in the general population as 4.4% and 12.9% 
respectively. Although prevalence of depression in HS was higher than in other 
dermatological diseases, this difference was not significant. 
 
There were various factors that were associated with prevalence of depression in 
participants with HS. In line with factors associated with anxiety, negative illness beliefs 
about HS (specifically about HS having adverse consequences) was a factor, and higher 
disease severity was associated with depression in 50% of the studies. Other factors 
associated with higher scores of depression were pain, itch, the number of flares and 
lesions inthe last month, the number of sick-days due to HS in the last three months, later 
age of HS onset, poorer quality of life, sexual distress, c-reactive protein levels and female 
gender. Depression being more common in females with HS supports research by WHO 
(2017) and Shavit et al. (2015). Kouris et al. (2016) found that female gender did not 
significantly impact depression rates, however as stated previously, this study was rated 
as poor methodologically and therefore it could not be determined how this sample was 
recruited and if this impacted findings. 
 
The numerous factors that were related to depression rates in people with HS 
(some of which overlapped with factors associated with anxiety) may link to Esmann and 
Jemec’s (2011) findings of feelings of being unworthy, helpless, unattractive and having 
a lack of control over HS. These feelings can promote social isolation through avoidance 
of work and activities they used to enjoy, not talking about their disease due to 
embarrassment (Joachim & Acorn, 2000), and use of camouflage to avoid HS sites being 
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exposed. The pain and unpredictability of flares may also be a source of feelings of 
helplessness, irritation and sadness. These experiences can also impact sexual 
functioning, particularly if lesions are in anogenital regions as indicated by Matusiak et 
al. (2010).  
 
As was found with anxiety, Pavon Blanco et al. (2018) demonstrated that illness 
beliefs had a stronger association with depression than disease severity. This is in 
accordance with previous research into psoriasis (Rapp et al., 1997; Scharloo et al., 2000) 
and other long-term conditions (Dempster, Howell & McCrory, 2015), and implies that 
how people with HS perceive their health has a stronger impact on psychological distress 
than how clinically severe their HS it. 
 
4.3   Prevalence of Poor Quality of Life and Associated Factors in People with HS 
Quality of life in HS was assessed in 91% of the eligible studies, with the DLQI 
being the most frequently used measure (90% of studies). In 63% of the studies that used 
the DLQI, HS had a very large impact on quality of life, and in the remaining 37% of 
studies HS had a moderate impact. Studies using other quality of life measures also 
indicated impaired quality of life, specifically in domains of pain, social functioning, self-
care, general health, and emotional response. In studies comparing people with HS to 
healthy controls, 75% of these studies found that people with HS had a significantly 
poorer quality of life. In people with HS quality of life was also found to be poorer than 
people in the general population (Kluger et al., 2017).  
 
Studies also compared HS to a range of other dermatological diseases and found 
participants with HS to have a poorer quality of life (in one study HS was the lowest of 
multiple diseases). Similar findings were also indicated in studies directly comparing HS 
to psoriasis. People with HS reported more distress and difficulties with social interaction, 
clothing choice, leisure activities and ability to study and work than people with psoriasis. 
These findings support research suggesting quality of life can be significantly poorer in 
people with HS both in comparison to the general population and other skin disorders 
(Gooderham & Papp, 2015; Kohorst, Kimball & Davis, 2015; Wolkenstein et al., 2007). 
 
The relatively large standard deviations of DLQI scores across 16 of the studies, 
irrespective of methodological quality, indicate the wide-ranging impact of HS on quality 
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of life. This large variation in scores highlights the importance of examining factors that 
may explain the differences in how people cope with HS.  
 
Demographic factors were not consistently related to quality of life. Similar to 
findings relating to depression in HS, age was not related to quality of life, and neither 
were education, employment and relationship status. Five studies (one rated as 
methodologically poor) found that females reported HS to have a very large or extremely 
large impact on their quality of life and males reported a lower impact, however three 
studies (two rated as methodologically poor) found no difference in gender. The quality 
ratings of these studies suggest that the findings of female gender as a factor may be more 
reliable and valid, and may be explained by the higher number of lesions in the lower 
abdomen in women than in men (Jemec, Heidenheim & Nielsen, 1996). 
 
Psychosocial and lifestyle factors were found to be related to quality of life in 
36% of the studies. As was found with anxiety and depression, Pavon Blanco et al. (2018) 
found that negative illness beliefs were related to poorer quality of life and shared some 
specific domains with those that related to anxiety and depression (beliefs about adverse 
consequences, large emotional response and lower treatment control). This supports 
previous research showing the impact of beliefs about negative consequences on health 
outcomes not only in other skin conditions (Cartwright, Endean & Porter, 2009) but also 
more generally in other long-term conditions (Dempster et al, 2015). This research shows 
that negative illness perceptions give rise to poorer coping which, in turn, leads to more 
adverse psychological and physical outcomes.  For example, having more negative beliefs 
about how much their treatment can help their HS may reduce adherence to treatments 
and further impact quality of life. Higher anxiety and depression were also factors that 
directly related to poorer quality of life. This can be partly explained by vicious cycles 
maintained by negative illness beliefs, physical elements such as painful and 
malodourous lesions that may limit engagement in social activities, which can lead to 
feelings of helplessness and loneliness, and further avoidance of daily activities (Kouris 
et al., 2016).  
 
Other psychosocial and lifestyle factors that were associated with poor quality of 
life were loneliness, poor sleep and sexual dysfunction (particularly in females), which is 
in keeping with psoriasis research (Ermertcan, 2009; Kouris et al., 2015; Ljosaa, Mork, 
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Stubhaug, Moum & Wahl, 2012). Females with HS may be more at risk of sexual 
dysfunction due the higher frequency of lesions in the lower abdomen than in men (Kurek 
et al., 2012). It is not surprising that loneliness was related to poor quality of life, as 
research has also found this in the general population with significant associations with 
depression, suicidal ideation and psychosis (Michalska da Rocha, Rhodes, Vasilopoulou 
& Hutton, 2017).  
 
Although lifestyle factors such as smoking, BMI and obesity have been reported 
as risk factors influencing prognosis and severity of HS (Kromann, Ibier, Kristiansen & 
Jemec, 2014), these factors in addition to alcohol consumption were not related to poor 
quality of life. This finding is important as clinicians may target weight loss and smoking 
cessation, which can result in people with HS feeling blamed or stigmatised. It may be 
more beneficial for clinicians to target illness perceptions, loneliness, mood, anxiety, 
sexual dysfunction and sleep. 
 
Clinical characteristics that were associated with poorer quality of life included 
disease severity, number of lesions, nape involvement, pain, itchiness, number of flares 
in last month, number of sick days in last three months, active disease and odour severity. 
Several of these findings are in line with previous studies (Jemec et al., 1996; Wolkenstein 
et al. 2007) and may be explained by the physical impact of HS on ability to engage in 
daily activities such as getting dressed, playing sports and generally moving around. This 
is particularly relevant to pain, which may be exacerbated by moving around and sweating 
(Kouris et al., 2016). Pain is a priority for research from the perspective of people with 
HS and their carers (Ingram et al., 2014), and evidence suggests that psychological 
intervention in skin diseases are less effective when accompanied by pain (Lavda, Webb 
& Thompson, 2012). Therefore, an increased focus on pain management in HS is 
warranted. 
 
It is important to note that although greater disease severity was associated with 
poorer quality of life in HS, and considered the most important factor by Matusiak et al. 
(2010), negative illness beliefs accounted for more variance than disease severity in 
Pavon Blanco et al.’s (2018) study. This study by Pavon Blanco et al. (2018) was rated 
as having good methodological quality as opposed to Matusiak et al.’s (2010) study which 
was rated as poor, suggesting less risk of bias and further supporting the implications for 
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consideration of how people perceive their HS alongside clinical characteristics. 
Furthermore, the number of HS episodes, time until diagnosis, duration of first symptom, 
region at onset, and duration of HS were not significantly related to quality of life. 
 
Approximately half of the total studies looked at how duration and age of onset 
of HS related to health outcomes. Only two of four studies measuring the relationship 
between age of HS onset and quality of life found significant correlations, and both 
indicated that younger age of onset was associated with poorer quality of life. Conversely, 
one study found that older age of onset was related to higher depression scores. These 
three studies linking age of onset with outcomes were all rated as methodologically poor 
and therefore should be interpreted with caution. All studies measuring the correlation 
between HS duration and quality of life and HS duration and depression found non-
significant correlations. Furthermore, the number of HS episodes, duration of first 
symptom and region at onset were not significantly related to quality of life. The 
inconsistency of these findings of the how time that participants were exposed to HS 
related to health outcomes further indicates that clinical characteristics of HS may have 
less impact than may often be assumed. HS duration may also not always be accurately 
reported as there is frequently a delay to diagnosis, often around seven years (Revuz, 
2009). 
 
The study by Alavi et al. (2018a) demonstrated that different measures of quality of life 
can reflect contrasting findings, as has been shown in the measurement of depression 
elsewhere in the dermatology literature (Dowlatshahi et al., 2014). Studies using the 
DLQI indicated a significant difference in quality of life between males and females, 
whereas those using the Skindex-29 did not find a significant difference in quality of life 
between genders. Odour severity was a significant factor on the DLQI but non-significant 
on the Skindex-29. They also found the overall mean score for the impact of HS on quality 
of life on the DLQI was in the second highest impact category (very large impact), 
whereas the Skindex-29 was in the highest severity range (severe impact). These 
variations may be due to the different domains assessed in the DLQI compared to the 
Skindex-29, however this implies that scores on these measures should be interpreted 
with caution. There is a lack of clarity as to where the true values of overall quality of life 
and associated factors lie in this study. 
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Overall, the studies reviewed indicate that demographic, psychosocial, lifestyle and 
clinical factors are associated with poorer quality of life in HS. Sexual functioning and 
negative illness beliefs have been shown to account for more variance than disease 
severity in predicting quality of life. Similarly, a study of people with atopic dermatitis 
also found that psychological variables explained more variance in quality of life 
outcomes compared with demographic and clinical variables (Wittkowski, Richards, 
Griffiths & Main, 2004). Taken together, these findings reinforce that psychosocial 
factors should be considered in addition to clinical characteristics of HS when assessing 
quality of life. 
 
4.4 Limitations of Previous Research 
All studies that met inclusion criteria for this review were cross-sectional in 
design. This does not allow for conclusions to be drawn around causality or factors that 
may predict anxiety, depression and poorer quality of life over time. Furthermore, all 
participants were recruited from hospitals or HS clinics (apart from one study recruiting 
from blood donors) and were predominantly female, which may affect generalisability of 
findings. The fact that 87% of the studies had a majority of females is in line with statistics 
stated by Dufour et al. (2014) that the HS global prevalence is 3:1 ratio of females to 
males, however this also means that overall findings may not be applicable to males with 
HS. Risk of recruitment bias is also evident due to some samples being from 
tertiary/specialist clinics, where it is likely that HS is more severe.  
 
Disease severity was measured using Hurley staging in 70% of the studies, 
indicating its popularity as a measure. These findings, however, may not be applicable to 
future research as new more dynamic measures of HS are being used in clinical practice 
(Kimball et al., 2014), especially when considering that the current review found that 
characteristics such as ‘active disease’ and number of lesions were associated with poorer 
quality of life. Indeed, recent research has criticized the use of Hurley staging due to 
inaccuracy about inflammatory activity in HS (Kimball et al., 2016), therefore the 
findings of the existing studies may or may not accurately reflect the true role of disease 
severity in its association with psychosocial variables.  
 
This review only looked at studies that included the use of validated screening 
measures as opposed to studies only using criteria-based diagnoses of anxiety and 
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depression. Previous research has indicated differences in findings between screening 
instruments, as well as differences in findings between screening tools and use of 
diagnostic criteria (Machado et al., 2019). Therefore, the findings of this study may be 
overestimates of prevalence. 
 
Throughout the quality assessment and data extraction process a number of 
methodological issues were evident. Four authors were contacted in order to gather 
information that was unavailable in their published studies. Agut-Busquet et al. (2018) 
were contacted to clarify the mean age and age range of their participants, Balieva et al. 
(2018) were contacted to clarify the total number of HS participants, their mean age and 
gender ratio, and Alavi et al. (2018b) were contacted to establish the mean DLQI score 
for people with HS. All authors replied and provided this information and gave consent 
for its use in this review. Kouris et al. (2016) were also contacted as it was not possible 
to access their materials and methods section for their article, however a response was 
not received therefore it was not possible to assess risk of bias and analysis for their study. 
It was also not possible to establish whether confounding variables had been adjusted or 
controlled for in nine studies, thus limiting replicability and confidence in drawing 
conclusions from the findings. There were three studies that used the same study cohort 
twice (Balieva et al., 2017; Kluger et al., 2017; Kurek et al., 2012), which did not impact 
their quality rating but should be considered when drawing conclusions from these 
studies. 
 
4.5   Strengths and Limitations of the Current Review 
This systematic review is the first to summarise research on anxiety, depression 
and quality of life in HS, as well as the first to consider factors associated with these 
outcomes.  Limiting inclusion of studies to those that only use validated measures with 
overall/total scores of anxiety, depression and quality of life ensured more reliability and 
validity of findings that could be discussed more broadly than non-standardised measures 
with multiple index totals. The evidence base for psychological factors and outcomes in 
HS is minimal therefore findings can be used to inform both future areas for research but 
also clinical practice in terms of assessment and treatment. 
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There are several limitations of this review. Firstly, over half of studies used in 
this review were rated as fair in terms methodological quality and around a third of studies 
were rated as poor, therefore this review does not provide a robust summary of data. It is 
also possible that relevant information was not included in this review due to the 
exclusion of studies that were not focused on psychological outcomes, interventional 
studies, abstracts, reviews, communications and correspondence. Therefore, findings may 
not be representative of people with HS who are part of HS drug trials or more recent 
research that has not yet been published in peer reviewed journals. There were also three 
studies that were relevant but not possible to access. Stricter inclusion criteria that 
overall/total scores of outcomes were required meant that two relevant studies were 
excluded due to validated measures that were unable to be calculated as one score. A 
second independent reviewer completed the initial key search to check numbers of papers 
retrieved, assessed 20% of the full texts screened and 22% of the final eligible studies in 
terms of meeting inclusion/exclusion criteria. The second reviewer also assessed 
methodological quality of all studies and following discussion there was 100% inter-rater 
agreement between both reviewers. There is potential for subjective bias at these stages, 
particularly as the screening and eligibility stages were not completed by a second 
reviewer due to time constraints. 
 
4.6   Implications for Future Research 
Future research into HS would benefit from using longitudinal and cohort study 
designs in order to explore predictive factors of these outcomes. This will enable HS 
clinics to screen for risk factors for anxiety, depression and poorer quality of life in order 
to intervene at earlier stages. An increase in studies in to anxiety and depression in HS is 
also required due the currently limited evidence base. Due to the majority of studies 
having higher proportions of female participants, it may be useful for future research to 
also explore these outcomes in males specifically in order to establish findings that are 
more generalizable to male populations.  
 
In terms of factors associated with anxiety, depression and quality of life in HS, 
it may be useful for future studies to use more recent disease severity measures, for 
example the HS-PGA or HiSCR in order to be applicable to current clinical practice and 
disease activity. Findings from Pavon Blanco et al.’s (2018) study indicate that illness 
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beliefs are significant factor in anxiety, depression and quality of life over and above 
disease severity therefore more research into this area will be useful as this can inform 
psychological treatments in HS. Moreover, it is recommended that these studies include 
measures of coping in order to understand the ways in which illness beliefs influence 
psychological outcomes.  It was also noticed that in Janse et al.’s (2017) study that when 
measuring sexual distress, the authors controlled for question nine of the DLQI which 
related to sexual difficulties. This was not reported in the other studies assessing sexual 
functioning, therefore future research that considers sexual distress and functioning as a 
factor relating to quality of life may benefit from controlling for responses to question 
nine of the DLQI. Studies had also not controlled for pain when measuring outcomes 
which could significantly impact these outcome measures, therefore upcoming research 
may wish to consider including pain as a covariate. Furthermore, due to the lack of studies 
with good methodological quality, future research should ensure that key potential 
confounding variables, validated measures, HS severity and clear information on 
participant recruitment are included. 
 
4.7   Implications for Clinical Practice 
The results of this review indicate that anxiety, depression and quality of life 
should be routinely and regularly assessed in HS clinics, particularly as these health 
outcomes have also been shown to be associated with each other. Furthermore, the use of 
these self-reported outcomes will support clinical care pathways for people with HS to 
gain access to psychological care in addition to medical services. Findings regarding the 
factors that were associated with poorer outcomes indicate that psychosocial and lifestyle 
factors can have a significant impact on rates of anxiety, depression and poor quality of 
life. For example, assessment of illness beliefs (including greater adverse consequences, 
lower treatment control and larger emotional response) and sexual function may be 
beneficial to identify people who may be at risk of anxiety, depression and poorer quality 
of life, and to refer people with HS to psychological services if necessary. In addition to 
assessment, targeting illness perceptions and sexual function in interventions may support 
improved outcomes such as mood, anxiety and overall quality of life. In line with previous 
research (Sampogna et al., 2017), this review has demonstrated that with females in 
particular sexual dysfunction has been associated with poorer health outcomes, therefore 




Historically a larger emphasis may have been placed on clinical measurement of 
HS (e.g. disease severity and duration), however various studies have indicated that 
psychological factors such as illness beliefs, anxiety and depression may predict quality 
of life over and above disease severity. Duration of HS and age were not related to 
depression and quality of life in some studies further indicating that poorer health 
outcomes may not be linked with long-standing HS. Therefore, assumptions should not 
be made based on disease severity alone. Routine assessment of psychological and 
lifestyle factors will be important in addition to medical assessment, and in turn the 
development of interventions to improve psychological wellbeing. 
 
4.8   Conclusions 
To conclude, the results of this systematic review are consistent with past research 
stating that people with HS have higher prevalence rates of anxiety, depression and poorer 
quality of life. Although there was some variation in the findings, the prevalence rates in 
HS were found to be typically higher than controls, the general population and other skin 
diseases that were studied. For anxiety, the prevalence was found to be 27%, depression 
was mostly found to range between 35% and 38%, and quality of life was typically within 
the moderate to very large impact ranges. There were many different demographic, 
psychosocial, lifestyle and clinical factors related to these outcomes. Overall, this 
suggests that people with HS may benefit from being routinely assessed for anxiety, 
depression and poor quality of life, and also factors that may be indicate higher risk of 
these, including psychosocial and lifestyle factors (such as illness beliefs and sexual 
function), clinical factors (such as disease severity and pain), and awareness of 
demographic factors such as gender. Development of psychological interventions to 
target such factors with multidisciplinary care and support people at risk of or with poor 
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Appendix A – Search Terms 
 
EMBASE: conducted on 28/01/19, n = 606 
Second reviewer APB: conducted on 16/09/19, n = 787 
1 exp suppurative hidradenitis/ 
2 Hidradenitis Suppurativa.mp. [mp=title, abstract, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, 
keyword, floating subheading word, candidate term word] 
3 Hidradenitis.mp. [mp=title, abstract, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword, floating 
subheading word, candidate term word] 
4 Acne Inversa.mp. [mp=title, abstract, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword, floating 
subheading word, candidate term word] 
5 exp anxiety/ or exp anxiety disorder/ or exp generalized anxiety disorder/ 
6 Anx*.mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading 
word, candidate term word] 
7 (Anxiety adj disorder$).mp. [mp=title, abstract, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword, 
floating subheading word, candidate term word] 
8 exp depression/ 
9 Mood.mp. [mp=title, abstract, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword, floating 
subheading word, candidate term word] 
10 Depress*.mp. [mp=title, abstract, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword, floating 
subheading word, candidate term word] 
11 (Mood adj disorder$).mp. [mp=title, abstract, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword, 
floating subheading word, candidate term word] 
12 (Depress* adj disorder$).mp. [mp=title, abstract, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword, 
floating subheading word, candidate term word] 
13 distress.mp. [mp=title, abstract, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword, floating 
subheading word, candidate term word] 
14 exp "quality of life"/ 
15 (Quality adj2 life).mp. [mp=title, abstract, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword, floating 
subheading word, candidate term word] 
16 (Life adj quality).mp. [mp=title, abstract, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword, floating 
subheading word, candidate term word] 
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17 HRQL.mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading 
word, candidate term word] 
18 QoL.mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading 
word, candidate term word] 
19 (Well adj being).mp. [mp=title, abstract, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword, floating 
subheading word, candidate term word] 
20 Well-being.mp. [mp=title, abstract, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword, floating 
subheading word, candidate term word] 
21 Wellbeing.mp. [mp=title, abstract, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword, floating 
subheading word, candidate term word] 
22 functioning.mp. [mp=title, abstract, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword, floating 
subheading word, candidate term word] 
23 1 or 2 or 3 or 4 
24 5 or 6 or 7 
25 8 or 9 or 10 or 11 or 12 or 13 
26 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 
27 24 or 25 or 26 
28 23 and 27 
29 limit 28 to (english language and yr="1990 -Current") 
 
 
MEDLINE: conducted on 28/01/19, n = 245 
Second reviewer APB: conducted on 16/09/19, n = 298 
1 exp Hidradenitis Suppurativa/ 
2 Hidradenitis Suppurativa.mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, floating sub-heading word, keyword 
heading word, organism supplementary concept word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier, 
synonyms] 
3 Hidradenitis.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, floating sub-heading word, keyword heading word, 
organism supplementary concept word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier, synonyms] 
4 Acne Inversa.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, floating sub-heading word, keyword heading word, 
organism supplementary concept word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier, synonyms] 
5 exp ANXIETY/ or exp ANXIETY DISORDERS/ 
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6 Anx*.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, floating sub-heading word, keyword heading word, organism 
supplementary concept word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier, synonyms] 
7 (Anxiety adj disorder$).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, floating sub-heading word, keyword heading word, 
organism supplementary concept word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier, synonyms] 
8 exp DEPRESSION/ 
9 Mood.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, floating sub-heading word, keyword heading word, organism 
supplementary concept word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier, synonyms] 
10 Depress*.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, floating sub-heading word, keyword heading word, organism 
supplementary concept word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier, synonyms] 
11 (Mood adj disorder$).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, floating sub-heading word, keyword heading word, 
organism supplementary concept word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier, synonyms] 
12 (Depress* adj disorder$).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, floating sub-heading word, keyword 
heading word, organism supplementary concept word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier, 
synonyms] 
13 distress.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, floating sub-heading word, keyword heading word, organism 
supplementary concept word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier, synonyms] 
14 exp "Quality of Life"/ 
15 (Quality adj2 life).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, floating sub-heading word, keyword heading word, 
organism supplementary concept word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier, synonyms] 
16 (Life adj quality).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, floating sub-heading word, keyword heading word, 
organism supplementary concept word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier, synonyms] 
17 HRQL.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, floating sub-heading word, keyword heading word, organism 
supplementary concept word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier, synonyms] 
18 QoL.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, floating sub-heading word, keyword heading word, organism 
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supplementary concept word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier, synonyms] 
19 (Well adj being).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, floating sub-heading word, keyword heading word, 
organism supplementary concept word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier, synonyms] 
20 Well-being.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, floating sub-heading word, keyword heading word, 
organism supplementary concept word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier, synonyms] 
21 Wellbeing.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, floating sub-heading word, keyword heading word, 
organism supplementary concept word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier, synonyms] 
22 functioning.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, floating sub-heading word, keyword heading word, 
organism supplementary concept word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier, synonyms] 
23 1 or 2 or 3 or 4 
24 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 
20 or 21 or 22 
25 23 and 24 
26 limit 25 to (english language and yr="1990 -Current") 
 
 
PsychInfo: conducted on 28/01/19, n = 6 
Second reviewer APB: conducted on 12/09/19, n = 6 
1. Hidradenitis Suppurativa.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures]  
2. Hidradenitis.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures]  
3. Acne Inversa.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures]  
4. exp ANXIETY DISORDERS/ or exp ANXIETY/ or exp GENERALIZED ANXIETY DISORDER/  
5. anx*.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures]  
6. (Anxiety adj disorder$).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures]  
7. exp MAJOR DEPRESSION/ or exp "DEPRESSION (EMOTION)"/  
8. Mood.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures]  
9. Depress*.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures]  
 69 
10. (Mood adj disorder$).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures]  
11. (Depress* adj disorder$).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures]  
12. distress.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures]  
13. exp "Quality of Life"/  
14. (Quality adj2 life).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures]  
15. (Life adj quality).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures]  
16. HRQL.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures]  
17. QoL.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures]  
18. (Well adj being).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures]  
19. Well-being.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures]  
20. Wellbeing.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures]  
21. functioning.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures]  
22. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21  
23. 1 or 2 or 3  
24. 22 and 23  
25. limit 24 to (english language and yr="1990 -Current") 
 
 
PubMed: conducted on 28/01/19, n = 671 







"Depressive Disorder, Major" 
"Quality of Life" 
 
Search 
Search (((("Hidradenitis Suppurativa") OR Hidradenit*) OR "Acne Inversa")) AND 
((((((Anxiety) OR "Anxiety Disorders") OR Anx*)) OR (((((("Depressive Disorder") 
OR "Depression") OR "Depressive Disorder, Major") OR mood) OR depress*) OR 
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distress)) OR ((((((("Quality of Life") OR HRQL) OR QOL) OR Wellbeing) OR Well-
being) OR "Well being") OR functioning))  
Filters: Publication date from 1990/01/01 to 2019/12/31; English 
 
 
CINAHL: conducted on 16/02/19, n = 66 
Second reviewer APB: conducted on 16/09/19, n = 84 
# Query Limiters/Expanders 
S13 S9 AND S10 




Search modes - 
Boolean/Phrase 
S12 S9 AND S10 
Limiters - English 
Language  
Search modes - 
Boolean/Phrase 
S11 S9 AND S10 
Search modes - 
Boolean/Phrase 
S10 S3 OR S4 OR S5 OR S6 OR S7 OR S8 
Search modes - 
Boolean/Phrase 
S9 S1 OR S2 
Search modes - 
Boolean/Phrase 
S8 
HRQL OR QOL OR Wellbeing OR well-being OR 
"well being" OR functioning OR "quality of life" 
Search modes - 
Boolean/Phrase 
S7 (MH "Quality of Life") 
Search modes - 
Boolean/Phrase 
S6 
Depress* OR mood OR distress OR "depress* 
disorder*" OR "mood disorder*" 
Search modes - 
Boolean/Phrase 
S5 (MH "Depression") 
Search modes - 
Boolean/Phrase 
S4 Anx* OR "anxiety disorder*" 
Search modes - 
Boolean/Phrase 
S3 
(MH "Generalized Anxiety Disorder") OR (MH 
"Anxiety") 
Search modes - 
Boolean/Phrase 
S2 
“Hidradenitis Suppurativa” OR Hidradenit* OR 
“Acne Inversa” 
Search modes - 
Boolean/Phrase 
S1 (MH "Hidradenitis Suppurativa") 





Web of Science (Core Collection): conducted on 16/02/19, n = 328 
Second reviewer APB: conducted on 16/09/19, n = 388 
#5 
#2 AND #1 
Refined by: [excluding]:  PUBLICATION YEARS: (1975) 
AND LANGUAGES: (ENGLISH)  
DocType=All document types; Language=All languages;  
#4 
#2 AND #1 
Refined by: [excluding]:  PUBLICATION YEARS: (1975)  
DocType=All document types; Language=All languages;  
#3 #2 AND #1  DocType=All document types; Language=All languages;  
#2 
TS=(Anx* OR "Anxiety disorder*" OR Mood OR Depress* OR “Mood disorder*” 
OR “Depress* disorder*” OR distress OR “Quality of life” OR HRQL OR QoL OR 
“Well being” OR Well-being OR Wellbeing OR functioning)  
DocType=All document types; Language=All languages;  




EThOS: conducted on 16/02/19, n = 0 
Second reviewer APB: conducted on 18/09/19, n = 0 
"hidradenit\* OR "acne inversa" AND "anx\* OR depress\* OR mood OR distress" 
AND "hrql OR qol OR "quality of life" OR wellbeing OR "well being" OR well\-being 
OR functioning" 
   
 
OpenGrey: conducted on 16/02/19, n = 3 (none in English language) 
Second reviewer APB: conducted on 18/09/19, n = 3 (none in English language) 
Search: hidradenitis 
Search: “acne inversa” 
 
 
WorldCat: conducted on 16/02/19, n = 3 
Second reviewer APB: conducted on 18/09/19, n = 3 
(ti: hidradenit* OR (ti: hidradenitis and ti: suppurativa) OR (ti: acne and ti: inversa)) 
and (kw: anx* OR kw: depress* OR kw: mood OR kw: distress OR kw: qol OR kw: 
hrql OR (kw: quality and kw: life) OR kw: wellbeing OR kw: well-being OR (kw: well 









Appendix B – Reasons for Exclusion at Screening and Eligibility Stages 
 
Stage 1 (title and abstract review): 982 
Excluded: 937 
- Focused on other health conditions: 59 
- Not focussed on psychological outcomes: 690 
- Focussed on psychological outcomes, article type = Review / abstract / 
correspondence: 128 
- Focussed on psychological outcomes, article type = Tool/guide development: 39 
- Focussed on psychological outcomes, article type = Intervention: 12 
- Focussed on psychological outcomes, sample = Mean age under 18: 5 
- Focussed on psychological outcomes, article type = Case study: 2 
- Focussed on psychological outcomes, article type = Qualitative: 2 
 
Stage 2 (full paper review): 45 
Excluded: 22 
- Unable to access: 3 
- Non-validated measures: 8 
- Intervention: 5 
- Not reporting HS separately from other conditions: 1 
- Studies without an overall/total (validated) measure of QoL / anxiety / depression: 
2 
- Other: intervention and unable to access; unable to access and qualitative; thesis 
















Appendix C – Quality Assessment Method 
 
The National Heart, Lung, and Blood Institute (NHLBI) Quality Assessment Tool for 
Observational Cohort and Cross-Sectional Studies (National Institutes of Health, 2014) 
 
Reference:          Date of ax:  




1. Was the research question or objective in this paper clearly 
stated? 
   
2. Was the study population clearly specified and defined?    
3. Was the participation rate of eligible persons at least 50%?    
4. Were all the subjects selected or recruited from the same or 
similar populations (including the same time period)? 
Were inclusion and exclusion criteria for being in the study 
prespecified and applied uniformly to all participants? 
   
5. Was a sample size justification, power description, or 
variance and effect estimates provided? 
   
6. For the analyses in this paper, were the exposure(s) of 
interest measured prior to the outcome(s) being measured? 
   
7. Was the timeframe sufficient so that one could reasonably 
expect to see an association between exposure and outcome if 
it existed? 
   
8. For exposures that can vary in amount or level, did the 
study examine different levels of the exposure as related to 
the outcome (e.g., categories of exposure, or exposure 
measured as continuous variable)? 
   
9. Were the exposure measures (independent variables) 
clearly defined, valid, reliable, and implemented consistently 
across all study participants? 
   
10. Was the exposure(s) assessed more than once over time?    
11. Were the outcome measures (dependent variables) clearly 
defined, valid, reliable, and implemented consistently 
across all study participants? 
   
12. Were the outcome assessors blinded to the exposure 
status of participants? 
   
13. Was loss to follow-up after baseline 20% or less?    
14. Were key potential confounding variables measured and 
adjusted statistically for their impact on the relationship 
between exposure(s) and outcome(s)? 
   
*CD, cannot determine; NA, not applicable; NR, not reported 
Quality Rating (Good, Fair, or Poor) 
Rater #1 initials: 
Rater #2 initials: 
Additional Comments (If POOR, please state why): 
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Appendix D – Quality Assessment Ratings 
Table D1. 
Quality Assessment Ratings 
Paper 
reference 
Qu.1 Qu.2 Qu.3 Qu.4 Qu.5 Qu.6 Qu.7 Qu.8 Qu.9 Qu.10 Qu.11 Qu.12 Qu.13 Qu.14 Quality 
rating 
Agut-Busquet 
et al. (2018) 
Y Y NA Y N N N Y Y N Y NR NA NR Fair 
Alavi et al. 
(2015) 
Y Y NR Y N N N Y Y N Y NR NA Y Fair 
Alavi et al. 
(2018a) 
Y Y NR Y N N N Y N N Y NR NA Y Fair 
Alavi et al. 
(2018b) 
Y Y NR Y Y N N Y Y N Y NR NA Y Fair 
Balieva et al. 
(2017) 
Y Y Y Y N N N N Y N Y NR NA Y Fair 
Balieva et al. 
(2018) 
Y Y Y Y N N N N Y N Y NR NA Y Fair 
Calao et al. 
(2018) 
Y Y N Y Y N N Y Y N Y Y NA N Fair 
Janse et al. 
(2017) 
Y Y N Y N N N Y Y N Y NR NA NR Poor 
Kaaz et al. 
(2018) 
Y Y NR Y N N N Y Y N Y NR NA N Fair 
Katoulis et al. 
(2017) 
Y Y NR Y N N N Y Y N Y NR NA Y Fair 
Kluger et al. 
(2017) 
Y Y Y Y N N N Y Y N Y NR NA Y Good 
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Kluger et al. 
(2018) 
N Y Y Y Y N N Y Y N Y NR NA N Fair 
Kouris et al. 
(2016) 
Y N NR NR N N N Y N N Y NR NA Y Poor 
Kurek et al. 
(2012) 
Y Y Y Y N N N Y Y N Y NR NA Y Fair 
Kurek et al. 
(2013) 
Y Y Y Y Y N N Y Y N Y NR NA Y Good 
Matusiak et al. 
(2010) 
N N NR NR N N N Y Y N Y NR NA Y Poor 
Onderdijk et 
al. (2013) 
Y Y Y CD N N N Y Y N Y NR NA NR Fair 
Pavon Blanco 
et al. (2018) 
Y Y NA Y Y N N Y Y N Y NR NA Y Good 
Rondags et al. 
(2019) 
Y Y NA Y N N N N N N Y NR NA N Poor 
Sartorius et al. 
(2009) 
Y Y NR Y N N N Y Y N N NR NA NR Poor 
Storer et al. 
(2018) 
Y Y CD N N N N Y Y N N NR NA Y Poor 
Theut Riis et 
al. (2019) 
Y N CD Y N N N N Y N Y NR NA Y Fair 
von der Werth 
& Jemec 
(2001) 
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Background: Hidradenitis Suppurativa (HS) is a chronic skin disease presenting in the 
apocrine glands as inflamed nodules that often develop into fistulas, sinus tracts and scars. 
Research has found substantial rates of anxiety, depression and impaired quality of life in 
people with HS. These health outcomes have been linked to psychosocial factors 
including how people with HS perceive their illness (illness perceptions), and clinical 
factors such as disease severity. One study found illness perceptions were more strongly 
related to outcomes in HS than disease severity, however the study did not establish 
whether or not illness perceptions are predictive of outcomes over time. 
Objectives: The first aim was to examine whether illness perceptions at baseline predict 
quality of life and symptoms of anxiety and depression over time, independently of 
disease severity. The second aim was to investigate the stability of illness perceptions 
over time, and if this is associated with health outcomes. The third aim was to  
explore the causal links between illness perceptions and depression over time. 
Method: This was a longitudinal study of 135 participants with HS. The Brief Illness 
Perceptions Questionnaire (BIPQ), Generalised Anxiety Disorder-2 (GAD-2), Patient’s 
Health Questionnaire-2 (PHQ-2), Dermatology Life Quality Index (DLQI) and Pain 
Visual Analogue Scale were completed at two time points (first appointment and a 
follow-up appointment). Doctors measured disease severity using Hurley staging. 
Results: Multiple regressions indicated that illness perceptions explained a significant 
amount of variance in health outcomes over time, independently of disease severity when 
baseline health outcomes were not included in the models. HS severity explained very 
little of the variance in health outcomes across all models. Illness perceptions were stable 
over time, apart from beliefs about identity and concern about HS. Reductions in negative 
illness beliefs about consequences, timeline, personal control and concern were 
associated with improved health outcomes. Apart from personal control beliefs, 
depressive symptoms and illness perceptions mutually influenced each other over time. 
Conclusions: Illness perceptions are better predictors of quality of life and symptoms of 
anxiety and depression over time than disease severity, most perceptions remain stable 
over time, and there is a mutual influence between depressive symptoms and illness 
perceptions over time. This has implications including routine assessment of illness 
perceptions in HS, and indicates the need for further research into interventions to modify 




Hidradenitis Suppurativa (HS), also referred to as acne inversa, is a skin condition 
that is chronic and presents in the apocrine glands as inflamed nodules that usually 
progress into abscesses, sinus tracts (tunnels) and scarring (Kouris et al., 2016; Smith, 
Chao & Teitelbaum, 2010). The ratio of females to males with HS is approximately 3:1, 
typically presenting in early twenties and remaining active throughout thirties and forties 
(Dufour, Emtestam & Jemec, 2014).  Reports of global prevalence of HS range from 
0.03% to 8%, however this may be underreported due to various reasons such as 
misdiagnosis, the average time from initial symptoms to diagnosis being 7 years, or 
shame (Jemec, 2012; Jemec & Kimball, 2015; Saunte et al., 2015; Slade, Powell & 
Mortimer, 2003). In order to meet diagnostic criteria for HS typical lesions must be 
present (such as painful nodules, abscesses, draining sinus and scars), be chronic and 
recurrent, and mainly present in more than one of the following areas: groin, axillae, 
perineal region, buttocks and infra- and intermammary folds (van der Zee & Jemec, 2015; 
Vinding et al., 2014). 
 
1.1  Disease Severity 
HS exists at different levels of severity and there are different measures used to 
assess this including Hurley staging (Hurley, 1989), HS-Physician’s Global Assessment 
(HS-PGA; Zouboulis et al.., 2015; Kimball et al., 2012), Modified Sartorius Score 
(Sartorius, Emtestam, Jemec & Lapins, 2009; Sartorius, Lapins, Emtestam & Jemec, 
2003), and the International Hidradenitis Suppurativa Severity Scoring System 
(Zouboulis et al., 2017), and the Hidradenitis Suppurativa Clinical Response (HiSCR; 
Kimball et al., 2016). Hurley staging has been widely used in research and clinical 
practice; this classification of severity is stated as follows (Hurley, 1989): 
 
- Stage I: Abscess formation, single or multiple, without sinus tracts and 
cicatrization (the process of wound healing that produces scar tissue) 
- Stage II: Recurrent abscesses with tract formation and cicatrization, single or 
multiple, and widely separated lesions 
- Stage III: Diffuse or near-diffuse involvement or multiple interconnected tracts 
and abscesses across the entire area (Hurley, 1989) 
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The prevalence of each stage is uncertain. Studies have reported that Hurley stages 
1 (24-68%) and 2 (28-54%) are most common whereas stage 3 (2-29%) is less common 
(Canoui-Poitrine et al., 2019; Delany et al., 2017; Katoulis et al., 2017; Matusiak, Bieniek 
& Szepietowski, 2009; Schrader, Deckers & van der Zee, 2014; Vazquez, Alikhan, 
Weaver, Wetter & Davis, 2013). In 30% of cases mild forms of HS may become more 
severe over time (Kromann et al., 2014).  
 
Treatment varies according to the severity of HS; currently there is no cure and 
there is a lack of high-quality evidence for HS therapy (Elkin, Daveluy & Avanaki, 2020; 
Ingram, 2016; Zouboulis et al., 2015). In the UK, topical antiseptics and antibiotics, and 
oral immunomodulators and retinoids are prescribed for HS in an escalating sequence 
(Ingram, 2016). Several randomised controlled trials have assessed efficacy of anti-
tumour necrosis factor-alpha (TNFa) therapies, which inhibit the protein TNF-alpha and 
are prescribed for severe HS (Ingram, 2016). For isolated nodules incisions and draining 
may be performed, whereas for extensive HS broader excision may be performed and has 
lower risk of recurrence (Ingram, 2016). Body mass index and smoking are associated 
with disease severity (Sartorius et al., 2009) therefore lifestyle changes are recommended 
in terms of obesity and smoking, with strong associations between HS and likelihood of 
spontaneous remission in non-smokers (Ingram, 2016; van der Zee, van der Woude, 
Florencia & Prens, 2010). Disease severity has also been found to reduce following 
bariatric surgery (Thomas, Gordon & Mortimer, 2014). 
 
1.2  Psychosocial Impact of HS 
There has been research into the psychosocial impact that HS can have. The 
abscesses can be painful and malodorous, presenting in areas such as the groin, armpits 
and anogenital regions. This has been found to elicit feelings of embarrassment, shame, 
sadness and anger about appearance and smell, and impact on romantic relationships 
(Esmann & Jemec, 2011; Keary, Hevey & Tobin, 2019). Research has also indicated that 
there are higher rates of unemployment and sick leave than the general population 






A recent systematic review of 10 studies by Machado et al. (2019) found the 
prevalence rate for anxiety in HS was 4.9%, whereas other studies have found prevalence 
rates of 6.9% and 27% (Huilaja et al., 2018; Pavon Blanco, Turner, Petrof & Weinman, 
2018). Anxiety has also been found to be more prevalent in HS than other dermatological 
conditions and the general population (Huilaja et al., 2018; Shavit et al., 2015). Symptoms 
of depression and higher disease severity have been found to be associated with anxiety 
in HS (Kouris et al., 2016; Kurek et al., 2013). These findings indicate that further 
research is required into depression and anxiety in HS and factors including disease 
severity, that may be predictive of these health outcomes. 
 
Depression 
Prevalence of depression in HS has been found to vary across research. Machado 
et al.’s (2019) systematic review found the prevalence to be 16.9% (26.8% in studies 
using screening tools), whereas other studies have found prevalence rates over 35% 
(Kluger, Ranta & Serlachius, 2017; Kurek, Peters, Sabat, Sterry & Schneider-Burrus, 
2013; Pavon Blanco et al., 2018). HS has also been found to have a higher prevalence of 
depression than healthy control groups and the general population (Kouris et al., 2016; 
Kurek et al., 2013; Shavit et al., 2015) and other dermatological conditions (Huilaja, Tiri, 
Jokelainen, Timonen & Tasanen, 2018; Onderdijk et al., 2013). Various factors have been 
found to be associated with depression in HS including pain, sick days, age of onset, 
gender, quality of life, anxiety and sexual distress. (Kluger, et al., 2017; Kurek et al., 
2012; Matusiak et al., 2010; Onderdijk et al., 2013). There are conflicting studies 
regarding the association of disease severity and depression in HS. Several studies 
indicate higher severity being related to higher depression scores (Kouris et al., 2016; 
Kurek et al., 2013; Matusiak et al., 2010; Onderdijk et al., 2013), whereas others have not 
found significant correlations (Kluger et al., 2017). There has also been debate about 
proinflammatory cytokines involved in HS development, also impacting the development 
of depression (Goldstein, Kemp, Soczynska, & McIntyre, 2009; Kelly & Prens, 2016; 
Kohler et al., 2017; van der Zee et al., 2011). 
 
Quality of Life 
Quality of life has also been widely researched in HS. It has been measured using 
different tools and constructs, including aspects of psychological, physical and social 
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functioning (de Korte, Sprangers, Mombers, Bos & Sprangers, 2004). One of the more 
commonly used patient-reported outcome measures in dermatological conditions is the 
Dermatology Quality of Life Index (DLQI; Finlay & Khan, 1994). This comprises of 
questions regarding symptoms, feelings, sport, daily activities, leisure, work/study, 
relationships and treatment. Research has indicated that people with HS have higher rates 
of impaired quality of life than the general population (Kluger et al., 2017). Studies using 
measures such as the DLQI have found HS to have a very large impact on peoples’ lives 
(Alavi et al., 2018; Balieva et al., 2018; Calao et al., 2018). They have also found higher 
rates of impairment than other skin disorders including atopic dermatitis and psoriasis 
(Matusiak et al., 2010).  
 
Psychosocial and lifestyle factors such as anxiety, depression, loneliness, poor 
sleep and sexual dysfunction have been found to be associated with poorer quality of life 
in people with HS (Janse et al., 2017; Kaaz, Szepietowski & Matusiak, 2018; Kouris et 
al., 2016). Demographic factors such as gender (being female) and later age of onset were 
associated with poorer quality of life (Kluger et al., 2017; Matusiak et al., 2010), whereas 
other studies did not find these to be linked (Alavi et al., 2018; Kurek et al., 2012). 
Clinical characteristics such as disease severity, odour severity and itchiness have also 
been linked with impaired quality of life (Alavi et al., 2015; Alavi et al., 2018; Onderdijk 
et al., 2013). Despite research demonstrating significant associations between HS severity 
and quality of life, Onderdijk et al. (2013) found a borderline significant correlation with 
a high degree of variability. This research has demonstrated evidence of impact HS has 
on quality of life but has largely used cross-sectional designs. Longitudinal research that 
predicts the impact of HS and associated factors on quality of life is required. 
 
Pain 
Previous research has found that pain causes considerable distress in people with 
HS (Keary et al., 2019), and is positively correlated with the impact of HS on quality of 
life (Wolkenstein et al., 2007). A qualitative study by Keary et al. (2019) found that 
people with HS reported that others were unable to understand their pain and therefore 
dismissed it, which led them to feel angry and isolated. These findings indicate that both 
in research and clinical practice pain should be considered when assessing the impact of 
HS on health outcomes. 
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1.3  Illness Perceptions 
Psychological research has used social cognitive models to understand the 
processing of information by patients regarding their illness. The Common-Sense Model 
(CSM) by Leventhal, Meyer and Nerenz (1980) proposes that individuals who experience 
new health threats build cognitive and emotional models of their illness (illness 
perceptions) derived from ‘lay’ information they have about the illness, information from 
authoritative or significant others, and their current experience with the illness 
(Leventhal, Nerenz & Steele, 1984). Schematic and conceptual illness representations are 
formed through concrete evidence (e.g. body symptoms) and abstract information (the 
symmetry rule), linking symptoms to diagnosis labels stored in semantic memory 
(Leventhal, 1990).  
 
 Research has identified five main components of these illness models, including 
beliefs about cause, timeline, control or cure, consequences and identity (Petrie & 
Weinman, 2006). Cause indicates the beliefs about factors that have caused the illness, 
and can strongly influence choice of treatments and emotional responses (Petrie & 
Weinman, 2006). Timeline represents beliefs about the course and time scale of the illness 
(e.g. acute or chronic), and can influence adherence to treatments. Controllability or cure 
refer to the beliefs about personal control over the illness (e.g. efficacy of coping 
behaviours) and how well it is controlled by treatment (Lau & Hartman, 1983). Higher 
control beliefs are often linked with shorter timeline beliefs (Petrie & Weinman, 2006). 
Consequences can refer to the impact of the illness on factors such as lifestyle, family and 
work, and can reflect the subjective views of the illness severity which may not be in line 
with clinical measures of severity (Petrie & Weinman, 2006). Identity refers to the label 
individuals have for their illness and the symptoms they associate with it, however beliefs 
about symptoms caused by the illness may differ from what is medically indicated (Petrie 
& Weinman, 2006). The Brief Illness Perception Questionnaire (Broadbent, Petrie, Main 
& Weinman, 2006) was created in order to provide clinicians with a theoretically-derived 
and rapid picture of how patients view their illness using these components. This measure 
also incorporates emotional components including emotional response and concern about 
the illness, in addition to understanding of the illness (Broadbent et al., 2006). 
 
In order for individuals to reduce the threat of their illness and their emotional 
response to it, their coping strategies and health outcomes are guided by their cognitive 
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model of illness perceptions (Leventhal et al., 1980; Petrie & Weinman, 2006). Their 
appraisal of their coping strategies may then change their illness perceptions and 
subsequent coping responses in a continuous feedback loop (Broadbent et al., 2006; 
Leventhal et al., 1980). A meta-analysis of 45 empirical studies measuring illness 
perceptions from the CSM (Leventhal, 1980) in 23 illnesses and conditions provided 
support for the construct and discriminant validity of these components and for measures 
using these components (Hagger & Orbell, 2003). Hagger, Koch, Chatzisarantis and 
Orbell (2017) conducted a further meta-analysis of 254 studies on chronic illnesses and 
found that although coping responses partially account for the effect of illness 
representations on outcomes, cognitive and emotional representations impact outcomes 
independently of coping. 
 
Illness Perceptions and Health Outcomes 
There is increasing evidence showing that illness perceptions across various 
chronic illnesses including heart failure, psoriasis, rheumatoid arthritis, and chronic 
obstructive pulmonary disease are significantly related to anxiety, depression and quality 
of life outcomes (Morgan, Villiers-Tuthill, Barker & McGee, 2014; Scharloo et al., 1998, 
2000). Gray and Rutter (2007) found that, in people with chronic fatigue syndrome, 
illness perceptions about greater treatment control and lower identity and emotional 
response were associated with better quality of life. Hagger and Orbell (2003) found that 
beliefs in a chronic timeline, serious consequences and a strong illness identity were 
associated with decreased psychological well-being and social functioning, and in Hagger 
et al.’s (2017) review consequences and identity were consistent positive predictors or 
greater distress and poorer well-being. Scharloo et al. (1998) and Kemp, Morley and 
Anderson (1999) also found identity and perceptions of symptoms explained the most 
overall variance in illness outcomes. High perceived control over the illness has been 
strongly related to better psychological well-being and reduced depression and anxiety 
(Bradley, Lewis, Jennings & Ward, 1990; Hagger et al., 2017; Hagger & Orbell, 2003; 
Morgan et al., 2014; Shillitoe & Christie, 1990). Chilcot et al. (2013), however, found 
that personal control was not associated with depression trajectory in people with end-
stage renal disease. Emotional representations have also been positively associated with 
distress and anxiety, and negatively associated with well-being (Hagger et al., 2017; 
Morgan et al., 2014). Overall, these findings suggest that individuals are more likely to 
experience better well-being and less distress if they perceive their illness as under 
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control, treatable, and having a lower effect on their life, and if they are able to reduce 
their emotional response and attribution of symptoms to their illness (Hagger et al., 2017). 
 
Illness Perceptions and Disease Severity 
Anxiety, depression and quality of life have been found to have stronger 
associations with illness perceptions than disease severity in conditions such as heart 
failure and multiple sclerosis (Jopson & Moss-Morris, 2003; Morgan et al., 2014).  Based 
on these findings, a recent research study by Pavon Blanco et al. (2018) found that illness 
perceptions about HS explained a greater amount of variance in anxiety, depression and 
quality of life outcomes in comparison to demographics and disease severity. Pavon 
Blanco et al. (2018) also found that there was a lack of association between disease 
severity and illness perceptions, indicating a weak link between them and between 
clinical measures and patients’ evaluations of HS. Compared to cohorts with asthma, 
diabetes and myocardial infarction, the participants with HS in this study demonstrated 
more negative beliefs about the consequences, experience of symptoms, concern about 
HS and a stronger emotional response, and less negative beliefs about personal and 
treatment control (Broadbent et al., 2006; Petrie, Perry, Broadbent & Weinman, 2012; 
Pavon Blanco et al., 2018). Emotional response was significantly correlated with 
symptoms of anxiety and impaired quality of life (Pavon Blanco et al., 2018). The 
perception of negative consequences was the most significant contributor to the health 
outcomes, and treatment control explained a significant amount of variance in depression 
and quality of life scores. Thus, illness perceptions about HS may be a more effective 
indicator of people at risk of poorer health outcomes as opposed to the traditional 
explanatory variable of disease severity.  
 
Longitudinal Impact of Illness Perceptions and Disease Severity 
Pavon Blanco et al.’s (2018) study was the first to explore the nature and impact 
of illness perceptions in HS, however the cross-sectional design did not allow for 
exploration of the predictive utility of illness perceptions over time. There is longitudinal 
research into other chronic illnesses including coronary artery disease and head and neck 
cancer, that has found illness perceptions to be predictive of depressive symptomatology 
over time (Llewellyn, McGurk & Weinman, 2007; Stafford, Berk & Jackson, 2009). 
Perceptions of illness have also been found to be strong predictors of recovery 
independently of illness severity in myocardial infarction and mild head injury (Petrie et 
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al., 1996; Whittaker, Kemp & House, 2007). Broadbent, Petrie, Ellis, Ying and Gamble 
(2004) found that in people with myocardial infarction (MI) recovery was more strongly 
predicted by their drawings of damage to their hearts than medical indicators (troponin-
T levels). When participants were asked to draw hearts over 6 months after MI the size 
of the heart predicted cardiac anxiety (Broadbent, Ellis, Gamble & Petrie, 2006). 
Prospective dermatological studies have found similar evidence; Scharloo et al. (2000) 
demonstrated that illness beliefs explained more variation in disability, psychological 
distress and psoriasis-related stresses than disease severity over time.  
 
Conversely, Wahl et al. (2014) showed that people with greater disease severity 
held stronger illness perceptions about the consequences, timeline and emotional impact 
of psoriasis, indicating that disease severity and these illness perceptions may not be 
independent of each other in this dermatological condition. Further longitudinal research 
is required in order to explore whether illness perceptions and disease severity are 
independent of each other in predicting outcomes in HS. 
 
Stability of Illness Perceptions and Relation with Depression Over Time 
Research into the stability of illness perceptions over time has not yet been 
explored in HS. The CSM (Leventhal et al., 1980, 1984) suggests that there are two 
processes which influence the development of illness perceptions. The first implies that 
when individuals are first aware of health threats they tend to perceive them as acute and 
therefore treatable with limited duration (Fischer et al., 2010). In chronic illnesses, 
perceptions of the timeline of the illness shift from acute to chronic. The second process 
is the reshaping of illness perceptions based on the outcomes of treatment (Leventhal, 
Brissette & Leventhal, 2003). Findings from previous research into chronic conditions 
have been varied. Cardiac studies have indicated that understanding of the illness 
(coherence) and perceptions of the timeline increase over time, whereas emotional 
responses and perceived controllability decrease (Fischer et al., 2010; Petrie & Weinman, 
1997). Diabetes research found similar findings apart from controllability which 
remained stable over time (Lawson, Bundy & Harvey, 2008). Studies into irritable bowel 
syndrome and lower back pain have found all illness perceptions to remain stable over 
time (Foster et al., 2008; Rutter & Rutter, 2007). Studies are limited in this area and to 
date research has not been conducted to investigate whether illness perceptions change 
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over time in an HS population, and whether change in illness perceptions has an impact 
on health outcomes.  
 
Leventhal et al.’s (1980) model is a parallel processing model with a cognitive 
and emotional pathway, however, most CSM research has focused on the impact of 
cognitions on emotional and behavioural outcomes (Revenson & Diefenbach, 2019). 
Leventhal and Scherer (1987) suggested that emotion and cognition are “always 
intertwined” in emotional behaviour and experience, and to find emotional responses 
completely independent of cognitive responses or perceptions would be rare. This 
emphasises the importance of investigating further the interaction between illness 
perceptions and emotions. Depression is highly prevalent in HS, and the strong 
associations that have been found between illness perceptions and depression have mainly 
been derived from cross-sectional studies. Longitudinal studies in other long-term 
conditions such as Chilcot et al. (2013) have focused on the direction of illness 
perceptions as predictors of depression, however, it is possible that depression may be 
determining illness perceptions as much as the reverse direction.  
 
There is extensive literature regarding the direction of influence between negative 
cognitions and depression (Kindt, Kleinjan, Janssens & Scholte, 2015; Rush, 
Weissenburger & Eaves, 1986; Teasdale, 1983), however this has not been examined in 
relation to beliefs about illness. Beck’s (1967) cognitive model suggests that the negative 
cognitive triad (negative thinking about the self, world and future) has a causal role in  
how depression develops and is maintained, and that maladaptive schemata may indicate 
a vulnerability to depression. Research indicates that mood can influence how accessible 
positive and negative cognitions are; depression may increase access to negative 
cognitions and decrease accessibility of positive cognitions (Bower, 1981; Teasdale, 
1983; Tversky & Kahneman, 1974). As a result, this may increase negative memories and 
attention towards negative elements of current experiences, reduce positive expectations 
and interpretations of outcomes and experiences of coping, thus reinforcing feelings of 
sadness (Beck, Rush, Shaw & Emery, 1979; Clark, Beck & Alford, 1999). This may 
impact behavioural responses and subsequent appraisal of their coping strategies, feeding 
into Beck’s (1967) negative cognitive triad, and thus increasing symptoms of depression 
(Teasdale, 1983). This demonstrates a vicious cycle between cognitions and depression, 
which may also be indicated between illness beliefs and depression. Leventhal et al. 
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(1980) and Petrie and Weinman (2006) have suggested that coping strategies and health 
outcomes are guided by perceptions of illness, and that this model is dynamic in that 
appraisal of coping informs the development of illness perceptions in a feedback loop. 
Therefore, it is possible that health outcomes such as depression can feedback and 
influence the formation of illness perceptions.  
 
Selectively attending to negative stimuli and interpreting ambiguous information 
as having negative meaning are automatic processes found to maintain depression 
(Disner, Beevers, Haigh & Beck, 2011; Phillips, Hine & Thorsteinsson, 2010). Orbell and 
Phillips (2019) have provided evidence that implicit processes of attentional and 
interpretation bias are possible antecedents of illness representations. Therefore, it is 
possible that depression may also impact illness perceptions over time, and research is 
required to examine this as it is a current gap in the literature of HS and other chronic 
illnesses. 
 
1.4  Study Aims and Hypothesis 
To date, most research has focused on clinical characteristics of HS relating to 
health and lifestyle outcomes (Revuz et al., 2008; Sartorius et al., 2009). Research is 
limited in exploring illness perceptions in HS, and has not investigated the extent to which 
illness perceptions are predictive of health outcomes over time in HS. Therefore, the first 
aim of this study is to follow-up on Pavon Blanco et al.’s (2018) study to examine whether 
illness perceptions at baseline predict quality of life and symptoms of anxiety and 
depression over time, independently of HS severity. The hypothesis is as follows: 
 
- Hypothesis: Illness beliefs assessed at first presentation to the clinic will be a 
stronger predictor of longitudinal outcomes (quality of life and symptoms of 
anxiety and depression) than HS disease severity. 
 
The second aim of the project is to investigate the stability of illness perceptions 
over time, and if this is associated with these health outcomes. Findings from this research 
are intended to be generalisable to the wider HS community in the UK and will indicate 
if illness perceptions are independent of disease severity in explaining and predicting 
outcomes. This will provide implications for the identification of people with HS who 
may be at higher risk of poor health outcomes (depression, anxiety and quality of life). 
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The findings will also inform the development and use of psychological intervention in 
HS alongside dermatological treatment. There has been research into interventions 
targeting cognitive change through modification of illness perceptions in other health 
conditions (Broadbent, Ellis, Thomas, Gamble & Petrie, 2009; Petrie, Cameron, Ellis, 
Buick & Weinman, 2002; Petrie et al., 2012), and it is hoped that findings from this study 
will further the development of psychological interventions in order to optimise health 
outcomes for people with HS.  
  
There is growing evidence that illness perceptions play a significant role in 
influencing psychological outcomes, however, the bi-directional link between illness 
perceptions and mood has not yet been explored. Prospective research is required to 
determine the direction of influence; therefore, the third aim of the project is to explore 
(i) the extent to which illness perceptions predict symptoms of depression over time and 
(ii) the extent to which symptoms of depression predict illness perceptions over time in 
people with HS. Findings will provide implications for identifying people who may be at 
risk of developing negative illness perceptions about HS which could impact on health 
outcomes. This may further inform interventions for these at-risk groups to target 
mechanisms that maintain both directions of influence. The project’s aims therefore also 
inform multidisciplinary care for people with HS and development of care pathways into 





2.1  Design 
This study is longitudinal in design, using data collected routinely in the HS 
tertiary clinics at a London teaching hospital. A portion of the data is collected for 
electronic patient records and the remaining data is gathered through Integrating Mental 
and Physical Healthcare: Research Training and Services (IMPARTS).  
 
The project is following up on 164 participants from a cross-sectional baseline 
study that was conducted between 2014 and 2015 by Pavon Blanco et al. (2018). The 
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information collected at baseline was gathered again from their first follow-up 
appointment that they had completed all the measures at.  
 
2.2 Ethical Approval and Informed Consent 
Ethical approval was granted by the NHS Health Research Authority (HRA) and 
Health and Care Research Wales (HCRW), and permission to implement the study was 
granted from the Guy’s and St Thomas’ (GSTT) NHS Foundation Trust Research and 
Development (R&D) Team. King’s College London Research Ethics Team were 
approached and confirmed that ethical approval was not required. This study was deemed 
as Research Ethics Committee (REC) exempt as the project is limited to the use of data 
collected routinely in the normal care of participants, and is anonymised to the researcher 
outside of the direct health care team. A non-substantial amendment was made to the 
protocol following a change in the research team members. This was approved by the 
HRA and GSTT R&D (see Appendices A - F for approval confirmations). 
 
The screening measures used to assess illness perceptions, pain, symptoms of 
anxiety and depression, quality of life, age and gender are routinely collected in the HS 
clinic as part of the IMPARTS initiative. Approval to access to this IMPARTS data was 
granted by the IMPARTS Oversight Committee (see Appendix F for approval emails). In 
keeping with IMPARTS ethical approval, formal informed consent was not given by 
participants, however they were able to opt out (IMPARTS Database REC reference: 
18/SC/0039). Informed consent was not sought from participants to gather HS severity 
data as this was collected by direct members of the health care team and pseudonymised 
by IMPARTS before the researcher outside of the direct health care team had access to 
this.  
 
2.3  Inclusion and Exclusion Criteria 
Participants were required to have a diagnosis of HS, with data available in the 
patient notes via the direct health care team. Participants were included if they had 
participated in Pavon Blanco et al.’s (2018) study (time point 1) and had a follow-up 
screening date with all the self-report questionnaires required for the study completed 
(time point 2). All baseline data was gathered at each participants’ first appointment at 
the HS clinic. 
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Participants were excluded if they had not completed all measures at baseline and 
follow-up, were unable to read English, were under the age of 18, had ‘opted out’ of their 
IMPARTS data being used for research, and if HS severity could not be determined from 
their notes. 
 
2.4  Measures 
 
2.4.1 Clinician-Rated HS Severity 
HS severity was measured using Hurley’s staging system (Hurley, 1989). Hurley 
staging is a visual classification of severity using a three-stage scoring system: stage I 
(mild), II (moderate) and III (severe). It measures static features including fistulas and 
scars, and patients’ stage of severity can increase (severity can become worse). Hurley 
staging was used as it is a well-established measure of HS severity that was used routinely 
in the HS clinic and allowed this study to follow-up on the baseline cohort of participants 
in Pavon Blanco et al.’s (2018) research.  
 
2.4.2 Illness Perceptions 
Illness perceptions were measured using the Brief Illness Perceptions 
Questionnaire (BIPQ: Broadbent et al., 2006). This is a valid and reliable self-report 
measure evaluating cognitive and emotional representations of illness. This 9-item scale 
assesses the following domains: perceived health outcomes of the illness (consequences); 
perceived duration of the illness (timeline); perceived control over the illness (personal 
control and treatment control); illness label and related symptoms (identity); emotional 
response to the illness (concern and emotional response); illness comprehensibility 
(understanding); and perceived causes of the illness. The causes component is not 
routinely collected in the HS clinic due to its qualitative format, therefore it was not 
collected at baseline or follow-up for this study. Items are rated on a 10-point scale; higher 
scores indicate a more threatening perception of the illness. The Cronbach’s alpha for the 
BIPQ in this sample was a = .673 at baseline which indicates acceptable reliability, and 
a = .750 at follow-up which is good reliability (Kline, 2013). It has nonetheless been 
recommended that each item value is considered in analysis; as opposed to the overall 
score (Broadbent et al., 2015). This questionnaire is administered on a six-monthly basis 
in the HS clinic. 
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2.4.3 Depression, Anxiety, Quality of Life and Pain  
Symptoms of depression was screened using the validated Patient’s Health 
Questionnaire-2 (PHQ-2: Kroenke, Spitzer & Williams, 2003), which is a self-report 
measure for assessing depressive symptoms within the past 2 weeks. The Generalised 
Anxiety Disorder-2 (GAD-2: Kroenke, Spitzer, Williams, Monahan & Löwe, 2007) was 
used to screen for anxiety symptoms. It is a validated self-report measure for assessing 
symptoms of GAD in the past two weeks. Previous research has indicated that the PHQ-
2 and GAD-2 have been reliable measures in chronic illness populations including lung 
cancer and cardiovascular disease (Celano et al., 2013; Randall et al., 2013). Items are 
rated on a 4-point scale from 0 (not at all) to 3 (nearly every day), with scores up to 6 on 
each. Higher scores indicate higher symptom severity; the recommended cut-off point (≥ 
3) represents clinically significant depression or anxiety (Kroenke et al., 2010). It should 
be noted that these tools are used as screening measures not clinical diagnostic tools; the 
cut-off points are used to prompt completion of the full PHQ-9 / GAD-7 measures or a 
clinical interview to determine disorders and whether referral or treatment is warranted 
(Kroenke et al., 2007; Kroenke et al., 2010). The Cronbach’s alpha for the GAD-2 was a 
= .893 at baseline and a = .877 at follow-up indicating good reliability (Kline, 2013). For 
the PHQ-2 the Cronbach’s alpha was a = .780 at baseline and a = .856 at follow-up also 
indicating good reliability (Kline, 2013). 
 
The 10-item Dermatology Life Quality Index (DLQI: Finlay & Khan, 1994) is a 
self-report questionnaire that was used to measure quality of life in dermatological 
illnesses. There is a maximum score of 30, with higher scores indicating poorer quality 
of life. Cut-off points for the DLQI stated by Hongbo, Thomas, Harrison, Salek and 
Finlay (2005) are as follows: 0 - 1 (no effect on patient’s life), 2 - 5 (small effect), 6 - 10 
(moderate effect), 11 - 20 (very large effect), and 21 - 30 (extremely large effect). The 
Cronbach’s alpha in for the DLQI was a = .723 at baseline and a = .744 at follow-up, 
indicating good reliability (Kline, 2013). 
 
Pain severity was measured using a visual analogue scale (Jensen & Karoly, 
2011); patients provided a single score from 0 - 100 (no pain – most severe pain possible). 
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2.5  Procedure 
In the HS clinics at a large teaching hospital in London, patients are administered 
the PHQ-2, GAD-2, DLQI and Pain VAS on a tablet device by registered nurses at every 
clinic visit, and the BIPQ is administered every 6 months. The Electronic Patient Record 
(EPR) is linked to the tablets through the IMPARTS initiative.  
 
A previous researcher with an honorary appointment with the NHS Trust screened 
the original 211 participants in Pavon Blanco et al.’s (2018) sample and identified 164 
participants with a follow-up appointment that they had completed all questionnaires at. 
These follow-up dates were added to an excel spreadsheet containing each participant’s 
hospital number and baseline screening date. Two doctors in the direct health care team 
used patient letters in EPR to extract each participant’s Hurley stage at both time points. 
They matched these to the hospital numbers and screening dates in the spreadsheet, and 
sent it securely to IMPARTS. IMPARTS then matched these participants with their 
screening measure data, and replaced all patient identifiers with a study ID code. This 
spreadsheet was then sent securely to the researcher outside of the direct health care team 
for analysis. A code-break spreadsheet providing the individual link back from the 
pseudoanonymised data sheet was sent to the two doctors in the direct health care team. 
This was kept in a separate password protected folder on an NHS server, accessible to the 
two doctors only. 
 
2.6  Statistical Analysis 
Data analysis was conducted using Statistics Package for the Social Sciences 
(SPSS) for Windows version 25. There were 27 participants excluded from this study due 
to missing data on pain severity and/or HS severity at follow-up and one participant being 
under age 18. G*Power 3.1 was used for post-hoc power analysis. A sample size of 135 
achieved a statistical power of 80% and 99% to detect a medium (0.15) and large (0.35) 
F2 effect size respectively at .05 alpha level. It should be noted that this sample size is 
smaller than recommended for multiple regression (requires > 150) to detect a medium 
effect with 15 predictors (Cohen, 1988). 
 
To support statistical analysis the following disease severity groups were 
clustered: participants who were recorded on EPR as stage I or I/II are referred to as 
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‘mild’, participants recorded as stage II or II/III are referred to as ‘moderate’ and 
participants recorded as stage III will be referred to as severe throughout this study. 
 
Relationships between illness perceptions at time 1 and health outcomes at time 
2, independent of HS severity, were analysed by conducting hierarchical multiple 
regressions with bias-accelerated bootstrap (1000 samples) on each dependent variable 
(depression, anxiety and quality of life). In order to control for possible confounders step 
1 of the regression analyses included gender, age (baseline) and pain (baseline). In order 
to investigate the predictive ability of illness perceptions when baseline anxiety, 
depression and quality of life are also accounted for, additional regressions were run for 
each outcome with the baseline measure of the outcome also included as a predictor at 
step 1. Two dummy variables were created for the three baseline Hurley stages and 
entered in at step 2.  Illness perceptions at baseline were entered into step 3 of the 
analyses. Statistical significance was defined as p < .05. 
 
Stability of illness perceptions over time were analysed by running a Friedman’s 
two-way analysis of variance by ranks to identify any statistically significant changes 
between baseline and follow-up. Wilcoxon-signed rank tests were used to follow-up 
significant findings using a Bonferroni correction (p < .0167 significance level). The 
association between change scores for illness perceptions over time and outcomes were 
analysed using Spearman’s rho correlation coefficients. 
 
To explore the bidirectional relationship between illness perceptions and 
symptoms of depression over time, Spearman’s rho were first conducted to identify 
illness perceptions that had correlations with symptoms of depression of .3 and over. A 
two-wave cross-lagged panel design (Kessler & Greenberg, 1981) was then used to 
measure the extent to which the cross-lagged relationships between the selected illness 
perceptions and symptoms of depression predict each other across times one and two 
(Figure 1). The six possible paths between each illness perception and depressive 
symptom scores at the two time points were tested by conducting six hierarchical linear 
regressions with bias-accelerated bootstrap (1000 samples). Causal inference was 
determined by examining which of the two cross-lagged coefficients was larger. If the 
cross-lagged coefficients were equal, this indicated that the variables were caused by 
another variable or were mutually influencing each other (Watkins & Styck, 2017). 
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Figure 1.  














3.1 Preliminary Analyses 
Mann-Whitney U tests were conducted to investigate any baseline differences 
between the 27 participants that were excluded and the 135 that were included. The 
majority of baseline measures of those who were included did not differ significantly 
from the participants that were dropped from the study. Illness perceptions about identity 
differed significantly between the excluded (Mdn = 9) and included (Mdn = 7) 
participants, U = 1309.50, z = -2.34, p < .05, r = -.18. Pain severity was also significantly 
different between the excluded (Mdn = 62) and included (Mdn = 41) participants, U = 
1293.50, z = -2.38, p < .05, r = -.019. 
 
Prior to the main analyses data screening was conducted to inspect assumptions 
of normality and outliers. Histograms, P-plots, z scores of skewness and kurtosis and 
Kolmogorov-Smirnov tests were used to check for normality. Baseline and follow-up 
DLQI, GAD-2 and PHQ-2 ranged from 0.11 to 4.22 and -2.46 to 0.01 for skewness and 
kurtosis respectively. This exceeded lower (1.96) and upper thresholds (3.29) of 










8.64 to -1.12 and -2.18 to 6.45 for skewness and kurtosis, respectively. Kolmogorov-
Smirnov tests also indicated that data on DLQI, GAD-2, PHQ-2 and illness perceptions 
all significantly differed from normality. Boxplots were then inspected for possible 
outliers. None were detected for DLQI, GAD-2 and PHQ-2 scores, however boxplots of 
illness perceptions including baseline consequences, concern and timeline and follow-up 
timeline and identity indicated possible outliers. Five of the outlying cases across these 
variables had an asterisk indicating that they are extreme outliers, and were checked for 
data entry errors, however no errors were identified. All analyses for the hypothesis were 
re-run with these five cases removed, however there were no changes to the results in 
terms of overall significance of the regression models and they were therefore retained in 
the study. In light of these preliminary analyses and assumptions of normality being 
violated non-parametric tests were run to analyse relationships between illness 
perceptions and outcomes.  
 
Multiple Regression Preliminary Analysis 
Three multiple linear regressions were conducted to assess the ability of baseline 
demographics, disease severity and illness perceptions to predict quality of life and 
symptoms of anxiety and depression at follow-up. Initially, baseline outcomes measures 
were included as predictors in these regressions in order to control for the effect of these 
variables. Since it was expected that the values of these baseline outcome measures would 
dominate the prediction models, an additional three multiple linear regressions were 
conducted to compare findings without baseline outcome measures included. Residual 
statistics of the regression models and examination of the histograms and scatterplots of 
standardised residuals of outcomes indicated that further inspection was required of 
possible outliers. Cook’s distance, average leverage, Mahalanobis distance, standardised 
DFBeta and covariance ratios (CVR) were analysed for each regression.  Cook’s distance 
and standardised DFBeta estimates were assessed in relation to the threshold of > 1, and 
average leverage in relation to the value of > 0.24 (2(k + 1) / n) and > 0.35 (3(k + 1) / n), 
(Cook & Weisberg, 1982; Field, 2009; Hoaglin & Welsch, 1978; Stevens, 2002).  
Mahalanobis distance estimates were checked with the cut off of > 20 and CVRs falling 
outside of the range of 0.65 - 1.35 (1 - (3(k + 1) / n and 1+ (3(k + 1) / n) were inspected 
(Barnett & Lewis, 1978; Belsey, Kuh & Welsch, 1980). To correct for outliers, 
heteroscedasticity and other influential areas found across the regressions, bias-
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accelerated (BCA) bootstrapping (1000 samples) was used (Efron, 1987; Frangos & 
Schucany, 1990; Hall, 1988). 
 
Inspection of residual statistics for the multiple regression of DLQI (with baseline 
DLQI included as a predictor) indicated that two cases were above the recommended cut-
off of > 2.5 (one was > 3). Visual inspection of scatterplots indicated one case as a 
potential outlier. Following closer inspection these cases met all criteria stated above, 
apart from two having CVRs slightly below threshold and one above threshold. The 
regression was re-run with these cases excluded to investigate impact on findings, 
however overall significance of variance explained by the models remained the same 
(pain severity became a significant predictor in models one and two). 
 
For the multiple regression of DLQI without baseline DLQI included as a 
predictor, one of the same cases had a residual statistic above 3 and the same potential 
outlier was found on the scatterplot. On closer inspection this case met all criteria stated 
above apart from a similarly high CVR above threshold on one case. The regression was 
re-run without these cases to investigate influence on findings. The overall significance 
of findings remained the same, however illness perceptions about consequences, 
treatment control, identity and emotional response became significant predictors). 
 
The multiple regression of GAD-2 with baseline GAD-2 included as a predictor 
also indicated two cases with residual statistics above 2.5, and the scatterplot indicated 
one case as a potential outlier. On closer inspection these cases met all criteria stated 
above, apart from two cases falling slightly below CVR threshold. After re-running the 
regression without these cases overall findings remained the same. For the multiple 
regression of GAD-2 without baseline GAD-2, two potential outliers were identified on 
the scatterplots, however on closer inspection these cases met all criteria stated above 
apart from one case with a slightly low CVR. When this regression was re-run with these 
cases removed there was no overall change, apart from gender and illness perceptions 
about consequences becoming significant predictors in model 3. 
 
There was one case with a residual statistic above 2.5 in the multiple regressions of 
PHQ-2 with and without baseline PHQ-2 included as a predictor, which is reasonable to 
expect within a sample of this size. Two potential outliers were identified on the 
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scatterplot of PHQ-2 scores with baseline PHQ-2 included. On closer inspection these 
cases met all criteria stated above, apart from one which had a CVR slightly below 
threshold. When these cases were removed from the regression including baseline PHQ-
2, change in variance explained from model one to model two (HS severity) became 
statistically significant, and in model three age and higher Hurley stages at baseline 
became significant predictors of PHQ-2 at follow-up. For the regression without PHQ-2 
baseline included the case with the residual statistic above 2.5 was removed, and variance 
explained by the models did not change significantly, however a higher Hurley stage at 
baseline became a significant predictor in models one and two. 
 
3.2 Demographic and Clinical Characteristics 
There was a total of 135 participants with HS aged 18-63 (M = 38.90, SD = 11.48) 
at baseline, and 19 - 63 (M = 39.62, SD = 11.39) at follow-up. The majority of participants 
were female (n = 79, 59%), had severe HS at both time points (T1 = 56%, T2 = 54%) 
followed by moderate HS (T1 = 30%, T2 = 26%), and mild HS (T1 = 15%, T2 = 20%) 
respectively. Pain severity scores ranged from 0-96 at baseline (M = 42.47, SD = 28.94), 
and 0 - 100 at follow-up (M = 40.99, SD = 30.07). The average duration between baseline 
and follow-up was 8.83 months (SD = 2.79, Mode = 5.98) ranging from 5.98 - 20.47 
months. Table 1 displays the demographic and clinical characteristics of the participants. 
 
3.3  Illness Perceptions 
The distribution of illness perception scores at baseline and follow-up, and the 
number and percentage of people who were above the mid-point of > 5 for each 
perception are shown in Table 2. At both time 1 and time 2, the highest numbers of 
participants scoring above mid-point were for illness perceptions about timeline (86% 
and 85% respectively) and concern about HS (86% and 72% respectively). This indicates 
that the majority of participants perceived HS as having a long timeline and were greatly 
concerned about HS. Over two thirds of participants rated at baseline and follow-up that 
HS has a strong impact on their life (consequences), they have high amounts of symptoms 
(identity) and that HS has a strong emotional impact on them.  Over half of the 
participants also felt that they have low control over their illness at both time points. Most 
participants felt they had a good understanding of their HS and perceived treatment for 
HS as fairly helpful. Numbers of participants scoring above mid-point reduced from 
baseline to follow-up for all illness perceptions. 
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Table 1.  
Demographic and Clinical Characteristics at Baseline and Follow-up 
 Baseline (T1) Follow-up (T2) 
Characteristic n (%) n (%) 
Gender   
Female 79 (59%) 79 (59%) 
Male 56 (42%) 56 (42%) 
Age (years)   
Mean (SD) 38.90 (11.48) 39.62 (11.39) 
Range 18 - 63 19 - 63 
Hurley stage of HS 
severity 
  
Stage I and I/II (Mild) 20 (15%) 27 (20%) 
Stages II and II/III 
(Moderate) 
40 (30%) 35 (26%) 
Stage III (Severe) 75 (56%) 73 (54%) 
Pain severity   
Mean (SD) 42.47 (28.94) 40.99 (30.07) 
Range 0 - 96 0 - 100 
 
 
3.4 Symptoms of Anxiety and Depression and Quality of Life 
Table 3 illustrates the distribution of anxiety and depression symptom scores, and 
the number and percentage of participants that were equal to or above the cut-off for 
clinically significant symptoms. At both time one and time two, participants typically 
scored below threshold for clinically significant symptoms of anxiety (T1: Mdn = 2, SD 
= 1.85; T2: Mdn = 2, SD = 1.78) and depression (T1: Mdn = 2, SD = 1.79; T2: Mdn = 2, 
SD = 1.93). Less than a third of participants scored above the cut-off for anxiety 
symptoms at both time points (28% and 27% respectively). Over a third of participants 
met threshold for clinically significant depressive symptoms at baseline (35%), however 
this reduced to just under a third at follow-up (32%). 
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Table 2.  
Illness Perception (BIPQ) Scores and Participants Numbers Above Mid-Point at Baseline 
and Follow-Up 










point (> 5) 
Dimension   n (%)   n (%) 
Consequences 7.02 
(2.53) 
7 104 (77%) 6.70 
(2.74) 
7 90 (68%) 
Timeline 8.56 
(2.43) 
10 116 (86%) 8.56 
(2.40) 





2 96 (71%) 3.29 
(2.93) 





5 44 (33%) 5.72 
(2.84) 
5 38 (28%) 
Identity 7.10 
(2.40) 
7 101 (75%) 6.61 
(2.41) 
7 94 (70%) 
Concern 8.11 
(2.24) 
9 116 (86%) 7.38 
(2.93) 
8 97 (72%) 
Understanding 7.23 
(2.64) 
8 18 (13%) 7.67 
(2.58) 





8 106 (79%) 7.08 
(2.69) 
8 95 (70%) 
*Higher scores indicate stronger endorsement of items. The number and percent of BIPQ 
scores above mid-point for personal control, treatment control and understanding are 
calculated using reverse scoring. 
 
Overall, participants rated that HS symptoms were having a very large impact 
(Hongbo et al., 2005) on QoL at baseline (DLQI Mdn = 15, SD = 8.22) and follow-up 
(DLQI Mdn = 13, SD = 8.13). Table 4 displays the distribution of DLQI scores in at each 
level of impact on QoL. Over a third of participants gave a score falling in the very large 
impact range on the DLQI at time 1 (35%) and 2 (39%) and almost a third scored 
symptoms as having an extremely large impact (31% and 24% respectively). Less than 




Table 3.  
Total Scores of Anxiety (GAD-2) and Depression (PHQ-2) Symptom, and Participant 
Numbers Reaching Threshold for Clinically Significant Symptoms at Baseline and 
Follow-Up 





















2 37 (28%) 1.77 
(1.78) 
2 36 (27%) 
PHQ-2 2.22 
(1.79) 
2 47 (35%) 2.04 
(1.93) 
2 43 (32%) 
 
 
Table 4.  
Total Scores of the Impact of HS on Quality of Life (DLQI) at Baseline and Follow-Up 
 DLQI category 














 n (%) n (%) n (%) n (%) n (%) 
Baseline 
(T1) 
5 (4%) 14 (10%) 27 (20%) 47 (35%) 42 (31%) 
Follow-up 
(T2) 
4 (3%) 21 (16%) 26 (19%) 52 (39%) 32 24%) 
 
 
3.5  Relationships Between Factors at Baseline and Quality of Life and Symptoms 
of Anxiety and Depression at Follow-Up 
Hypothesis: Illness beliefs assessed at first presentation to the clinic will be a stronger 
predictor of longitudinal outcomes (quality of life and symptoms of anxiety and 
depression) than HS disease severity. 
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Tables 5, 7 and 9 display the multiple regressions with baseline outcome measures 
included as predictors, and Tables 6, 8 and 10 display the multiple regressions without 
baseline outcome measures included.  
 
Anxiety 
For anxiety symptom scores at follow-up, Table 5 demonstrates that when 
baseline anxiety symptoms were included in the model, HS severity (Hurley stage) did 
not explain a significant amount of additional variance over and above demographics, 
pain severity and baseline anxiety (ΔR2 = .015, ΔF(2, 128) = 1.35, p = .263). When illness 
perceptions were added into the model this produced a larger increase in variance 
explained (4.7%), however this was not statistically significant (ΔR2 = .047, ΔF(8, 120) 
= 1.07, p = .386). Standardised beta coefficients indicated that baseline anxiety scores 
remained a significant contributor to the model after Hurley stage and illness perceptions 
were entered (β = .37, p < .01, 95% CI [0.11, 0.60]). Greater emotional response to HS at 
baseline also explained a significant amount of variance in anxiety symptoms at follow-
up (β = .18, p < .05, 95% CI [-0.02, 0.23]).  
 
Table 6 demonstrates the same model with baseline anxiety symptoms removed. 
HS severity (Hurley stage) still did not significantly increase the amount of variance 
explained over and above demographic variables and pain severity (ΔR2 = .017, ΔF(2, 
129) = 1.24, p = .293). Illness perceptions made the largest contribution to the model 
explaining a statistically significant increase in variance (13.7%) in anxiety symptoms at 
follow-up (ΔR2 = .137, ΔF(8, 121) = 2.79, p < .01), with baseline emotional response 
remaining a significant contributor to this model (β = .30, p <. 01, 95% CI [0.05, 0.30]). 
Standardised beta coefficients also indicated that pain severity at baseline explained a 
significant amount of variance in anxiety scores at follow-up when Hurley stage was 
included in the model (β = .30, p < .01, 95% CI [0.01, 0.03]) however this was no longer 
significant when illness perceptions had been accounted for (β = .09, p = .459, 95% CI [-
0.01, 0.02]).   These findings from Tables 5 and 6 support hypothesis 1 that illness beliefs 
were a stronger predictor of anxiety at follow-up than disease severity.
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Table 5.  
Hierarchical Multiple Regressions of Variables on Anxiety (GAD-2) Symptoms at Time 2 
 Model 1 Model 2 Model 3 
Variables at T1 β SE P (95% CI) β SE P (95% CI) β SE P (95% CI) 
Gender -.06 0.26 .463 (-0.73, 0.27) -.08 0.28 .340 (-0.81, 0.21) -.10 0.30 .271 (-0.95, 0.24) 
Age -.01 0.01 .923 (-0.02, 0.02) .035 0.01 .653 (-0.02, 0.03) .09 0.01 .305 (-0.01, 0.04) 
GAD-2 total .46 0.10 .001 (0.22, 0.65) .46 0.10 .001 (0.23, 0.65) .37 0.11 .004 (0.11, 0.60) 
Pain  .13 0.01 .214 (-0.00, 0.02) .15 0.01 .163 (-0.00, 0.02) .04 0.01 .735 (-0.01, 0.02) 
Lower Hurley stage (I vs. II)    -.08 0.47 .520 (-1.23, 0.47) -.06 0.48 .646 (-1.08, 0.59) 
Higher Hurley stage (I vs. III)    -.18 0.44 .155 (-1.50, 0.15) -.16 0.46 .230 (-1.43, 0.23) 
Consequences       .09 0.10 .514 (-0.13, 0.27) 
Timeline       -.06 0.09 .631 (-0.18, 0.13) 
Personal control       -.05 0.04 .511 (-0.11, 0.07) 
Treatment control       -.05 0.05 .581 (-0.13, 0.08) 
Identity       .06 0.08 .569 (-0.13, 0.18) 
Concern       -.03 0.08 .729 (-0.18, 0.13) 
Understanding       .04 0.06 .660 (-0.09, 0.14) 
Emotional response       .18 0.06 .048 (-0.02, 0.23) 
R2 .282 .297 .344 
ΔR2 (P) .282 (.000) .015 (.263) .047 (.386) 
Note. β = standardised coefficient. ΔR2 = change in R2. SEs, P values and 95% CIs are bootstrapped (1000 samples). 
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Table 6.  
Hierarchical Multiple Regressions of Variables on Anxiety (GAD-2) Symptoms at Time 2 Without GAD-2 at Baseline 
 Model 1 Model 2 Model 3 
Variables at T1 β SE P (95% CI) β SE P (95% CI) β SE P (95% CI) 
Gender -.11 0.29 .180 (-1.00, 0.20) -.13 0.30 .131 (-1.19, 0.20) -.15 0.31 .074 (-1.18, 0.11) 
Age -.08 0.01 .423 (-0.04, 0.02) -.03 0.01 .745 (-0.03, 0.02) .09 0.02 .370 (-0.02, 0.05) 
Pain  .28 0.01 .006 (0.00, 0.03) .30 0.01 .005 (0.01, 0.03) .09 0.01 .459 (-0.01, 0.02) 
Lower Hurley stage (I vs. II)    -.06 0.52 .667 (-1.18, 0.73) -.03 0.50 .800 (-1.08, 0.79) 
Higher Hurley stage (I vs. III)    -.18 0.49 .198 (-1.60, 0.44) -.15 0.48 .259 (-1.44, 0.45) 
Consequences       .20 0.09 .097 (-0.03, 0.33) 
Timeline       -.08 0.08 .434 (-0.18, 0.09) 
Personal control       .01 0.05 .940 (-0.08, 0.11) 
Treatment control       -.10 0.05 .198 (-0.16, 0.03) 
Identity       .05 0.09 .690 (-0.15, 0.20) 
Concern       -.09 0.08 .372 (-0.23, 0.08) 
Understanding       .01 0.06 .884 (-0.10, 0.12) 
Emotional response       .30 0.05 .001 (0.05, 0.30) 
R2 .102 .119 .256 
ΔR2 (P) .102 (.003) .017 (.293) .137 (.007) 
Note. β = standardised coefficient. ΔR2 = change in R2. SEs, P values, and 95% CIs are bootstrapped (1000 samples). 
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Depression 
For symptoms of depression, Table 7 indicates that when baseline depression 
symptoms are included in the model, Hurley stage did not explain a significant amount 
of additional variance over and above that explained by baseline demographics, pain 
severity and depression scores (ΔR2 = 0.034, ΔF(2, 128) = 2.90, p = .059), however it did 
reach borderline statistical significance. Baseline illness perceptions also did not explain 
a significant amount of additional variance in depression symptom scores at follow-up 
(ΔR2 = .063, ΔF(8, 120) = 1.39, p = .208). The standardised beta coefficients show that 
baseline depression scores (β = .31, p < .01, 95% CI [0.14, 0.54]) and pain severity (β = 
.28, p < .01, 95% CI [0.01, 0.03]) remain significant contributors until illness perceptions 
are added to the model. Higher Hurley stage at baseline was a significant contributor to 
depression scores at follow-up when illness perceptions were not accounted for (β = -.26, 
p < .05, 95% CI [-1.96, -0.13]), however this reduced to borderline significance when 
illness perceptions were entered (β = .23, p = .052, 95% CI [-1.84, 0.01]). Similar to 
findings with anxiety, greater emotional response to HS explained a significant amount 
of variance in depression symptom scores at follow-up (β = .21, p < .05, 95% CI [-0.01, 
0.26]). 
 
Table 8 displays the same model with baseline depression symptom scores 
removed. Entry of baseline Hurley stage into the model only explained an additional 2.5% 
of the variance which was not a statistically significant increase from that explained by 
demographics and pain severity (ΔR2 = .025, ΔF(2, 129) = 1.94, p = .147). Illness 
perceptions at baseline explained an additional 11.2% of the variance which was a 
significant increment (ΔR2 =.112, ΔF(8, 121) = 2.41, p < .05), with emotional response 
to HS having the greatest impact on the model (β = .22, p < .05, 95% CI [0.01, 0.26]. Pain 
severity also remained a significant contributor to the model when Hurley stage was 
accounted for, however this became non-significant when illness perceptions were added 
(β = .21, p = .091, 95% CI [-0.00, 0.03]). These findings from Tables 7 and 8 support the 
hypothesis that illness beliefs were a stronger predictor of symptoms of depression at 
follow-up than HS disease severity. 
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Table 7.  
Hierarchical Multiple Regressions of Variables on Depression (PHQ-2) Symptoms at Time 2 
 Model 1 Model 2 Model 3 
Variables at T1 β SE P (95% CI) β SE P (95% CI) β SE P (95% CI) 
Gender .01 0.31 .931 (-0.58, 0.61) -.02 0.31 .814 (-0.66, 0.48) -.03 0.35 .739 (-0.83, 0.58) 
Age -.01 0.01 .900 (-0.03, 0.02) .06 0.01 .503 (-0.02, 0.03) .14 0.01 .076 (-0.00, 0.05) 
PHQ-2 total .29 0.11 .007 (0.11, 0.50) .31 0.11 .006 (0.14, 0.52) .21 0.12 .061 (-0.02, 0.45) 
Pain  .27 0.01 .013 (0.00, 0.03) .28 0.01 .009 (0.01, 0.03) .16 0.01 .180 (-0.01, 0.03) 
Lower Hurley stage (I vs. II)    -.11 0.50 .357 (-1.45, 0.51) -.09 0.50 .460 (-1.32, 0.61) 
Higher Hurley stage (I vs. III)    -.26 0.44 .024 (-1.96, -0.13) -.23 0.45 .052 (-1.84, 0.01) 
Consequences       .13 0.10 .314 (-0.09, 0.33) 
Timeline       -.10 0.07 .264 (-0.22, 0.08) 
Personal control       .01 0.06 .872 (-0.11, 0.14) 
Treatment control       -.03 0.06 .745 (-0.14, 0.12) 
Identity       .09 0.10 .465 (-0.12, 0.25) 
Concern       -.02 0.09 .797 (-0.20, 0.16) 
Understanding       -.01 0.06 .879 (-0.13, 0.09) 
Emotional response       .21 0.07 .029 (-0.01, 0.26) 
R2 .225 .258 .321 
ΔR2 (P) .225 (.000) .034 (.059) .063 (.208) 
Note. β = standardised coefficient. ΔR2 = change in R2. SEs, P values, and 95% CIs are bootstrapped (1000 samples). 
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Table 8.  
Hierarchical Multiple Regressions of Variables on Depression (PHQ-2) Symptoms at Time 2 Without PHQ-2 at Baseline 
 Model 1 Model 2 Model 3 
Variables at T1 β SE P (95% CI) β SE P (95% CI) β SE P (95% CI) 
Gender -.04 0.32 .649 (-0.76, 0.48) -.06 0.32 .440 (-0.87, 0.37) -.07 0.33 .426 (-0.90, 0.37) 
Age -.02 0.01 .848 (-0.03, 0.03) .04 0.02 .669 (-0.02, 0.04) .15 0.01 .078 (-0.00, 0.05) 
Pain  .40 0.01 .001 (0.02, 0.04) .42 0.01 .001 (0.02, 0.04) .21 0.01 .091 (-0.00, 0.03) 
Lower Hurley stage (I vs. II)    -.11 0.53 .376 (-1.55, 0.57) -.10 0.50 .431 (-1.33, 0.57) 
Higher Hurley stage (I vs. III)    -.23 0.49 .069 (-1.87, 0.18) -.22 0.48 .088 (-1.78, 0.17) 
Consequences       .21 0.09 .079 (0.00, 0.35) 
Timeline       -.08 0.07 .360 (-0.19, 0.08) 
Personal control       .03 0.06 .805 (-0.10, 0.15) 
Treatment control       -.09 0.06 .285 (-0.17, 0.06) 
Identity       .08 0.10 .506 (-0.12, 0.23) 
Concern       -.02 0.09 .824 (-0.19, 0.15) 
Understanding       -.01 0.07 .922 (-0.14, 0.11) 
Emotional response       .22 0.07 .035 (0.01, 0.28) 
R2 .161 .186 .298 
ΔR2 (P) .161 (.000) .025 (.147) .112 (.019) 
Note. β = standardised coefficient. ΔR2 = change in R2. SEs, P values, and 95% CIs are bootstrapped (1000 samples). 
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Quality of Life 
For QoL, Table 9 demonstrates that when baseline QoL scores were included in 
the model in addition to demographics and pain severity, Hurley stage (ΔR2 = .003, ΔF(2, 
128) = .377, p = .686) and illness perceptions (ΔR2 = .016, ΔF(8, 120) = .481, p = .868) 
at baseline did not significantly increase the variance explained for scores of QoL at 
follow-up. Baseline QoL explained the most variance in QoL at follow-up when all 
variables were entered into the model (β = .50, p < .01, 95% CI [0.26, 0.73]).  
 
When baseline QoL was removed as a predictor (Table 10), Hurley stage only 
explained an additional 1.1% of the variance for QoL at follow-up (ΔR2 = .011, ΔF(2, 
129) = .965, p = .384), whereas illness perceptions explained an additional 12.1% of the 
variance (ΔR2 =.121, ΔF(8, 121) = 3.09, p < .01). Pain severity at baseline made a 
consistently significant contribution to the model with all other variables accounted for 
(β = .28, p < .01, 95% CI [-0.02, 0.13]). Greater experiences of HS symptoms (Identity) 
was also a significant contributor to QoL at follow-up (β = .21, p < .05, 95% CI [-0.02, 
1.48]).   Overall these findings support the hypothesis that illness perceptions are a 
stronger predictor of quality of life impairment than disease severity in HS. 
 
3.6 Stability of illness perceptions over time 
Table 11 demonstrates that Friedman’s two-way analysis of variance by ranks 
revealed that illness perceptions did not significantly change between baseline and 
follow-up, apart from Identity (X2(1) = 7.84, p < .05 and Concern (X2(1) = 9.00, p < .05). 
Wilcoxon signed-rank tests were conducted to follow-up these findings. A Bonferroni 
correction was used therefore a .0167 level of significance was applied to all effects. It 
appeared that perceptions about Identity (Mdn = 2, T = 1706.00, z = -2.842, p < .05, r = 
-.17) and Concern (Mdn = 1, T = 984.50, z = -3.204, p < .05, r = -.20) were not stable 








Table 9.  
Hierarchical Multiple Regressions of Variables on Quality of Life (DLQI) at Time 2 
 Model 1 Model 2 Model 3 
Variables at T1 β SE P (95% CI) β SE P (95% CI) β SE P (95% CI) 
Gender -.06 1.07 .338 (-3.11, 1.01) -.07 1.13 .341 (-3.43, 1.11) -.06 1.25 .440 (-3.33, 1.38) 
Age .06 0.05 .344 (-0.05, 0.14) .07 0.05 .310 (-0.05, 0.15) .10 0.05 .182 (-0.03, 0.18) 
DLQI total .59 0.08 .001 (0.43, 0.72) .59 0.08 .001 (0.42, 0.75) .50 0.11 .001 (0.26, 0.73) 
Pain  .14 0.02 .092 (-0.01, 0.09) .14 0.02 .096 (-0.01, 0.09) .11 0.03 .276 (-0.02, 0.09) 
Lower Hurley stage (I vs. II)    -.08 1.83 .439 (-5.08, 2.31) -.07 1.85 .478 (-4.72, 2.16) 
Higher Hurley stage (I vs. III)    -.07 1.71 .531 (-4.25, 2.29) -.04 1.81 .734 (-4.10, 2.76) 
Consequences       -.01 0.37 .911 (-0.81, 0.70) 
Timeline       -.02 0.22 .759 (-0.50, 0.40) 
Personal control       .06 0.17 .311 (-0.17, 0.49) 
Treatment control       -.04 0.20 .592 (-0.47, 0.33) 
Identity       .12 0.35 .245 (-0.29, 1.05) 
Concern       .03 0.36 .768 (-0.63, 0.71) 
Understanding       -.04 0.22 .589 (-0.54, 0.25) 
Emotional response       .09 0.31 .429 (-0.41, 0.82) 
R2 .474 .477 .494 
ΔR2 (P) .474 (.000) .003 (.686) .016 (.868) 
Note. β = standardised coefficient. ΔR2 = change in R2. SEs, P values, and 95% CIs are bootstrapped (1000 samples). 
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Table 10.  
Hierarchical Multiple Regressions of Variables on Quality of Life (DLQI) at Time 2 Without DLQI at Baseline 
 Model 1 Model 2 Model 3 
Variables at T1 β SE P (95% CI) β SE P (95% CI) β SE P (95% CI) 
Gender -.10 1.24 .187 (-4.05, 0.65) -.09 1.26 .256 (-3.91, 1.11) -.08 1.29 .346 (-3.91, 1.50) 
Age .02 0.06 .816 (-0.10, 0.13) -.01 0.06 .920 (-0.12, 0.14) .10 0.06 .221 (-0.03, 0.18) 
Pain  .52 0.02 .001 (0.10, 0.19) .51 0.02 .001 (0.09, 0.19) .28 0.03 .008 (0.02, 0.13) 
Lower Hurley stage (I vs. II)    -.06 1.98 .599 (-4.76, 3.27) -.04 1.86 .701 (-4.34, 3.31) 
Higher Hurley stage (I vs. III)    .06 1.89 .587 (-2.27, 4.89) .08 1.77 .484 (-2.04, 4.68) 
Consequences       .12 0.37 .287 (-0.39, 1.15) 
Timeline       -.05 0.25 .489 (-0.66, 0.48) 
Personal control       .10 0.19 .166 (-0.48, 0.63) 
Treatment control       -.10 0.19 .162 (-0.64, 0.06) 
Identity       .21 0.33 .035 (-0.02, 1.48) 
Concern       .00 0.40 .980 (-0.84, 0.75) 
Understanding       -.11 0.22 .123 (-0.74, 0.04) 
Emotional response       .19 0.31 .086 (-0.18, 1.04) 
R2 .278 .288 .409 
ΔR2 (P) .278 (.000) .011 (.384) .121 (.003) 
Note. β = standardised coefficient. ΔR2 = change in R2. SEs, P values, and 95% CIs are bootstrapped (1000 samples).
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Table 11.  
Summary of Friedman’s Two-Way Analysis of Variance by Ranks and Wilcoxon Signed-
Ranks Test Statistics Assessing Change in Illness Perceptions Between Baseline and 
Follow-Up 
Illness perception Friedman test 
statistic of 
change between 
T1 and T2 
                       
(X2) 









Consequences 3.18 .075 - - 
Timeline 0.02 .895 - - 
Personal control 0.25 .615 - - 
Treatment control 0.09 .765 - - 
Identity 7.84 .005* 1706.00 .004** 
Concern 9.00 .003* 984.50 .001** 
Understanding 1.36 .244 - - 
Emotional response 2.71 .100 - - 
*p < .01 (2-tailed), **p < .0167 (2-tailed). 
 
Table 12.  
Spearman’s Rho Correlation Coefficients Between Change Scores in Illness Perceptions 
Over Time and Quality of Life (DLQI) and Symptoms of Anxiety (GAD-2) and Depression 
(PHQ-2) at Follow-Up 
*p < .05 (2-tailed), **p < .01 (2-tailed). 
 Outcome (T2) 
Illness perception GAD-2 PHQ-2 DLQI 
Consequences .091 .082 .244** 
Timeline .076 .182* .192* 
Personal control -.073 -.185* -.169 
Treatment control .073 .037 .010 
Identity .038 .123 .101 
Concern .316** .132 .241** 
Understanding -.004 .038 -.039 
Emotional response .094 .068 .168 
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Relationships Between Changes in Illness Perceptions Over Time and Symptoms of 
Anxiety and Depression and Quality of Life 
Spearman’s rho correlation coefficients in Table 12 show that there was a 
significant positive relationship between the DLQI total score at follow-up and change in 
illness perceptions about consequences (rs = .244, p < .01), timeline (rs = .192, p < .05), 
and concern (rs = .241, p < .01). Personal control (rs = -.169, p = .05) and emotional 
response (rs = .168, p = .051) were on the borderline of statistical significance for negative 
and positive relationships, respectively with DLQI total score. Changes in illness 
perceptions were not significantly related to the GAD-2 total score at follow-up, apart 
from reductions in illness perceptions about concern (rs = .316, p < .001) which were 
associated with lower GAD-2 scores. Changes in illness perceptions were not 
significantly related to the PHQ-2 total score at follow-up, apart from a positive 
correlation with change in illness perceptions about timeline (rs = .182, p < .05) and a 
negative correlation with change in personal control (rs = -.185, p < .05). In contrast to 
anxiety and quality of life, increases in understanding over time were associated with 
higher PHQ-2 scores at follow-up. 
 
3.7 Cross-Lagged Panel Analysis of Illness Perceptions and Symptoms of 
Depression Over Time 
Spearman’s rho analyses were run prior to cross-lagged analyses to identify illness 
perceptions that correlated with symptoms of depression at the level of .3 or over. 
Consequences, personal control, identity, concern and emotional response met this 
criterion and all other illness perceptions were excluded from this part of the analyses.  
 
Figure 2 demonstrates the standardised regression coefficients for each pathway 
between illness beliefs about consequences of HS and symptoms of depression over time 
(see Table 13 for further details of each regression). All paths were statistically significant 
at p £ .001. Symptoms of depression and beliefs about consequences of HS showed a 
similar pattern of stability over time (.41 and .55 respectively) and the synchronous paths 
(associations at the same time point) had similar effect sizes in both directions at each 
time point, as shown in Table 13 (.54 and .47, respectively). Both significant cross-lagged 
paths indicate that more negative beliefs about the consequences of HS predict higher 
scores of depression symptoms over time (β = .42, p £ .001, 95% CI [0.21, 0.43]) and 
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higher scores of depression symptoms predict more negative beliefs about consequences 
over time (β = .45, p £ .001, 95% CI [0.45, 0.94]). The similar effect sizes and level of 
significance for all paths indicate that symptoms of depression and beliefs about 
consequences of HS had a mutual influence on each other regardless of time. Although 
the directions of influence were mutual, the influence of depression symptoms and beliefs 
about consequences on each other at baseline was slightly larger than over time, as shown 
by the lower effect sizes of the cross-lagged paths. 
 
The standardised regression coefficients for each pathway between illness beliefs 
about personal control over HS and symptoms of depression over time are displayed in 
Figure 3 (see Table 14 for further details). Personal control beliefs at baseline were 
significantly associated with these beliefs at follow-up, even though the pattern was the 
least stable of the illness perceptions measures. Synchronously, effect sizes were 
negatively associated and similar in both directions at each time point (as shown in Table 
14), however the synchronous coefficients changed from non-significant to significant 
over time (-.12 and -.31, respectively). The cross-lagged effect of depression symptoms 
on personal control was significant (β = -.20, p < .05, 95% CI [-0.58, 0.06]), whereas the 
impact of personal control on depression symptoms over time was non-significant (β = -
.14, p = .104, ns, 95% CI [-0.20, 0.02]). These negative cross-lagged paths suggest that 
higher scores of depression symptoms only predicted lower personal control scores at a 
later time not at the same time point (baseline). Personal control beliefs did not predict 
depression symptoms at baseline or follow-up. This suggests that depressive symptoms 
had more of an impact over time than personal control beliefs. 
 
Figure 4 shows the standardised regression coefficients for the pathways between 
identity beliefs and depressive symptoms over time (see Table 15 for further details). All 
paths were statistically significant at p £ .001. The synchronous paths had similar effect 
sizes in both directions at each time point (.37 and .43). The trend of similarity in both 
cross-lagged paths suggests that identity beliefs and symptoms of depression had a mutual 
influence on each other from baseline to follow-up. Higher identity beliefs at baseline 
predicted higher scores of depression symptoms (β = .35, p £ .001, 95% CI [0.16, 0.42]), 
and higher scores of depressive symptoms at baseline predicted higher identity beliefs 
over time (β = .35, p £ .001, 95% CI [0.24, 0.69]). 
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Figure 2.  
Standardised Regression Coefficients (β) in a Cross-Lagged Panel Model Demonstrating 
the Effect of Illness Beliefs About the Consequences of HS on Symptoms of Depression, 










Note. P values are bootstrapped (1000 samples).  
*Coefficient is significant at p < .05, **coefficient is significant at p <.01, ***coefficient 
is significant at p £ .001. 
 
Table 13.  
Linear Regression Analyses Explaining the Cross-Lagged Panel Model of Illness Beliefs 
About the Consequences of HS and Symptoms of Depression 
Linear regression pathways β SE P (95% CI) 
Consequences T1 -> Consequences T2 .55 .08 .001 (0.42, 0.75) 
PHQ-2 T1 -> PHQ-2 T2 .41 .09 .001 (0.27, 0.61) 
Consequences T1 -> PHQ-2 T1 .54 .05 .001 (0.28, 0.48) 
PHQ-2 T1 -> Consequences T1 .54 .10 .001 (0.56, 0.96) 
Consequences T2 -> PHQ-2 T2 .47 .05 .001 (0.23, 0.43) 
PHQ-2 T2 -> Consequences T2 .47 .11 .001 (0.45, 0.89) 
Consequences T1 -> PHQ-2 T2 .42 .05 .001 (0.21, .0.43) 
PHQ-2 T1 -> Consequences T2 .45 .11 .001 (0.45, 0.94) 






















Figure 3.  
Standardised Regression Coefficients (β) in a Cross-Lagged Panel Model Demonstrating 
the Effect of Illness Beliefs About Personal Control Over HS on Symptoms of Depression, 










Note. P values are bootstrapped (1000 samples).  
*Coefficient is significant at p < .05, **coefficient is significant at p <.01, ***coefficient 
is significant at p £ .001. 
 
Table 14.  
Linear Regression Analyses Explaining the Cross-Lagged Panel Model of Illness Beliefs 
About Personal Control of HS and Symptoms of Depression 
Linear regression pathways β SE P (95% CI) 
Personal control T1 -> Personal control T2 .23 .09 .019 (0.02, 0.43) 
PHQ-2 T1 -> PHQ-2 T2 .41 .09 .001 (0.27, 0.61) 
Personal control T1 -> PHQ-2 T1 -.12 .06 .228 (-0.18, 0.03) 
PHQ-2 T1 -> Personal control T1 -.12 .16 .210 (-0.48, 0.09) 
Personal control T2 -> PHQ-2 T2 -.31 .06 .001 (-0.32, -0.10) 
PHQ-2 T2 -> Personal control T2 -.31 .13 .001 (-0.72, -0.22) 
Personal control T1 -> PHQ-2 T2 -.14 .06 .104 (-0.20, .0.02) 
PHQ-2 T1 -> Personal control T2 -.20 .14 .024 (-0.58, 0.06) 






















Figure 4.  
Standardised Regression Coefficients (β) in a Cross-Lagged Panel Model Demonstrating 
the Effect of Illness Beliefs About Identity on Symptoms of Depression, and the Effect of 










Note. P values are bootstrapped (1000 samples).  
*Coefficient is significant at p < .05, **coefficient is significant at p <.01, ***coefficient 
is significant at p £ .001. 
 
Table 15.  
Linear Regression Analyses Explaining the Cross-Lagged Panel Model of Illness Beliefs 
About Identity and Symptoms of Depression 
Linear regression pathways β SE P (95% CI) 
Identity T1 -> Identity T2 .53 .08 .001 (0.35, 0.71) 
PHQ-2 T1 -> PHQ-2 T2 .41 .09 .001 (0.27, 0.61) 
Identity T1 -> PHQ-2 T1 .37 .07 .001 (0.16, 0.41) 
PHQ-2 T1 -> Identity T1 .37 .09 .001 (0.30, 0.68) 
Identity T2 -> PHQ-2 T2 .43 .06 .001 (0.23, 0.46) 
PHQ-2 T2 -> Identity T2 .43 .10 .001 (0.34, 0.74) 
Identity T1 -> PHQ-2 T2 .35 .06 .001 (0.16, .0.42) 
PHQ-2 T1 -> Identity T2 .35 .11 .001 (0.24, 0.69) 























The standardised regression coefficients for the paths between levels of concern 
about HS and depressive symptoms over time were all positive and statistically 
significant and are shown in Figure 5 (see Table 16 for further details). Synchronously 
the effect sizes were similar in both directions between depression symptoms and concern 
beliefs (.33 and .31). Both cross-lagged paths were significant and similar in effect size. 
Higher levels of depressive symptoms at baseline were associated with a higher level of 
concern at follow-up (β = .28, p £ .001, 95% CI [0.20, 0.75]), and higher baseline concern 
about HS was associated with more depression symptoms at follow-up (β = .25, p < .01, 
95% CI [0.09, 0.33]). This indicates that overall depression symptoms and concern beliefs 
had similar levels of influence on each other over time, and these associations were 
slightly lower than the influence on each other at baseline. 
 
Figure 6 demonstrates the standardised regression coefficients for each pathway 
between emotional response to HS and symptoms of depression over time (see Table 17 
for further details). All paths were statistically significant at p £ .001. Trends of 
depressive symptoms and emotional response to HS were relatively stable across time 
(.41 and .60 respectively). Synchronously the directions of influence had similar effect 
sizes at each time point (.37 and .50). Both significant cross-lagged paths indicate that 
greater emotional response to HS predicted higher scores of depression symptoms over 
time (β = .40, p £ .001, 95% CI [0.17, 0.35]) and higher levels of depressive symptoms 
predict greater emotional response to HS over time (β = .35, p £ .001, 95% CI [0.24, 
0.76]). Greater emotional response to HS at baseline had a stronger association with more 
depressive symptoms over time than baseline, indicating that emotional response at 
baseline may predict higher scores of depression symptoms at a later time point than at 
baseline assessment. Overall, depression symptoms and emotional response had a similar 







Figure 5.  
Standardised Regression Coefficients (β) in a Cross-Lagged Panel Model Demonstrating 
the Effect of Concern About HS on Symptoms of Depression, and the Effect of Depressive 










Note. P values are bootstrapped (1000 samples).  
*Coefficient is significant at p < .05, **coefficient is significant at p <.01, ***coefficient 
is significant at p £ .001. 
 
Table 16.  
Linear Regression Analyses Explaining the Cross-Lagged Panel Model of Illness Beliefs 
About Concern About HS and Symptoms of Depression 
Linear regression pathways β SE P (95% CI) 
Concern T1 -> Concern T2 .46 .11 .001 (0.36, 0.84) 
PHQ-2 T1 -> PHQ-2 T2 .41 .09 .001 (0.27, 0.61) 
Concern T1 -> PHQ-2 T1 .33 .06 .001 (0.15, 0.38) 
PHQ-2 T1 -> Concern T1 .33 .10 .001 (0.21, 0.59) 
Concern T2 -> PHQ-2 T2 .31 .05 .001 (0.11, 0.31) 
PHQ-2 T2 -> Concern T2 .31 .11 .001 (0.24, 0.69 
Concern T1 -> PHQ-2 T2 .25 .06 .003 (0.09, .0.33) 
PHQ-2 T1 -> Concern T2 .28 .14 .001 (0.20, 0.75) 






















Figure 6.  
Standardised Regression Coefficients (β) in a Cross-Lagged Panel Model Demonstrating 
the Effect of Emotional Response to HS on Symptoms of Depression, and the Effect of 












Note. P values are bootstrapped (1000 samples).  
*Coefficient is significant at p < .05, **coefficient is significant at p <.01, ***coefficient 
is significant at p £ .001. 
 
Table 17.  
Linear Regression Analyses Explaining the Cross-Lagged Panel Model of Emotional 
Responses to HS and Symptoms of Depression 
Linear regression pathways β SE P (95% CI) 
Emotional response T1 -> Emotional response T2 .60 .09 .001 (0.36, 0.73) 
PHQ-2 T1 -> PHQ-2 T2 .41 .09 .001 (0.27, 0.61) 
Emotional response T1 -> PHQ-2 T1 .37 .06 .001 (0.09, 0.34) 
PHQ-2 T1 -> Emotional response T1 .37 .15 .001 (0.31, 0.91) 
Emotional response T2 -> PHQ-2 T2 .50 .06 .001 (0.25, 0.46) 
PHQ-2 T2 -> Emotional response T2 .50 .10 .001 (0.51, 0.88) 
Emotional response T1 -> PHQ-2 T2 .40 .04 .001 (0.17, .0.35) 
PHQ-2 T1 -> Emotional response T2 .35 .13 .001 (0.24, 0.76) 






















Previous research into HS has mostly maintained a focus on the role of clinical 
characteristics in influencing health outcomes. The present study builds on research by 
Pavon Blanco et al. (2018) by gathering data from the participants at a follow-up 
appointment after baseline, allowing a longitudinal design. The first aim of this study was 
to examine whether illness perceptions at baseline predict quality of life and symptoms 
of anxiety and depression at follow-up, independently of HS severity. The second aim 
was to investigate the stability of these illness perceptions over time, and whether changes 
in illness perceptions were associated with the same health outcomes. The third aim was 
to explore the extent to which illness perceptions predict symptoms of depression, and 
the extent to which depressive symptoms predict illness perceptions over time.  
 
Overall, illness perceptions at baseline explained a significant amount of variance 
in health outcomes at follow-up independent of disease severity when baseline health 
outcomes were not included in the model. In keeping with Pavon Blanco et al., (2018) 
HS severity at baseline explained very little of the variance in health outcomes at follow-
up, both with and without baseline health outcomes being accounted for. Illness 
perceptions did not change significantly over time, apart from beliefs about experiencing 
high levels of symptoms (identity) and concern about HS. Changes in perceptions about 
how long HS will continue (timeline) were significantly associated with depressive 
symptoms and quality of life, levels of concern about HS were associated with anxiety 
symptoms and quality of life outcomes, and changes in beliefs about the consequences of 
HS were related to quality of life. Symptoms of depression and illness perceptions 
(consequences, identity, level of concern and emotional response to HS) were found to 
have an asymmetrical but reciprocal influence on each other over time, apart from 
personal control beliefs. Depression symptoms were found to predict personal control 
over time, but personal control beliefs were not predictive of depression scores over time. 
 
4.1 Illness Perceptions and Health Outcomes 
The number of illness perceptions scoring above mid-point at follow-up remained 
relatively similar to baseline. In line with Pavon Blanco et al.’s (2018) study, illness 
beliefs at follow-up showed that this cohort of people with HS continued to report higher 
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perceptions of consequences, experiences of symptoms, concern and emotional response 
than people with asthma, diabetes and myocardial infarction and lower personal and 
treatment control (Broadbent et al., 2006; Petrie et al., 2012). The most negatively scored 
illness perceptions were for timeline and concern about HS, and the most positive were 
for understanding of HS and how helpful treatment is. Previous research has indicated 
that higher control beliefs are often linked with shorter timeline beliefs (Petrie & 
Weinman, 2006), however the present cohort were recruited from tertiary care where 
participants are more likely to have experienced HS for longer and therefore views of a 
chronic timeline are more likely and often more in keeping with HS duration (Dufour et 
al., 2014). This length of time and experience with HS may also explain why their 
perceptions of understanding of HS is high. 
 
Symptoms of anxiety and depression were also similar at baseline and follow-up 
with a slight reduction in the number meeting clinical threshold over time. Prevalence of 
clinically relevant anxiety scores in this cohort was higher than that found in previous 
studies of HS (Huilaja et al., 2018; Machado et al., 2019). Prevalence of clinically 
significant depression scores were slightly lower than that found in studies by Kluger, 
Ranta and Serlachius (2017) and Kurek et al. (2013) and higher than in the recent 
systematic review by Machado et al. (2019). Quality of life scores were slightly more 
variable between baseline and follow-up, however on average HS was having a very large 
impact on participants’ lives. This extent of impact is consistent with previous research 
using the DLQI, and mean scores were actually higher than in several HS cohorts (Balieva 
et al., 2018; Calao et al., 2018; Kluger et al., 2017; Matusiak et al., 2010). Studies of other 
chronic conditions that have measured illness perceptions found lower scores of negative 
illness beliefs which may explain the higher prevalence rates of impaired quality of life 
and symptoms of anxiety and depression in HS (Broadbent et al., 2006; Petrie et al., 
2012). This would correspond to past findings about decreases in psychological well-
being and social outcomes (Gray & Rutter, 2007; Hagger & Orbell, 2003; Hagger et al., 
2017; Morgan et al., 2014; Scharloo et al., 1998, 2000). 
 
4.2 Predictive Ability of HS Severity and Illness Perceptions on Outcomes 
Overall, illness perceptions contributed small improvements to all models and 
made significantly large improvements to models without baseline health outcomes 
included, whereas disease severity did not greatly improve any models. This is consistent 
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with the hypothesis that illness perceptions at baseline were a stronger predictor of quality 
of life and symptoms of anxiety and depression than HS severity (Hurley stage). The 
importance of illness perceptions in predicting health outcomes provides evidence for the 
dimensions included in the CSM (Leventhal et al., 1980; Leventhal et al., 1984), and 
shows that they are not directly linked to disease severity in HS. By distinguishing the 
influence of disease severity and illness perceptions these results highlight the need to 
acknowledge patient reported evaluations of HS in addition to clinical assessment in order 
to optimise health outcomes. 
 
Anxiety 
After controlling for demographics (age and gender), pain severity and anxiety 
symptoms at baseline both disease severity and illness perceptions did not significantly 
predict anxiety symptoms at follow-up. Unsurprisingly, this finding suggests that baseline 
anxiety symptoms are a strong predictor of anxiety symptoms at follow-up, however 
illness perceptions still explained more variance in anxiety over time than disease 
severity, in support of the hypothesis. Furthermore, when baseline anxiety scores were 
removed from the model illness perceptions were a significant predictor independently 
of Hurley stage, and made the largest contribution to anxiety scores at follow-up over and 
above demographics, pain and disease severity. This is in line with findings by Pavon 
Blanco et al. (2018) and other research (Broadbent et al., 2004, 2006; Jopson & Moss-
Morris, 2003; Morgan et al., 2014; Petrie et al., 1996; Scharloo et al., 2000; Whittaker et 
al., 2007), and is in contrast to findings by Wahl et al. (2014). This indicates the 
importance of targeting illness perceptions in reducing risk of clinically significant 
anxiety, even if people with HS are not currently meeting threshold for anxiety disorders 
or are at lower levels of disease severity and pain.  
 
Emotional response was a significant contributor in both models, which supports 
Pavon Blanco et al. (2018) and other cross-sectional findings in chronic conditions 
(Hagger et al., 2017; Morgan et al., 2014). The impact of emotional response increased 
greatly when baseline anxiety scores were removed, which is not surprising as the GAD-






When baseline depression scores were accounted for in addition to demographics 
and pain, disease severity and illness perceptions were not significant predictors of 
depression symptoms over time. However, illness perceptions explained more variance 
than Hurley stage, and baseline depression scores became a non-significant contributor 
when illness perceptions were inserted into to the model. Baseline anxiety symptoms 
remained a significant predictor with disease severity and illness perceptions included in 
the model unlike baseline depression symptoms which indicates that baseline depression 
symptoms were a weaker predictor of follow-up depression scores than baseline anxiety 
symptoms were of follow-up anxiety scores. In contrast to Pavon Blanco et al.’s (2018) 
findings, when baseline depression scores were not included in the model, disease 
severity did not significantly predict depression symptoms independently of illness 
perceptions, whereas illness perceptions were a significant predictor. This finding 
supports the hypothesis, previous cross-sectional research (Broadbent et al., 2004, 2006; 
Jopson & Moss-Morris, 2003; Morgan et al., 2014; Pavon Blanco et al., 2018; Petrie et 
al., 1996; Scharloo et al., 2000; Whittaker et al., 2007) and longitudinal research in other 
chronic conditions (Llewellyn et al., 2007; Stafford et al., 2009). This is also evidence 
against findings by Wahl et al. (2014), suggesting that in people with HS illness 
perceptions may predict risk of depression at a later time point, independently of disease 
severity. 
 
Emotional response was the most consistently significant variable contributing to 
anxiety and depression symptoms, both with and without baseline anxiety and depression 
scores included as predictors. This suggests that higher emotional response at baseline 
predicts more anxiety and depression symptoms at follow-up, which supports previous 
research into anxiety, distress and well-being (Hagger et al., 2017; Morgan et al., 2014). 
This corresponds to findings by Broadbent et al. (2015) and demonstrates the robustness 
of emotional response as a dimension in the BIPQ and emotional representations in the 
CSM (Leventhal et al., 1980). It should be noted, however, that the construct of emotional 
response may have a lot of overlap with measures of mood and anxiety and therefore its 





Quality of Life 
Scores on the baseline measure of quality of life were highly predictive of quality 
of life scores at follow-up, remaining consistently significant when demographics, pain, 
disease severity and illness perceptions were also measured. When baseline quality of life 
was removed, illness perceptions were a significant predictor of quality of life whereas 
disease severity was not. This result supports Pavon Blanco et al.’s (2018) findings and 
those from research into other conditions (Jopson & Moss-Morris, 2003; Morgan et al., 
2014; Scharloo et al., 1998, 2000). The result also provides evidence against Wahl et al. 
(2014), and may indicate that Matusiak et al.’s (2010) finding that disease severity was 
the most important factor influencing quality of life and depression was because they had 
not included a measurement of illness perceptions.  
 
Interestingly, when baseline quality of life had been removed, identity was a 
significant contributor. Consistent with findings in chronic fatigue syndrome (Gray & 
Rutter, 2007) this suggests that higher identity predicts poorer quality of life. Higher 
identity was also found to be associated with greater distress and poorer well-being and 
social functioning in other conditions (Hagger & Orbell, 2003; Hagger et al., 2017; Kemp 
et al., 1999; Scharloo, 1998). Identity can be indicative of the individual’s view of the 
label and symptoms associated with this, and can be different to the view of clinicians 
treating the illness (Petrie & Weinman, 2006). This highlights the importance of assessing 
identity beliefs in people with HS regardless of their clinically defined HS severity, as 
symptoms or side effects may be misattributed symptoms to HS that may not be medically 
related (Petrie & Weinman, 2006).  
 
In contrast to Pavon Blanco et al.’s (2018) and Gray and Rutter (2007), emotional 
response was not a significant contributor to prediction of quality of life outcomes. This 
may be due to the overarching variance explained by pain severity, which was a strong 
and significant contributor to quality of life over time when baseline quality of life had 
been removed. Pain had also contributed significantly to anxiety and depression scores 
when demographics and disease severity had been accounted for, however illness 
perceptions explained more variance and pain became non-significant. Taken together 
with other HS research into pain (Keary et al., 2019; Wolkenstein et al., 2007), the 
importance of assessing pain when considering the impact of HS on quality of life is 
evident. 
 129 
Associations Between Illness Perceptions and Outcomes 
Beliefs about timeline, personal control, and understanding were not significant 
predictors, and in contrast to findings by Pavon Blanco et al. (2018) and other studies of 
chronic illnesses (Hagger & Orbell, 2003; Hagger et al., 2017) perceptions about 
treatment control, negative consequences and concern were also not significant 
predictors. This contrast with other studies may be explained by the addition of pain 
severity as a predictor to the model, which has previously been indicated to influence 
feelings of anger and isolation in HS due to the lack of understanding about pain from 
others (Keary et al., 2019).  
 
Overall, although most illness perceptions were not significant contributors 
independently, together they explained a significant amount of variance, and specifically 
higher identity and emotional response may be indicative of poorer outcomes over time. 
Therefore, interventions targeting emotional representations of HS and the reduction of 
attribution of symptoms to HS may improve health outcomes over time. Past 
interventions aimed at supporting people to tolerate emotional experiences have included 
mindfulness and acceptance-based techniques (Hayes, Strosahl & Wilson, 1999; Veehof, 
Trompetter, Bohlmeijer & Schreurs, 2016) and stress management interventions such as 
controlled breathing and progressive muscle relaxation (Varvogli & Darviri, 2011). An 
intervention study of people with breast cancer found that weekly group sessions of 
discussions about emotional experiences, writing about fears, cognitive exercises linked 
with core values, and techniques such as relaxation and imagery improved emotional 
well-being and coping efficacy (Cameron, Booth, Schlatter, Ziginskas & Harman, 2007). 
 
4.3 Stability of Illness Perceptions Over Time 
The majority of illness perceptions did not change significantly between baseline 
and follow-up. This suggests that in HS populations the majority of illness perceptions 
remain stable over time, as also found in studies of irritable bowel syndrome and lower 
back pain (Foster et al., 2008; Rutter & Rutter, 2007). The only illness beliefs that 
significantly changed were regarding the illness label and associated symptoms (identity) 
and the concern they have about having HS which both decreased over time. It is likely 
that for this cohort of participants their perception of the health threat had shifted from 
acute to chronic prior to this study due to recruitment being from a tertiary service. In line 
with the process of illness perception development proposed by the CSM (Leventhal et 
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al., 1980, 1984), these participants are likely to have experienced HS for longer than those 
in primary and secondary services and therefore may view HS as less treatable in a short 
duration of time and hold less concern about its progression. In line with the dynamic 
process in the CSM (Leventhal et al., 1980), decreases in identity and concern beliefs 
may be due to changes in coping responses as the participants gained more experience 
and information about symptoms and treatment over time (Leventhal, Phillips & Burns, 
2016). These coping responses may have been evaluated and subsequently their beliefs 
about symptoms caused by HS were re-shaped (Leventhal et al., 1980, 2003). 
 
The findings do not support previous research in diabetes and cardiac conditions 
that found understanding and timeline beliefs significantly increase, and emotional 
response decreases over time (Fischer et al., 2010; Lawson et al., 2008; Petrie & 
Weinman, 1997). Although not significant, the mean score for emotional response did 
decrease slightly over time, and the mean score for understanding increased slightly over 
time. This small increase in understanding could be explained by the acquisition of 
knowledge and experience with HS over time, however being in tertiary services it is 
likely that many participants may have plateaued in this area.  
 
Association Between Changes in Illness Perceptions Over Time and Outcomes 
Although changes in identity perceptions were significant over time, this change 
was not significantly related to outcomes at follow-up, whereas decreases in concern over 
time were significantly related to lower anxiety scores at follow-up. In terms of 
depression symptoms, participants whose beliefs about chronicity of HS increased over 
time had higher depression scores at follow-up, whereas increases in beliefs about 
personal control over HS over time was associated with lower depression scores.  
Surprisingly, increases in understanding over time were related to higher depression 
scores. This may be partly explained by the way that information about HS is shared and 
interpreted; people with HS may be basing their understanding on unreliable sources. 
This may increase depressive symptoms through ruminative processes and activation of 
depressive cognitions such as helplessness and hopelessness. Decreases in negative 
illness perceptions about consequences, timeline and concern about HS over time were 
related to better quality of life at follow-up. Reductions in emotional response and 
increases in beliefs about personal control were also close to significance. These findings 
provide further support for interventions aimed at reducing negative illness perceptions 
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(Broadbent et al., 2009; Petrie et al., 2002, 2012) and identifies specific illness beliefs to 
focus on. Targeting beliefs about consequences, timeline, concern, emotional response 
and controllability may reduce the risk of anxiety, depression and impaired quality of life. 
 
4.4 Cross-Lagged Effects of Illness Perceptions and Symptoms of Depression 
The findings from the cross-lagged analyses indicated mutual influences between 
depression symptoms and illness perceptions (apart from personal control) regardless of 
time, suggesting no temporal precedence. Personal control beliefs were not significantly 
predictive of depression scores at baseline or follow-up, whereas depression scores were 
predictive of personal control beliefs over time but not at baseline. 
 
The predictive ability of depression symptoms on personal control over time is 
not in line with findings by Chilcot et al. (2013) who found no association between the 
trajectory of depression and personal control in people with renal problems, but may fit 
with the argument that other variables such as proinflammatory cytokines involved in HS 
may precede development of depression in HS (Goldstein, Kemp, Soczynska & 
McIntyre, 2009; Kelly & Prens, 2016; Kohler et al., 2017; van der Zee et al., 2011). These 
symptoms of depression may influence how people perceive the amount of control they 
have over HS. This finding of depression symptoms leading to lower personal control 
beliefs also supports literature by Bower (1981), Teasdale (1983) and Tversky and 
Kahneman (1974). Participants’ baseline depression symptoms may have increased 
access to negative cognitions and memories, and feelings of hopelessness and low energy 
and motivation are likely to have impacted coping behaviours. Rumination is a common 
process in low mood that has been found to impair concentration, central executive 
functioning and problem-solving (Lyubomirsky, Kasri & Zehm, 2003; Noelen-
Hoeksema, 2000; Watkins and Brown, 2002). Difficulties with problem-solving and 
increases in cognitive biases such as catastrophising, predictive thinking and minimising 
about their ability to have control over HS may have impacted their coping appraisals, in 
particular beliefs about personal control over HS and level of concern about the future. 
This is consistent with the theory of learned helplessness (Maier & Seligman, 1976). 
Participants may also have believed that others have been able to change their outcomes 
and impact of HS, whereas they were not able to (Abramson, Seligman & Teasdale, 
1978). In addition, increased attention towards negative elements and physical symptoms 
of their current experience of HS are likely to impact their interpretation of how HS is 
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impacting their life. This demonstrates how symptoms of depression can inform the 
development of illness perception in the feedback loop described by Leventhal et al. 
(1980) and Petrie and Weinman (2006). This also demonstrates the vicious cycle of 
behaviours, emotions and negative cognitions reinforcing each other as described by 
Beck (1967), that may also explain the overall mutual influence of illness perceptions and 
symptoms of depression on each other both at the same time points and over time.  
 
The association between higher depressive symptoms and lower personal control 
over time is also consistent with the theory of learned helplessness (Abramson et al., 
1978; Maier & Seligman, 1976). Participants who are depressed may hold more negative 
beliefs about believe that others have been able to change their outcomes and impact of 
HS, whereas they are not able to and therefore have a sense of helplessness 
 
The strongest reciprocal influence was between negative beliefs about 
consequences of HS and symptoms of depression which was expected based on cross-
sectional findings by Pavon Blanco et al. (2018). Emotional response was the only illness 
perception that had a stronger influence on depressive symptoms over time rather than at 
baseline. This suggests that people who are scoring more highly on the emotional 
response item at a baseline assessment may be more likely to develop more symptoms of 
depression over time. This has implications for referring people to illness perception 
interventions who are scoring highly on the emotional response regardless of their 
depression score, and for interventions to specifically target emotional response and 
prevent depressive symptoms from worsening. As previously stated, this finding should 
be interpreted with caution due to the likely overlap of the construct with measures of 
depression.  
 
Overall, Leventhal et al.’s (1980) CSM has been useful across research to 
understand the impact of illness representations as determinants on outcomes in different 
illnesses. The findings of this project also indicate that illness representations have a 
predictive impact on health outcomes in HS, however, the cross-lag relationships between 
outcomes (depression symptoms) and illness perceptions were not specified in the model. 
Although the model demonstrates parallel processing of cognitions and emotions, it is not 
clear how these strands interact. It will be important for future research to look at their 
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interactions rather than treating them as disconnected processing entities (Revenson & 
Diefenbach, 2019). 
 
4.5 Strengths and Limitations 
To date, this is the first longitudinal study investigating the predictive ability of 
illness perceptions on health outcomes over time in an HS population. This improves on 
previous HS research as it is better able to infer the direction of causality on outcomes 
than cross-sectional studies, and is therefore able to inform screening procedures in 
clinical practice regarding risk of anxiety, depression and impaired quality of life. It is 
also the first study to explore stability of illness perceptions over time in HS, and the 
impact this has on outcomes. These findings can directly inform psychological 
interventions to reduce negative outcomes, by referring to unique impact of each illness 
perception and their direction of change over time.  The cross-lagged analysis in this study 
also addresses the gap in literature about the influence of depressive symptoms on illness 
perceptions. This is extending the literature on development of illness perceptions and 
how these can be modified at intervention level. The validated and reliable outcome 
measures allow for this study to be compared to previous studies and replicated in future 
research, and is directly applicable to measures used routinely in clinical practice. 
Furthermore, this study is the first to account for the impact of pain severity on outcomes 
in HS alongside illness perceptions and disease severity, as this has become increasingly 
evident as an influential factor in past HS research. 
 
This study has several limitations. Although it is longitudinal in design, absolute 
causality cannot be established as the possibility of other explanations and variables 
influencing outcomes cannot be ruled out, and the study is not experimental or 
intervention based. In line with this, confounding factors such as HS treatment and/or 
psychological treatments at baseline were not controlled for in the analysis and may have 
influenced the outcomes. A substantial limitation of this study is sampling bias. Firstly, 
there were no participants over the age of 63, therefore findings may not be generalisable 
to older adults with HS. It should be noted however, that research has found HS 
prevalence may reduce over time (Alikhan, Lynch & Eisen., 2009) with significantly 
lower prevalence in those age 55 and older compared to younger ages (Revuz et al., 2008). 
Generalisability may also be more limited due to recruitment from one London teaching 
hospital in a tertiary service of patients with more severe HS. This was evident in the 
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statistics of HS severity, with 73-75% of the sample having severe HS compared to 15-
20% having mild HS. Due to the majority of participants being at higher Hurley stages, 
the findings of this study may not be representative of participants with milder forms of 
HS. Furthermore, the sample size was smaller than required for a regression analysis with 
up to 15 predictors, according to Cohen (1988) and Green (1991). Cohen (1998) stated 
that more than 150 participants are required to detect a medium effect size, and Green’s 
(1991) rule indicates a sample of 170 (50 + 8k, k = number of predictors) would be 
required therefore findings from the regressions should be interpreted with caution. 
 
A further limitation is that findings are based on disease severity measured by 
Hurley staging, which recent research has deemed inaccurate as it does not assess current 
levels of inflammation (Kimball et al., 2016; Scuderi et al., 2017). It is also unable to 
measure decreases from stage 2 due to the irreversibility of scarring which is the main 
feature of Hurley staging (van der Zee & Jemec, 2015). Findings may therefore not reflect 
the true predictive ability of disease severity on outcomes, and may not be directly 
applicable to future research and clinical practice as more dynamic measures continue to 
be implemented (Kimball et al., 2014). Other measurement limitations include the use of 
a single visual analogue scale to measure pain severity and the single item measures for 
each illness perception component on the BIPQ. These unidimensional methods risk 
oversimplifying the complexity of pain and each illness perception and thus results may 
have limited validity (Chapman & Syrjala, 1990; Revenson & Diefenbach, 2019). 
 
The results of the cross-lagged panel analyses should also be interpreted with 
caution due to violation of several assumptions that this is based on (Kearney, 2017). 
Synchronicity was not fully adhered to due to participant data being collected at different 
clinic dates, with times between baseline and follow-up ranging from approximately 6 to 
20 months. This range of time between measurements will have also limited the initial 
analyses of stability of illness perceptions over time. It is also possible that assumptions 
of stability and stationarity may have been violated due to potential for inter-individual 
differences and other variables (e.g. trait influences and different levels of pain) that may 
have impacted changes in causal structure (Kearney, 2017). We can also not assume that 
variables were measured without error. Therefore, findings may be biased and should be 
interpreted in terms of influence rather than direct causality. The time lag is assumed to 
be conceptually viable based on past longitudinal findings of illness perceptions 
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predicting depression (Llewelyn et al., 2007), however it is not clear whether this time 
frame is too short to identify effects of mood on illness perceptions. There were also some 
differences in the synchronous effect sizes between baseline and follow-up, therefore 
other factors may have impacted the findings, such as how long participants had been 
living with HS and treatment effects. Overall, the use of regression to measure panel data 
is reported to be a plausible method, however further research is required into robust 
statistical techniques for assessing causal influence (Rogosa, 2017). 
 
4.6 Future Research 
Following on from the limitations, if this study is to be replicated in future 
research a larger sample should be recruited with a minimum of 170 participants to 
sufficiently power the study. It would be beneficial to include the causes component of 
the BIPQ in future research as this will provide further insight into outcomes over time 
and has already been shown to be an effective illness perception to target in psychological 
interventions (Broadbent et al., 2015). In addition to this, variables of current HS 
treatment and any ongoing psychological interventions would also be useful to include to 
control for treatment effects. To build on the findings of this study and the CSM 
theoretical model, future research could also examine coping mechanisms in an HS 
population and the impact this has on outcomes, and the extent to which psychological 
variables and disease severity predict illness perceptions. The findings regarding pain as 
a predictor of outcomes supports perspectives of patients, carers and clinicians in a study 
by Ingram et al. (2014) that pain management is a priority for HS research; investigating 
whether pain is a mediator of the impact of illness perceptions on outcomes would be 
useful particularly in clinical practice. This study is the first to explore the bi-directional 
links between illness perceptions and depression in an HS cohort over two time points. 
Studies of coronary heart disease and kidney failure have started to explore the 
association between illness perceptions and trajectories of psychological distress 
including depression and anxiety (Chilcot et al., 2013, 2019), therefore future research 
should aim to explore patterns between illness perceptions and emotions using trajectory 
analysis over multiple time points. It would also be beneficial to extend research into the 
cross-lagged influences of illness perceptions on outcomes by looking at other factors 
that may influence the link between illness perceptions and mood. 
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HiSCR is a more recently developed and validated HS severity tool which allows 
for simple assessment of disease severity over time. It has been used in clinical trials of 
treatments for HS (Kimball et al., 2016), and recommended by the National Institute for 
Health and Care Excellence (NICE, 2016). In comparison to Hurley stage and other HS 
scoring systems, HiSCR increases sensitivity to HS-specific lesions and is more 
responsive to the acute phase and improvements in disease activity (Kimball et al., 2016). 
Therefore, future research would benefit from replicating this study but using HiSCR as 
the measure of disease severity in order to assess whether this more accurate measure has 
stronger predictive ability on outcomes than Hurley staging and illness perceptions. 
 
4.7 Clinical Implications 
The finding that illness perceptions were a stronger predictor of quality of life and 
symptoms of anxiety and depression in people with HS over and above disease severity 
implies that clinicians should assess illness perceptions as well as clinical characteristics 
of HS in order to identify people at risk of poorer outcomes over time. In particular, 
people reporting higher emotional response to HS may indicate risk of anxiety and 
depression over time, and higher identity beliefs and pain severity may indicate risk of 
quality of life impairment over time.  It may also be the case that people with HS could 
present with symptoms of depression without significantly negative illness beliefs 
(personal control in particular). The finding that depression symptoms were not predictive 
of personal control beliefs at baseline but were at follow-up has implications for screening 
and intervention. People with HS who report depressive symptoms at an assessment may 
be more likely to develop lower beliefs in their personal control over HS, regardless of 
their current beliefs about personal control. Referring them for support with symptoms of 
depression or brief psychoeducation may reduce this risk and the negative impact this 
may have on psychological well-being (Bradley, Lewis, Jennings & Ward, 1990; Hagger 
& Orbell, 2003; Hagger et al., 2017; Morgan et al., 2014; Shillitoe & Christie, 1990). This 
is particularly relevant to the clinics that the current participants attended as the illness 
perception measure was only administered every 6 months compared to depression, 
anxiety, and quality of life measures that are administered on every visit. 
 
A further clinical implication is that psychological interventions to modify illness 
perceptions such as those demonstrated in other research (Broadbent et al., 2009; Petrie 
et al., 2002, 2012) may be imperative alongside dermatological treatment in 
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multidisciplinary care in order to optimise health outcomes over time. A systematic 
review by Jones, Smith and Llewellyn (2015) evaluated nine interventions using the CSM 
to change illness beliefs and adherence behaviour, and only found one that had a large 
significant effect on control and cure illness perceptions (Petrie et al., 2002). This 
intervention used information about antecedents, problem-solving, action planning (how 
to cope with distress and negative consequences) and reattribution, and may therefore be 
useful in future interventions aimed at modifying illness perceptions. The findings 
showing mutual influence between illness perceptions and depression further support 
implications for specialised interventions targeting illness perceptions, in addition to 
options to offer referrals into a depression pathway. 
 
The changes in illness perceptions over time and the reciprocal influence between 
symptoms of depression and illness perceptions indicate that focusing solely on 
cognitions may not be the only intervention worth exploring. Cognitive behavioural 
interventions may be useful in breaking the cycle between depression and negative 
cognitions (Beck, 1967; Teasdale, 1983), and it has been recommended that CSM-based 
interventions should focus on both threat-focused and emotion-focused regulation 
strategies (Cameron et al., 2007; Cameron & Jago, 2008). In particular, psychological 
interventions could include strategies aimed at restructuring and challenging negative 
beliefs about consequences, timeline and controllability, behavioural interventions such 
as behavioural activation, and developing emotional regulation strategies. In light of 
Orbell and Phillips (2019) discussion regarding the influence of attentional and 
interpretational biases, they suggest that interventions address automatic processes as 
well as beliefs. This has been found to be effective in changing beliefs and medication 
adherence in patients following a stroke (O’Carroll, Chambers, Dennis, Sudlow, & 
Johnston, 2014). Interventions could include planning responses to illness or treatment 
experiences and rehearsing these; this may improve attitudes towards managing threats 
and their self-efficacy for managing them (Orbell & Phillips, 2019). Incorporating these 
different aspects into interventions may reduce the prevalence of anxiety, depression and 
impaired quality of life in people with HS. 
 
4.8 Conclusions 
This study was the first to investigate the impact of demographics, pain, disease 
severity and illness perceptions on longitudinal outcomes of anxiety and depression 
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symptoms and quality of life in HS. The results showed that illness perceptions were 
predictive of health outcomes independently of disease severity and accounted for more 
variance in all outcomes. It was also found that most illness perceptions remain stable 
over time (although reductions in negative illness beliefs were related to better outcomes 
over time), and the relationships between illness perceptions and symptoms of depression 
over time were bi-directional. The findings of this study emphasise the importance of 
patients’ evaluations of their illness, as well as clinician rated severity; milder disease 
severity may not be indicative of lower risk of anxiety, depression and impaired quality 
of life. It is hoped that this study will encourage routine assessment of illness beliefs in 
people with HS, and emphasise the need for further research and development of 
interventions to modify illness perceptions in order to improve health outcomes. Further 
research is required into the development and predictive ability of illness perceptions in 
HS, and will benefit from recruiting a larger sample from different services and taking 
into consideration dermatological and psychological treatment that participants are 
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Abdelrahman Wedad <Wedad.Abdelrahman@gstt.nhs.uk> 




The Oversight Committee are happy with the revised application, which I can confirm 
has now been approved. 
 








IMPARTS Oversight Committee Amendment Approval Email 
 
 
From: Rayner, Lauren <lauren.rayner@kcl.ac.uk> 
Sent: 17 September 2019 13:53 
To: Jones, Kelsey <kelsey.jones@kcl.ac.uk> 


































































































Appendix K – King’s Health Partners Honorary Passport 
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